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Abstract 
Bacterial contamination and persistent infection is a common cause of 
impaired wound healing. Generally, non-healing wounds display similar 
physiological features with regards to mixed bacterial flora, ischemia and 
production of exudate. The application of topical, broad spectrum antimicrobial 
compounds embedded in absorbent dressings has been shown to control 
bioburden and improve healing. Lyophilised, biopolymeric antimicrobial wafers 
can offer a contemporary, user-friendly, self-adhesive and effective approach 
for the management of suppuration and polybacterial contamination in a wide 
range of non-healing wounds.  
 Cohesive, non-friable, porous, disc shape wafers were successfully 
produced with sodium alginate (SA) (18.17 ± 0.70 Pa.s), guar gum (GG) 
(82.21 ± 5.41 Pa.s; 95.87 ± 2.31 Pa), xanthan gum (XG) (2.86 ± 0.12 Pa.s; 
23.61 ± 0.68 Pa), karaya gum (KAG) (12.89 ± 0.93 Pa.s) and an original gel 
consisting of a blend of a synergistic SA-KAG (7.75 ± 0.64 Pa.s; 86.34 ± 5.19 
Pa) (1:1 ratio). Clinical concentrations of the broad spectrum, topical, 
antimicrobial compounds, neomycin sulphate (0.5 % w/v NS), chlorhexidine 
digluconate (0.5 % v/v CHD), povidone iodine (1.0 % v/v PVP-I) and silver 
sulfadiazine (1.0 % w/v SS) were mixed with compatible biopolymers and 
appeared to alter the rheological properties of the biopolymers. Rheological 
analysis of pre-lyophilised gels was undertaken to quantify the flow properties 
of the gels. The necessity of producing sterile wafers was investigated by 
exposing all biopolymer-antimicrobial combinations to 25 and 40 kGy of 
gamma irradiation. Gamma-rays caused total degradation of GG, KAG, SA and 
SA-KAG, while XG appeared to withstand irradiation. 
A novel free standing dissolution raft (FSDR) was designed and used to 
quantify the CHD released from both gels and wafers. CHD released from 
wafers ranged from 3.5 ± 0.01 to 17.4 ± 0.39 %. Gels and wafers released 
CHD in a sustained manner and the release profile of wafers was similar to the 
respective gels, with the exception of GG. Neither gels nor wafers released 
100 % of the incorporated antimicrobial indicating that drug-polymer 
interactions governed the general performance of antimicrobial wafers, in 
terms of adhesion, expansion ratio (ER), inhibition ratio (IR), water uptake 
capacity (WUC) and antimicrobial delivery. Molecular modelling studies 
v 
 
undertaken for KAG-antimicrobial complexes demonstrated an unusual ‘Z-
shape’ geometry for cationic CHD. The charge and geometry of CHD was 
plausibly responsible for the antimicrobial’s entrapment within biopolymeric 
networks.  
The efficacy of antimicrobial wafers was demonstrated in vitro under 
simulated conditions of an exuding wound using modified disc diffusion and an 
original antimicrobial diffusion cell (ADC). All wafers were effective in vitro 
against common chronic wound pathogens of such as methicillin-resistant 
Staphylococcus aureus (MRSA), methicillin-sensitive Staphylococcus aureus 
(MSSA), E. coli and P. aeruginosa. Antimicrobial activity depended on the 
sensitivity of the microorganisms to a specific antimicrobial compound and the 
presence of organic material. Data obtained demonstrated that the presence 
of protein (BSA) in the pseudo-exudate inhibited the antimicrobial activity of 
CHD and PVP-I, while enhancing the antimicrobial activity of SS and NS 
against MRSA.  
The general findings summarised in this thesis conclude that factors 
such as protein content, electrolyte content and pH of exudate play a key role 
in the efficacy of self-adhesive, absorbent formulations intended for the topical 
delivery of antimicrobial compounds to non-healing, infected wounds. Drug-
polymer interactions developed between biopolymers and incorporated 
antimicrobial compounds have a profound effect on the general performance 
of lyophilised antimicrobial wafers. 
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1.1 Prevalence of chronic wounds 
In the United Kingdom (UK), chronic wounds are a considerable burden 
to patients and the National Health Service (NHS). It has been estimated that 
around 200,000 patients suffer from a chronic wound, where the most 
affected population is over the age of 65. In particular, the prevalence of 
venous leg ulcer ranges from 1.2 - 3.2 per 1000 people. The number of 
patients who develop pressure ulcers in the UK is estimated to be around 
400,000 annually. In addition, around 64,000 individuals suffer from an active 
foot ulcer as a common complication of diabetes.  Apart from the fact that 
chronic wounds are a major source of pain and disability for patients, their 
treatment involves a considerable economic budget. The cost absorbed for the 
treatment of patients with chronic wounds has been estimated as £ 2.3 – 3.1 
billions per year, which was around 3 % of the total expenditure on health 
during 2005 - 2006. Future trends in the UK population are likely to lead to a 
significant increase in the incidence of chronic wounds over the next 20 years. 
This increase in numbers of chronic wounds in the UK will be associated mainly 
with a 36 % increase in population aged over 65 and also due to an increase 
of lifestyle diseases, including diabetes, obesity and cardiovascular diseases 
(Posnett and Franks 2008). 
With this in mind, this introductory review, aims to provide background 
information on wound healing and key factors that delay or prevent it. In 
addition, it will discuss the impact of chronic wounds in hospitals, community 
acquired infections and the use and role of antibiotics or antimicrobials. It will 
also focus on existing therapies and topical delivery of therapeutic compounds 
via polymeric biomaterials, where emphasis will be given to the delivery of 
antimicrobial compounds in a sustained fashion. Furthermore, it will discuss 
and provide information on the formulation of novel delivery systems, such as 
lyophilised wafers, and their potential role as contemporary formulations in 
wound management. 
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1.2 The healing process 
    Human skin is a complex and uniquely constructed organ consisting of 
approximately 10 % of the body mass of an average person. The functions of 
healthy skin are vital and include protection, thermoregulation and 
preservation of body fluids. In addition, intact skin plays a key role in 
metabolic functions such as the vitamin D metabolism, neurosensory and 
immunological functions (Church et al. 2006; Williams 2003). For the purposes 
of transdermal and topical drug delivery, the structure and function of human 
skin can be classified into four main parts as presented in Figure 1.1 (Williams 
2003):  
 
 
 
Figure 1.1 A diagrammatical cross-section through human skin (Adapted from 
Williams 2003) 
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 the stratum corneum is the exterior, non-viable epidermal layer. 
 the epidermis is a viable, but non-vascular layer that varies in 
thickness (0.06 - 0.8 mm) over different body surfaces.  
 the dermis is the vital layer of the human skin (3 - 5 mm thick) 
which consists of connective tissue such as collagen fibrils and 
elastine, blood and lymphatic vessels, sebaceous glands, nerve 
endings and sweat glands. The largest component of the dermis 
is the extracellular matrix (ECM), which is composed of a variety 
of polysaccharides and collagen proteins that provide strength, 
elasticity and compressibility to the skin. In addition, this layer is 
capable of regenerating new epithelial cells to replace the lost 
and/or damaged ones and therefore plays an important role in 
wound healing (Schultz et al. 2005). Table 1.1 summarizes the 
main component molecules and their function in the properties of 
the dermal skin and their role in the healing process. 
 the hypodermis  is the inner subcutaneous fat layer which mainly 
provides insulation and physical protection. 
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Table 1.1 Main ECM components and their function (Schultz et al. 2005) 
ECM Components Function 
Collagen type I (80 – 85 %) and 
collagen type III (8 – 11 %) 
Tensile strength and stability 
Elastin 
Elasticity (resilience to recoil after 
stretching) 
Fibronectin (glycoprotein of both 
plasma and tissue) 
Interacts with different types of ECM 
molecules stimulating cell signalling 
and promoting cell attachment, 
migration and differentiation 
Hyaluronic acids (HA) 
HA increases in damaged tissue 
stimulating cytokine production of 
macrophages and promoting 
angiogenesis 
Proteoglycans 
Facilitate the lubrication around and 
between cells. Prolongs the 
inflammatory response by binding 
chemokine molecules on the surface 
of endothelial cells 
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Wounds occur when the integrity of the skin tissue is disrupted. The 
most common causes of tissue trauma which can lead to skin wounds are as 
follows: physical and chemical traumas; pressure sores (vascular 
compromised, arterial, venous or mixed); neuropathic and metabolic diseases 
including diabetes; neoplastic malignancies; immunodeficiency (HIV patients); 
autoimmune and haematologic diseases and skin infections from bacterial, 
fungal and viral organisms (Keast and Orsted 1998).  
Tissue injury triggers a cascade of events between ECM and blood 
molecules aimed at quick repair (Table 1.2). Wound healing is generally 
considered to be a complicated but very orderly process, which includes four 
overlapping phases: haemostasis, inflammation, proliferation and remodelling. 
Each phase is mediated by specific biological markers and has a certain time 
limit during the normal healing process.  Cell-ECM and cell-cell interactions are 
essential at all stages of this process and are mediated by different cytokines 
and growth factors. Each cytokine is responsible for multiple actions at the 
various phases of the healing process and their effect is almost never 
restricted to one single phase of healing (Jurjus et al. 2006). 
Immediately after injury, formation of a fibrin plug (coagulation) 
consisting of platelets, provide an instant protection to the external 
environment and a temporary wound coverage. At the same time, the 
aggregations of platelets within the fibrin plug are also needed for the 
initiation of haemostasis (Falanga 2005). During haemostasis, blood platelets, 
the main mediators of the process, come into contact with collagen and other 
components of the extracellular matrix (Diegelmann and Evans 2004). This 
contact activates the platelets to produce clotting factors, essential growth 
factors such as platelet-derived growth factor (PDGF), transforming growth 
factor beta (TGF-β), insulin-like growth factor 1 (IGF-1), epidermal growth 
factor (EGF) and other cytokines. These growth factors start the wound 
healing cascade by the activation of polymorpho-nuclear leucocytes (PMNLs), 
macrophages and fibroblasts. In addition, the triggered platelets release 
vasoactive amines such as serotonin that increase the microvascular 
permeability. An overlap between haemostasis and inflammation occurs as the 
neutrophils then enter the wound site and phagocytosis (removal of foreign 
materials, bacterial and damaged tissue) begins (Diegelmann and Evans 
2004). This process is completed by the presence of macrophages, which are 
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the most important cells in the late inflammatory (42 - 72 hours) phase, and 
not only by continuing phagocytosis and the production of growth factors such 
as TGF-β and PDGF, but also by acting as key regulatory cells for proliferation, 
producing tumour necrosis factor alpha (TNF-α) and matrix metalloproteinase 
enzymes (MMPs) (Enoch and Price 2004).  
    Proliferation commences at about 72 hours after injury, and is 
characterised by the migration of fibroblasts activated by TGF-β and PDGF. 
Fibroblasts have the main role in the formation and regeneration of ECM.  
They are responsible for the production of the main proteins of ECM such as 
fibronectin, hyaluronan and later on, collagen and proteoglycans. In addition, 
proliferation is completed with collagen synthesis, angiogenesis, granulation 
tissue formation and epithelialisation. Collagen synthesis and granulation 
tissue formation occur as the result of fibroblast migration. Angiogenesis is the 
process during which new blood vessels are formed and occurs during all 
stages of the healing process. The macrophages, in particular, play a major 
role in angiogenesis by releasing a number of angiogenic factors such as TNF-
α, TNF-β, PDGF and fibroblast growth factor beta (FGF-β) (Enoch and Price 
2004). 
The remodelling phase and matrix synthesis start simultaneously with 
the development of granulation tissue and continues over a prolonged period 
of time. The cross-linked collagen results from continuously ongoing collagen 
synthesis and its breakdown as ECM is continually remodelled.  The 
equilibrium between reconstruction and degradation of collagen matrix is 
maintained by specific matrix metalloproteinases (MMPs) and tissue inhibitors 
of metalloproteinases (TIMPs) (Enoch and Price 2004). 
The family of MMPs are produced by many cells during the healing 
process such as macrophages, fibroblasts and endothelial cells (Mannelo and 
Raffetto 2011).  The most important of these MMPs are: MMP-1 (collagenase); 
MMP-2 and MMP-9 (gelatinase); and MMP-3 (stromelysin), which cut intact 
collagen at a single site, degrade partially denatured collagen and multiply 
protein substrate in the ECM, respectively. The role of the MMPs is important 
in the remodelling phase as they facilitate specific interactions between 
collagen molecules that result in the formation of new, strong collagen fibrils 
(Schultz et al. 2005). As remodelling in the wound site continues, MMP activity 
decreases and the activity of tissue inhibitors of metalloproteinases (TIMPs) 
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increases (Enoch and Price 2004). However, this process is carefully controlled 
and equilibrium is maintained by TGF-β, which promotes matrix accumulation 
(Diegelmann and Evans 2004). 
Although most dermal wounds heal in an uncomplicated fashion 
following the aforementioned process, there are a large number of non-healing 
wounds that fall into three major categories: burns, pressure ulcers and 
diabetic ulcers. In these types of wounds, the normal healing has been 
disrupted in more than one stage, where the type, size and depth of the 
wound influences the continuation of healing phases at both cellular and 
molecular levels (Falanga 2005). Despite the differences in origin of non-
healing wounds, these wound types display common clinical features which 
include: the presence of necrotic and unhealthy tissue, excess exudate and 
slough, lack of adequate blood supply, absence of healthy granulation tissue, 
failure of re-epithelialisation, cyclical and persistent pain, recurrent wound 
breakdown and clinical and sub-clinical infection. However, each category also 
presents specific dissimilarities that have to be appreciated for effective 
therapy (Enoch and Price 2004). 
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Table 1.2 Phases of wound healing (Adapted from Falanga 2005). 
Time Phase 
Main 
cell type 
Specific 
event 
 
 
 
 
 
Hours 
 
 
 
 
 
Days 
 
 
 
 
 
Weeks 
to 
months 
Coagulation 
Fibrin plug formation, 
release of growth factors, 
cytokines, hypoxia 
 
 
Inflammation 
Cell recruitment and 
chemotaxis, wound 
debridement 
 
 
Migration/proliferation 
Epidermal resurfacing, 
fibroplasia, angiogenesis, 
ECM deposition, 
contraction 
 
Remodelling 
Scar formation and 
revision, ECM degradation, 
further contraction and 
tensile strength 
Platelets 
 
 
 
Neutrophils, 
monocytes 
 
 
Macrophages 
 
 
Keratinocytes, 
fibroblasts, 
endothelial 
cells 
 
Myofibroblasts 
 
Platelet aggregation and 
release of fibrinogen 
fragments and other 
proinflammatory 
mediators 
 
Selectins slow down 
blood cells and binding 
to integrins – diapedesis 
 
Hemidesmosome 
breakdown – 
keratinocyte migration 
 
 
Cross-talk between 
MMPs, integrin cells, 
cytokines – cell 
migration, ECM 
production 
 
Phenotypic switch to 
myofibroblasts from 
fibroblasts 
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1.3 Pathophysiology of three major categories of non-healing 
wounds 
1.3.1 Burns 
Serious thermal injury resulting from a burn causes total loss of the skin 
surface over large areas of the body. This results in cellular damage, alteration 
of molecular conformation and disruption of intermolecular bonds to the skin 
(Church et al. 2006).  High temperatures applied to the skin surface lead to 
cell membrane dysfunction, protein denaturation and eventually death of the 
cell, with the formation of burn eschar. These dysregulations result in 
increased capillary leakage. Significant thermal injuries are characterised by 
electrolyte imbalance, significant protein loss, circulatory insufficiency and 
immuno-deficiencies that predispose burn patients to infection complications 
(Joneidi-Jafari et al. 2009). The large, damaged and necrotic areas of 
extracellular matrix (ECM), which produce excessive amounts of exudate,  
with considerable loss of intravascular proteins, lead to inefficient cell-matrix 
and intracellular interactions resulting in non-healing wounds (Church et al. 
2006). Under these circumstances the exposed wounded surface (partial or 
full-thickness) provides an ideal environment for bacterial growth.  
   Thermo-resistant pathogens such as Staphylococcus ssp. heavily 
colonise the wound surface within the first 48 hours. The open wounded skin is 
eventually further infected (5 - 7days) with other pathogens that include 
Gram-positive, Gram-negative bacteria and yeast derived from external 
and/or internal sources, where P. aeruginosa is the most common cause of 
burns infection. Chronic burn wounds are considered to be a host niche for 
resistant bacterial strains such as methicillin resistant S. aureus (MRSA), 
increasing the risk of spreading the antibiotic-resistant strains in health care 
units and between health care workers, enhancing cross contamination 
between other patients and exacerbating the treatment of chronic burn 
wounds (Church et al. 2006).  
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1.3.2 Pressure ulcers 
This kind of chronic ulcer is caused by constant pressure, usually over a 
bony prominence that results in destruction to underlying tissue. Elderly 
people between the ages of 70 - 80 years are worst affected. The pressure 
ulcer is characterized by non-blanched erythema of intact skin. However, the 
clinical features of pressure ulcers depend on several characteristics of each 
ulcer such as the ulcer size and depth, the colour and the necrotic tissue mass 
involved. As such a comprehensive assessment of an ulcer includes four 
phases. General symptoms of phases I and II are partial thickness of skin loss 
from epidermis and/or dermis. The ulcer in the IIIrd and the IVth phase is 
characterized by further destruction and tissue devitalisation, or damage of 
muscles and bones. Generally, pressure ulcers promote infections by 
pathogens such as P. aeruginosa, staphylococci and enterroccoci and 
anaerobes such as Clostridium spp., that lead to a prolonged delay of the 
healing process. In addition, further complications such as cellulitis and 
osteomyelitis can occur as a result of bacterial colonization (Dhamarajian and 
Ugalino 2002).  
 
1.3.3 Neuropathic (diabetic) ulcers 
Diabetic ulcers result from a combination of vascular and neurological 
abnormalities of the disease. Continuous studies have shown that diabetic 
patients have an excessive thickness of the basement membrane in the 
muscle. Compared to healthy people, the thickness of the basement 
membrane is up to 2-fold greater in diabetics (Falanga 1993). This 2-fold 
increase of the basement membrane can lead to further complications in 
dermal capillaries and other physiological, microvascular abnormalities, which 
are demonstrated by increased perivascular localization of albumin. Poor blood 
supply results in low oxygen tension (hypoxia), which constitutes a well 
established phenomenon in chronic wounds. Tissue hypoxia results in cell 
death and tissue necrosis. This physio-biochemical change generally leads to 
failure of autonomic nerves and results in neuropathy (Falanga 1993). As a 
result of sensory insufficiency in diabetic patients, breakdown of the skin after 
prolonged pressure occurs and the initiation of trauma leads to ulceration 
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(Falanga 2005).  Ischemia and infection also play a critical role in impaired 
healing of diabetic patients. The combination of factors described above leads 
to polybacterial (aerobes and anaerobes) infection. The additional presence of 
biofilms, generally leads to further complications and failure of the healing 
process (Falanga 2005). 
    All the above examples of chronic wounds contribute to the fact that a 
non-healing injury can be the result of discontinuation of the normal healing 
process at one or more points in the main stages of haemostasis, 
inflammation, proliferation or remodelling. In addition, disruption of the 
healing process results from the coexistence of both endogenous and 
exogenous factors. Endogenous factors include the presence of neuropathy 
and metabolic disease (diabetes), neoplastic malignancies, immunodeficiency, 
autoimmune and/or haematologic diseases, while exogenous factors include 
post-injury consequences such as bacterial, fungal and viral infections. 
Although, endogenous factors can lead to a diverse pathophysiology of chronic 
wounds, which vary from patient to patient, generally the main clinical 
features that result after wounding are similar and include abnormal 
exudation, ischemia (poor blood supply) and bacterial infection. 
 
1.4 Exudate profile of non-healing wounds  
    Exudate production from open wounds is essential for moist wound 
healing. In acute wounds, exudate is an essential fluid in the wound bed, 
containing all the necessary components for healing. Table 1.3 lists the 
components of wound fluid and their function in the healing process. 
Production of excessive wound fluid occurs as a result of uncontrolled 
expression of inflammatory mediators such as histamine and bradykinin. The 
presence of such mediators increase vascular permeability and consequently 
increase the amount of extracellular fluid.  When wounds produce inadequate 
or excessive exudate and infection becomes established, the composition of 
the wound fluid takes an abnormal guise. This will result in problematic 
conditions that ultimately delay or prevent healing and generate clinical 
challenges (White and Cutting 2006). 
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Assessment of abnormal wound fluid, in terms of volume, colour, odour 
and consistency can provide useful information on the status of the wound 
(Cutting 2003).  Although, there is little published information with regards to 
the volume of exudate that chronic wounds produce, non-healing wounds are 
traditionally categorised as light, moderate and heavy exudative (Thomas et 
al. 1996). It has been reported that the amount of fluid produced by non-
healing wounds varies from 3.4 – 10 grams /m2/day, where leg ulcers and 
burns are the most exudative wounds (Thomas 2007). Based on colour and 
odour, exudates have been categorised as bloody, serosanguineous, serous, 
purulent and foul purulent indicating the level of suppuration and the amount 
of pus present (Cutting and White 2002). However, the aforementioned 
characterizations of exudate are subjective, while different types of wounds 
produce various types and volumes of exudates during the non-healing period 
(Cutting 2003).  
Analysis of wound fluid with regards to biochemical and cellular 
examination can provide useful information and a complete picture of the non-
healing environment. Exudate produced from non-healing wounds  is, in its 
essence, a modified and anomalous serum which contains electrolytes (e.g. 
Na+, K+, Ca2+, Cl-), lactate, urea, glucose and high protein content with a 
specific gravity greater than 1.020 (White and Cutting 2006, Cutting 2003). 
Estimation of the protein level in wound fluid has shown a total amount higher 
than 40 g/l, of which approximately 60 % is albumin (Clough and Noble 
2003). In non- healing wounds, in particular during inflammation, the exudate 
presents an environment with an increased number of neutrophil and 
leukocyte counts, which result in production of proteases and oxidants that 
degrade the ECM and inhibit cell migration, hence prevent wound closure 
(Mustoe 2004). In vitro studies have shown that the elevated levels of MMPs 
and serine proteases degrade growth factors and fibronectin (essential 
mediators of the remodelling phase) (Enoch and Price 2004).  Recently, 
Rayment et al. (2008) have reported that there is an excessive protease 
activity in the exudate of chronic wounds compared with both human serum 
and acute wound fluids. The latter authors have also shown that MMP-9 was 
the predominant protease in chronic wounds that was correlated with a 
clinically worse wound. In addition, TIMPs (TIMP-1 in particular) levels were 
lower in chronic wounds than in healing wounds (Bullen et al. 1995). 
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Consequently, the lost balance between proteolytic enzymes and their 
inhibitors contributes to failure of new tissue deposition, preventing healing in 
open wounds. 
Table 1.3 Constituents of exudate and their function in wound healing 
(Adapted from White and Cutting 2006) 
Components Function 
Fibrin Clotting 
Platelets Clotting 
Polymorpho-nuclear 
neutrophils (PMNs) 
Immune defence, production of growth 
factors 
Lymphocyte Immune defence 
Macrophage 
Immune defence, production of growth 
factors 
Plasma proteins, albumin, 
globulin, fibrinogen 
Maintain osmotic pressure, immunity, 
transport of macromolecules 
Lactic acid 
Product of cellular metabolism and indicating 
biochemical hypoxia 
Glucose Cellular energy source 
Inorganic salts pH buffering of hydrogen ions in solution 
Growth factors Protein controlling specific healing activities 
Wound debris/dead cells No function 
Proteolytic enzymes 
Enzymes that degrade protein, including 
serine, cystine, aspartic protease and MMPs 
Tissue inhibitors of 
metalloproteinases (TIMPs) 
Controlled inhibition of MMPs 
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 1.5 Ischemia  
Ischemia is considered another serious contributing factor to the non-
healing process. A deficiency in blood supply prevents the progress of healing 
due to continued tissue injury. From a clinical point of view, ischemia is 
usually associated with aggravating factors such as diabetes, malnutrition and 
age (Schäffer et al. 2002). Most examples of chronic wounds are associated 
with elderly people suffering from diabetes, pressure and arterial ulcers. The 
cellular characteristics of non-healing wounds generally include low mitotic 
activity, impaired fibroblast proliferation and migration, lack of response of 
fibroblasts to growth factors in conjunction with impaired venous arterial blood 
flow (Enoch and Price 2004). These cellular features of chronic wounds are 
further impaired with advancing age. Aged skin presents essential differences 
to young skin and appears to have decrease mobility of fibroblasts, reduced 
turnover of keratinocytes to epidermis and low response to stimulatory growth 
factors. This impaired cellular activity leads to reduced rates of formation of 
granulation tissue and epithelisation, hence preventing or delaying healing. 
Consequently, elderly patients suffering from non-healing ulcers present 
another clinical challenge in the treatment of chronic wounds (Enoch and Price 
2004).  
 
1.6 Bacterial infection  
As previously mentioned, the condition of injured, non-healing skin 
promotes bacterial contamination within the first 24 hours. The sources of 
contamination arise from the patient’s surrounding skin, gastrointestinal and 
respiratory flora (internal sources), as well as from the local hospital 
environment and health care workers (external sources) (Church et al. 2006). 
As a consequence, the microbiological profile of a wound bed often presents a 
complex polymicrobial environment. In addition, the protein rich environment 
provided by the excessive production of wound fluids serves as a suitable 
niche for bacterial contamination and growth in the wound bed.  
   The most predominant bacterial species are Staphylococcus aureus and 
Staphylococcus epidermidis, which colonize wounds within the first hours. 
Pseudemonas aeruginosa, Escherichia coli, Streptococcus spp and other Gram-
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positive and Gram-negative aerobes and anaerobes, will further colonize the 
injured, exposed tissue after an average of 4 - 7 days. Recent studies using 
molecular techniques have emphasised the complex microbiological flora of 
non-healing wounds (Howell-Jones et al. 2005). A longitudinal study 
performed in patients with persisting venous leg ulcers demonstrated that the 
most common bacteria found were S. aureus, Enterococcus faecalis, P. 
aeruginosa, coagulase-negative staphylococci, Proteus species and anaerobic 
bacteria (Gjødsbøl et al. 2006). Tables 1.4 (a) and (b) list all the pathogens 
that have been found in chronic wounds.  
 
Table 1.4 (a) Aerobic and facultative aerobic isolates from chronic wounds 
with varied aetiology (Adapted from Bowler et al. 2001) 
Aerobic and facultative bacteria 
Gram-positives Gram-negatives 
*Coagulase-negative staphylococci              *Enterobacter cloacae 
*Staphylococcus aureus                             Enterobacter aerogenes 
Beta-haemolytic Streptococcus (group G) *Escherichia coli 
*Streptococcus spp. (faecal)                          *Klebsiella pneumoniae 
*Streptococcus spp. (viridans)                     *Klebsiella oxytoca 
*Acinetobacter calcoaceticus Serratia liquefaciens 
Corynebacterium xerosis *Pseudomonas aeruginosa 
*Corynebacterium spp.                               *Proteus mirabilis 
Micrococcus spp.                                        Proteus vulgaris 
  Citrobacter freundii 
  Morganella morganii 
  Sphingobacterium multivorum 
 
(* Isolates also present in acute wounds) 
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Table 1.4 (b) Anaerobic isolates from chronic wounds with varied aetiology 
(Adapted from Bowler et al. 2001) 
Anaerobic bacteria 
Gram-positives Gram-negatives 
Streptococcus intermedius *Gram-negative pigmented bacillus 
*Clostridium perfringens *Prevotella oralis 
*Clostridium clostridioforme Prevotella oris 
*Clostridium cadaveris Prevotella bivia 
*Clostridium histolyticum Prevotella buccae 
Clostridium ramosum *Prevotella corporis 
*Clostridium sporogenes Prevotella melaninogenica 
Clostridium difficile *Bacteroides fragilis 
*Peptostreptococcus asaccharolyticus *Bacteroides ureolyticus 
*Peptostreptococcus anaerobius *Bacterodies uniformis 
*Peptostreptococcus magnus Bacteroides stercoris 
*Peptostreptococcus micros Bacteroides capillosus 
*Peptostreptococcus prevotii Bacteroides thetaiotaomicron 
Peptostreptococcus indolicus Bacteroides caccae 
*Peptostreptococcus sp. Fusobacterium necrophorum 
*Propionibacterium acnes *Porphyromonas asaccharolytica 
Eubacterium limosum   
 
(* Isolates also present in acute wounds)
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The presence of pathogens in chronic wounds has been traditionally 
classified in four levels: contamination, colonization, critical colonization and 
wound infection (Collier 2004). Only, recently, the term ‘wound infection’ was 
subcategorized into local and systemic infection (Healy and Freedman 2007). 
A variety of techniques such as swab culture and tissue cultures, obtained 
from biopsies of the chronic wound environment, have been used in order to 
estimate the number of pathogens responsible for infection. Research studies 
have demonstrated a correlation of the number of bacteria found between the 
two methods used, and experimentally have shown that a bacterial density of 
1×105 colony forming units (cfu)/g tissue is equivalent to 1×103 cfu/ml 
(Bowler et al. 2001). This bacterial density has been generally defined as an 
infective population (Cutting 2003). However, in a poly-contaminated niche 
such as a chronic wound bed, the established infection would depend on the 
expressed pathogenicity of each bacterium rather than density of 
microorganisms, where the interaction between the host and the pathogens 
would better classify the levels of wound infection. For instance, for an 
organism such as haemolytic Streptococcus, a lower tolerance is accepted due 
to its high virulence (Kirketerp-Møller et al. 2011). 
   Concurrently, wound care research studies have emphasized the ability 
of pathogens to harvest the sustainable nutrition provided from the inflamed 
wound bed in order to produce and surround themselves in a protective 
polysaccharide cover defined as a biofilm (Wolcott et al. 2008).  James et al. 
(2008) have investigated the microbiological profile of 50 chronic and 16 acute 
wounds and demonstrated that 60 % of chronic wounds contain bacteria in the 
composite state of biofilms. As such, investigators have accentuated the 
critical role that biofilms may play in persistence of chronicity of infection, and 
prevention of healing (Kirketerp-Møller et al. 2011).  Additionally, it has been 
shown that the host response is often not effective against biofilms. It has 
been suggested that the community of bacteria assembled in biofilms are able 
to release planktonic seeds of bacteria, which confuse the host immune 
response permitting biofilms to withstand phagocytosis (Wolcott et al. 2008). 
This mechanism of biofilms, however, is not fully understood and further 
investigations are being undertaken. Another major concern in the 
management of infected wounds is the fact that bacteria in a composite state 
such as biofilms become more tolerant and consequently resistant to 
                                                       
19 
 
antimicrobial therapies when compared with their unicellular existence 
(Widgerow 2008). For example, both mupirocin cream and the triple antibiotic 
ointment containing cetrimide, bacitracin and polymyxin B sulphate were 
effective in decreasing planktonic S. aureus cells, while the same applications 
had reduced antimicrobial activity against S. aureus biofilms (Widgerow 2008). 
    The role of bacteria in non-healing wounds has detrimental effects and 
bacterial infection is undoubtedly considered to be a common reason for 
impaired wound healing and chronicity. In addition, the complex poly-
microbial environment of the infected wound bed, with regards to density, 
diversity, virulence and biofilm formation, present a major challenge for the 
treatment and therapy of infected chronic wounds. 
 
1.7 Chronic wounds in both hospital and community acquired 
MRSA  
Chronic wounds have an important impact on patients’ health and their 
quality of life. This results from the fact that non-healing wounds are a major 
source of pain, disability, psychiatric morbidity and even mortality for patients 
(Franks and Moffat 1999). Apart from the fact that the infected and non-
healing profile of wounds represent a significant burden to both patients and 
healthcare workers, their hospitalisation appear to be an important risk factor 
in the spread and/or acquisition of pathogens, including antibiotic resistant 
organisms such as  methicillin resistant S. aureus (MRSA) (Weber et al. 1999).  
The Nosocomial Infection National Surveillance Service (NINSS) has 
reported that in 2002 the prevalence of hospital acquired infections (HAI) 
related to surgical wounds was 10 % (Collier 2004).  The Royal College of 
Physicians of Edinburgh (RCPE) has reported that health care workers are 
passive contributors to the spread of MRSA. Cross contamination amongst 
patients may occur by the transfer of organisms via hands and lab coat 
sleeves. Also, poor hand hygiene can spread contamination in the environment 
(equipment, dissemination while bed-making etc). In addition, healthcare 
workers may also act as active distributors of MRSA if they themselves are 
carriers of the pathogen (Baird et al. 2006). 
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Bearing this in mind, it’s not difficult to believe that the majority of 
chronic wounds are found to be colonised with multi-drug resistant organisms, 
including MRSA (Landis 2008). The main risk factor that predisposes 
acquisition of MRSA is the prolonged hospitalisation of patients suffering from 
a non-healing wound and MRSA has been found to be the most prevalent 
pathogen in UK hospitals and worldwide (Elston and Barlow 2009). In addition, 
it has been reported that MRSA is the most common pathogen of hospitalised 
patients in emergency departments with skin and soft tissue infections (Frazee 
et al. 2005). Other factors such as previous antibiotic misuse and transfer 
between hospital facilities may also increase the likelihood of acquiring multi-
drug resistant infection (Landis 2008).  
Recently, concerns have also been raised with regards to the prevalence 
of community associated MRSA infection (CA-MRSA), as an increased number 
of wounds are infected with CA-MRSA strains (Landis 2008). Genetic screening 
and antimicrobial susceptibility tests have demonstrated that CA-MRSA strains 
are different from MRSA strains in hospitals, with regards to both genetic and 
phenotypic profiles. Although CA-MRSA strains are found to be susceptible to a 
broader range of anti-staphylococcus drugs, they appear to be more virulent 
than the hospital associated MRSA strains (Frazee et al. 2005). It has been 
reported that the acquisition of CA-MRSA infections is mainly associated with 
increased transmission and hospitalisation of patients suffering from skin and 
soft tissue infections. Moreover, CA-MRSA strains are rapidly spreading 
worldwide. In the UK, although infection with such strains have been rarely 
reported, the prevalence of CA-MRSA infections is showing an increasing trend 
(Elston and Barlow 2009). The prevalence of resistant strains in emergency 
departments in the USA, where CA-MRSA stains were found to be the 
dominant isolates, have concerned research communities, who recommend a 
change in the empirical way that skin and soft tissue infections are treated 
(Elston and Barlow 2009). 
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1.8 Control of bacterial bio-burden (systemic or topical 
treatment) 
There is a ubiquitous debate regarding how an infected, non-healing 
wound should be treated, what therapeutic agents should be used, and 
whether systemic or topical antimicrobial therapy should be applied. As 
previously described, the presence of bacteria in chronic wounds is categorized 
as contamination, colonization, critical colonization and wound infection (local 
and systemic). This classification of wound bioburden was mainly established 
as a guideline for diagnostic purposes and determination of suitable 
treatments, however, this classification is arguable and remains controversial 
with regards to the density of pathogens present in an infected, non-healing 
wound.  
Established infection is clinically defined as the situation where the non-
healing wound appears discoloured, presents friable granulation tissue, 
produces non-purulent exudate and abnormally foul odour (Lipsky and Hoey 
2009). Under these circumstances, it has been suggested that clinically 
infected wounds could benefit from systemic antibiotic treatment, especially in 
cases of advanced deeper tissue infections.  However, it is well known, that 
antibiotics are compounds that usually kill or inhibit one or very few specific 
groups of pathogens, in other words they demonstrate a narrow spectrum of 
activity. Moreover, they have been found to have decreased activity against 
the polysaccharide shield of biofilms formed around bacterial pathogens and 
consequently lose their effectiveness. As discoloured tissue is related to poor 
blood circulation and ischemic conditions, their efficacy at the infected wound 
site is questionable. 
 
1.9 Debridement 
Traditionally, prior to the application of any suitable therapy, 
debridement is one of the principle stages in the treatment of non-healing 
wounds. It has been suggested that all non-healing wounds can only benefit 
from effective debridement, since removing devitalised tissue, suppuration and 
foreign materials results in the reduction of bacterial load (Bowler et al. 2001). 
In addition, debridement is considered to play an important role in cleaning 
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the wound bed from bacterial biofilms while revealing the healthy tissue 
required for wound healing (Kirketerp-Møller et al. 2011).  
There are several available methods for debridement, which include: 
surgical (performed with scissors, scalpels and recently lasers); autolytic 
(performed with occlusive and semi-occlusive dressings, which soften the 
eschar and allow the proteolytic enzymes within the wound fluid to digest the 
devitalised tissue); mechanical (performed with irrigation fluids baths and 
removal of tissue from wet to dry dressings); enzymatic (include the use of 
topical enzymes, such as collagenase, papain and urea, to digest necrotic 
tissue); and biological debridement (include the use of maggots) (Ayello and 
Cuddigan 2004).  
A clinical guide to debridement decisions suggests that surgical and 
enzymatic debridement could be used for wounds that present all levels of 
bacterial loads, particularly in advanced tissue sepsis. Autolytic and 
mechanical debridement could be used with caution in wounds with less 
bacterial load, before the stage of local extended infection (Ayello and 
Cuddigan 2004). The use of maggot larvae in wound debridement is however, 
controversial. Although this method of debridement, involves mainly the 
secretion of proteolytic enzymes and ammonia in conjunction with 
antimicrobial substances from maggots (Chan et al. 2007), there use is found 
to be ineffective in wounds heavily colonised with P. aeruginosa. Additionally, 
recent experimental research with maggots has shown that these, at least 
initially, benefit biofilm formation for S. aureus and P. aeruginosa (Kirketerp-
Møller et al. 2011).  
 
1.10 The role of topical antimicrobials  
Non-healing, chronic wounds have been treated topically since ancient 
times. Potential advantages that topical approaches provide include: adequate 
and sustained concentrations of therapeutic agent at the site of infection, 
avoidance of using systemic antibiotics that usually lead to development of 
antibiotic resistance strains and easy application in outpatients (Lipsky and 
Hoey 2009). Nowadays, topical antimicrobial compounds are grouped as 
antiseptics and antibiotics. Replacement of systemic antibiotics with topical 
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broad spectrum antimicrobials (mostly antiseptics), in the absence of 
advanced cellulitis, bacteraemia and fever is thought to offer the most useful 
first line of treatment (Bowler et al. 2001).  Antiseptics are antimicrobial 
compounds usually limited to external application which possess a broad 
spectrum of activity against pathogens and often demonstrate cytotoxicity 
against main cell mediators of the healing process.  
The most effective and widely used topical antimicrobials include 
chlorhexidine, ionic silver and its sulfadiazine salt and iodophores (iodine-
carriers). These antimicrobials have demonstrated rapid bactericidal properties 
against a wide range of Gram-positive and Gram-negative bacteria, fungi and 
even viruses and cases of developed resistance by pathogens are less evident 
than for topical antibiotics (Lipsky and Hoey 2009). It has been suggested that 
the exceptional antimicrobial properties of these compounds are likely due to 
multi-targeted mechanisms of action against bacteria. For example, the 
bactericidal activity of chlorhexidine (Figure 1.2) is mediated by the ability of 
this cationic compound to damage the outer cell layers as well as cytoplasmic 
targets of the microorganism, inducing leakage of cellular components. 
Despite the fast bactericidal activity of chlorhexidine, cases of acquired 
resistance for MRSA have been documented (Cooper 2004). 
 
Figure 1.2 Chemical structure of chlorhexidine (Adapted from PubChem). 
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Antimicrobial properties of silver have been reported for over a century. 
Usually this compound is used as ionic silver, silver sulfadiazine (Figure 1.3) 
and/or silver nitrate (White and Cooper 2005). Although this antimicrobial 
compound has been widely used, its mechanism of action is still not well 
defined. It has been suggested that silver ions have an affinity for thiol groups 
and also interact with carboxylates, phosphates, hydroxyls, imidazoles, indoles 
and amines. As such, silver ions bind to proteins and nucleic acids, thus 
inducing structural alterations in bacterial cell walls, membranes and nucleic 
acids. Hence, its dynamic antimicrobial nature is likely due to multi-targeted 
antimicrobial events, which appear to simultaneously cause damage to 
bacterial cells and affect the viability of a wide variety of pathogens (Cooper 
2004). Despite the dynamic antimicrobial activity of silver, resistance to this 
antimicrobial has been reported from both clinical and environmental isolates 
(Woods et al. 2009).  
 
 
 
Figure 1.3 Chemical structure of silver sulfadiazine (Adapted from PubChem) 
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Iodine has been extensively used for over 150 years either as an alcohol 
solution of potassium iodide salt or incorporated in iodophores such as 
polyvinylpyrrolidone-iodine complex (PVP-I) (Figure 1.4) and cadexomer 
iodine formulations. In vitro experiments have shown broad bactericidal 
properties against bacteria, fungi, protozoa and viruses (Cooper 2004) and 
despite its prolonged application, only one case of resistant MRSA has been 
clinically reported (Mycock 1985). As with silver, iodine’s mechanism of action 
is not yet fully understood. It has been suggested that iodine may possess 
multiple mechanisms of action, which can induce multiple lethal cellular effects 
(Cooper 2004). These modes of action include the ability of iodine to bind to 
key groups of proteins (e.g. free sulphur amino acids, cysteine and 
methionine), nucleotides (adenine, cytosine and guanine) and fatty acids 
(McDonnell and Russell 1999). 
 
 
Figure 1.4 Chemical structure of polyvinylpyrrolidone-iodine complex 
(Adapted from International Speciality Products 2004). 
 
 
 
 
                                                       
26 
 
In vitro, topical antimicrobials, in particular antiseptics, have 
demonstrated broad and rapid bactericidal properties against a wide variety of 
microorganisms. However, a considerable limitation of such compounds is that 
their aggressive cidal properties may also be toxic to different mammalian 
cells which construct the skin tissue.  A significant amount of in vitro research 
has shown that most of these agents are highly cytotoxic to different cell lines. 
For example, silver has been shown to be highly toxic to both keratinocytes 
and fibroblasts in monolayer cultures (Poon and Burd 2004). Giannelli et al. 
(2008) showed that chlorhexidine digluconate demonstrates different degrees 
of cytotoxicity as tested on osteoblastic, endothelial and fibroblastic cell lines. 
Povidone iodine solutions (Betaisodona and Braunol) have also demonstrated 
an ability to decrease cell viability for keratinocytes and fibroblasts (Hirsch et 
al. 2010).  
Other in vitro studies have tried to link the cytotoxic potential of topical 
antimicrobials, in respect to their antimicrobial effect against common chronic 
wound pathogens, in order to establish a clinical, therapeutic and less toxic 
concentration of topical antimicrobial (Kautzky et al. 1996; Hirsch et al. 2010). 
However, the in vitro results, with regards the role of antiseptics in infection 
control and promotion of healing in chronic wounds, remains controversial 
when compared to clinical trials. There are a significant number of published 
works referring to the therapeutic role of antiseptics in infection control and 
closure of non-healing wounds in humans. For example, a clinical investigation 
of the antimicrobial effect and healing rates of chronic leg ulcers treated with 
chlorhexidine digluconate, silver sulfadiazine or PVP-I, demonstrated that all 
three antimicrobials decreased the microbial load. Silver sulfadiazine and 
chlorhexidine digluconate caused slight improvements in the healing rate of 
leg ulcers, altering the microvessels and dendrocyte population. In addition, 
PVP-I significantly increased the healing rate and induced less histological 
changes (Fumal et al. 2002). Another study has reported that 1 % silver 
sulfadiazine (Flamazine) showed a significant improvement in antimicrobial 
activity in treatment of burn patients compared to povidone iodine (Hadjiiski 
and Lesseva 1999). 
Scientists have indicated that despite the fact that antiseptic agents 
have been applied to treat infected wounds for centuries, their proper role in 
wound healing remain unclear. The contradictory and confusing evidence with 
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regards to the efficacy of antiseptics in wound management originates from 
different sources. Firstly, the difficulty in realistically modelling non-healing 
wounds in vitro or in wounded animal models is a major disadvantage. 
Secondly, the lack of specific in vitro standardised tests and methods for the 
evaluation of the efficacy of topical therapies (Lipsky and Hoey 2009). Many 
factors such as temperature, bacterial species, concentration, number of 
organisms and the presence of organic material and electrolytes may influence 
the results obtained (Cooper 2004). Thirdly, there is insufficient evidence 
provided from limited and incomparable clinical trials (Lipsky and Hoey 2009). 
 
1.11 The role of growth factors in the treatment of non-healing 
wounds 
Growth factors are the essential mediators of the healing process, as 
they are directly involved in the active physiological processes of haemostasis, 
inflammation, proliferation and remodelling. Molecules such as epidermal 
growth factor (EFG), platelet-derived growth factor (PDGF), transforming 
growth factor beta (TGF-β) and fibroblast growth factor (FGF) have been 
considered as the most important mediators of the healing process (Sullivan et 
al. 2001; Pierce and Mustoe 1995). It is not known whether the topical 
application of specific growth factors or a mixture of growth factors would 
facilitate healing. 
Several in vivo studies, involving wounded small animals, have 
produced positive results. For example, investigations by Lee and colleagues 
(2005) have showed that in vivo wound healing accelerated when EGF was 
applied in combination with silver sulfadiazine. In addition, EFG has shown 
clear stimulation of epidermal and dermal repair in an animal wound model 
(Lee et al. 2005). The role of TGF-β was tested in small mammals, but results 
obtained were contradictory. Although TGF-β is a potent inducer of fibronectin 
and inhibitor of MMPs, experiments with wounded animal models 
demonstrated that its effect depends on the dose applied. This growth factor 
could also act as an inhibitor of cell growth when applied in increased doses. 
As such, further in vivo and eventually clinical investigations are required to 
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elucidate its role in treatment of non-healing wounds (Pierce and Mustoe 
1995). 
PDGF, isolated from human platelets, mediates many processes 
required for tissue repair including chemotaxis (neutrophils, macrophage, 
monocytes and fibroblasts), proliferation, angiogenesis and wound 
remodelling.  Preclinical studies have been conducted in patients suffering 
from diabetic foot ulcers and pressure sores, where PDGF was applied daily to 
non-healing wounds for 28 days. The results obtained demonstrated an 
accelerated rate of healing, however this was not significant compared to the 
control groups (Pierce and Mustoe 1995). Further preclinical studies of PDGF 
delivered via a gel formulation to diabetic foot ulcers, daily for 20 weeks, 
showed significant healing and complete ulcer closure compared to the 
untreated patients (Pierce and Mustoe 1995).  These encouraging results 
obtained from preclinical studies, led a few years later to a definitive clinical 
trial using Regranex (PDGF gel, Ortho-McNeil Pharmaceutical, Inc, Raritain, 
NJ). The results generated from over 1000 patients with diabetic ulcers, 
revealed that only a 10 % increase in total wound closure was achieved 
(Mustoe 2005). Although, this low percentage in wound closure could be 
considered as a failure of the PDGF product in treating diabetic ulcers, the 
latter author considered it debatable that other critical factors, such as 
debridement and elimination of ischemia reperfusion injury, probably 
influenced the final results (Mustoe 2005). Consequently, the role of topically 
applied growth factors in wound healing is not totally understood and further 
investigations are required to elucidate their multi-functional roles as 
mediators of the healing process. 
 
1.12 Other popular and supplementary treatments  
1.12.1 Honey 
Topical antimicrobials and growth factors are undoubtedly the main 
compounds whose roles have been extensively discussed and investigated in 
chronic wound treatment. However, in the last decade, there has been an 
increased interest in the antimicrobial and therapeutic properties of honey. 
Curative properties of honey vary with floral sources, origin and processing 
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(Molan 2001). Antimicrobial properties of honey are associated with high 
osmolarity, release of hydrogen peroxide and methylglyoxal, cationic 
antimicrobial peptide (bee-defencin-1), phytochemical components such as 
flavonoids and antioxidants (Kwakman et al. 2010; Molan 2001; Cushnie and 
Lamb 2005).  
  In vitro research has demonstrated that honey possesses remarkable 
antimicrobial properties against a wide range of Gram-positive and Gram-
negative bacteria, such as S. aureus and P. aeruginosa, including antibiotic 
resistant strains such as MRSA and vancomycin-resistant enterococci (VRE) 
(Molan 2001). In addition, dilutions of 2 - 4 % of pasture honey and manuka 
honey have shown to inhibit the growth of 58 coagulase-positives S. aureus 
strains isolated from patients with infected wounds (Cooper et al. 1999). 
Recently, it was discovered that in particular, manuka honey and Sird honey 
from Yemen, demonstrated in vitro bacteriocidal properties against biofilms of 
S. aureus and P. aeruginosa (Alandejani et al. 2009). 
Although honey’s antimicrobial mechanism of action has not been 
determined yet, its therapeutic role in accelerating healing is thought to be 
related to its anti-inflammatory properties. Similarly, in vitro studies were 
undertaken using immuno-competent monocytic MM6 cell lines treated with 
different honey solutions. Results obtained indicated that all honey types 
significantly stimulated the release of inflammatory cytokines, such as TFN-α, 
IL-β and IL-6, when compared to untreated and artificial honey-treated cells 
(Tonks et al. 2003). The healing properties of honey were further supported 
by in vivo studies undertaken on wounded animal models, where the 
application of 5 ml pure honey improved epithelialisation and tissue strength, 
indicating acceleration of healing (Oryan and Zaker 1998). 
A recent review aimed to evaluate the therapeutic effect of honey 
applied on the mixed aetiology of both acute and chronic wounds (Jull et al. 
2009). The author’s conclusion from the data analysis of 19 randomised and 
quasi-randomised trials (n = 2,554), summarized that “honey may improve 
healing time in mild to moderate superficial and partial thickness burns 
compared with some conventional dressings”. However, “honey dressings as 
an adjuvant to compression do not significantly increase leg ulcer healing at 
12 weeks”, where additionally, adverse side effects such as pain, deterioration 
of ulcer and increased exudate were observed (Jull et al. 2009; Jull et al. 
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2008). In conclusion, these results indicate that the remedial properties of 
honey and its role in wound healing will continue to be of interest. 
 
1.12.2 Vitamin and mineral supplements 
Vitamins and minerals, such as A, C, E, zinc and cooper, are considered 
adjuvant compounds in treatment of non-healing wounds. Vitamins are 
actively involved at different stages of cellular activities including tissue 
development. For example, the role of vitamin A is associated with 
epithelisation, collagen synthesis, fibroplasia, angiogenesis and rapid 
inflammatory response (Keller and Fenske 1998).  
The active form of vitamin C (L-ascorbic acid) is one of the most 
important compounds in biological processes and cellular activities. Ascorbic 
acid has a pivotal role in wound healing as this compound acts as a co-factor 
for several enzymes during collagen synthesis and other intracellular activities 
of matrix tissue, including bones, capillary walls and connective tissues (Keller 
and Fenske 1998, Boateng et al. 2007). In addition, ascorbic acid possesses 
anti-oxidative activities by quenching free radicals and also acts as a 
regenerator of vitamin E from its radical form (Keller and Fenske 1998). 
Free D-alpha tocopherol is the main active fraction of vitamin E. The 
role of this compound is associated with antioxidant and anti-inflammatory 
activity, angiogenesis and/or reduction of scars (Boateng et al. 2007). 
However, effects of vitamin E tested in pre-clinical and clinical trials have been 
controversial and usually associated with adverse local effects such as papular 
and follicular dermatitis (Keller and Fenske 1998). Thus, the aid of this vitamin 
in improving healing by topical application requires further investigation 
(MacKey and Miller 2003). 
Zinc is an important trace mineral, which is required for approximately 
300 enzymatic activities during tissue repair including DNA synthesis, cell 
division and protein synthesis. Although zinc deficiency is usually associated 
with poor wound healing and decreased collagen deposition in wounded tissue, 
there is insufficient clinical data to support the supplementary role of this 
mineral in improved wound healing. Further investigation is needed to confirm 
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the efficacy of zinc supplements in the healing process (MacKey and Miller 
2003). 
 
1.13 Wound management 
General principles of local wound management apply in a wide variety 
of chronic wounds.  Management of non-healing wounds can be characterised 
as a multi-operational process, which includes debridement, control of 
exudate, inhibition of infection, optimal conditions of moisture, temperature, 
oxygen, blood circulation and protection (Werdin et al. 2009). Based on these 
principles of wound management, the ideal properties of a topical application 
were determined. The ideal dressing could be characterised as the one which 
could provide continued and consistent delivery and activity of therapeutic 
compounds over the entire surface of the wound; absorbs and restrains the 
exudate, maintaining moisture balance in the wound bed; conformable and 
comfortable, providing thermo-insulation; protects the wounded skin from 
external contamination and foreign materials while being non-adherent, non-
toxic, oxygen permeable and pain-free on removal (Werdin et al. 2009). 
 
1.14 Existing topical applications  
Traditionally, therapeutic compounds used for topical applications have 
been prepared as liquid formulations, such as solutions, suspensions and/or 
emulsions or semi-solid preparations such as ointments (occlusive) and 
creams (less occlusive) (Boateng et al. 2007). Generally, such preparations 
were incorporated into cotton wool bandages and gauzes, in order to inhibit 
infection and protect the open wound from the external environment. This way 
of wound care is also referred as traditional wound management. Traditional 
wound management relies on the application of non-extensible, extensible, 
adhesive/cohesive, tubular and medicated paste bandages (Thomas 1990). 
Although the majority of these categories of dressing are still in use, mainly as 
secondary dressings, the application of such materials, especially as primary 
dressings, are associated with major disadvantages. 
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Firstly, non-extensible bandages were found to be not particularly 
comfortable and difficult to apply correctly (Thomas 1990).  Secondly, the 
materials from which they were made were unsuitable in providing a moist 
wound bed as the outer surface gets easily moistened by wound fluids. The 
application of a gauze dressing was associated with adhesion at the wound site 
and their use was associated with painful removal and patient discomfort 
(Boatang et al. 2007). There was also the necessity of incorporating 
therapeutic and/or antimicrobial compounds in a practical and comfortable 
formulation that had a suitably long residence time in the wound bed. Liquid 
or semi-liquid dosage forms had a limited residence time in the wound bed, 
particularly when wounds produced significant amount of fluids.  
The use of novel, natural, hydrophilic and non-toxic polymeric materials 
was associated with innovations in administering therapeutic compounds in 
order to achieve an effective therapy with minimal toxicity. The concept of 
continued and controlled rates of delivery of therapeutic compounds, also 
known as sustained drug delivery, was initially based on the hydration of 
polymers and their ability to retain absorbed liquids and consequently swell 
(swelling behaviour). During this process, the incorporated compounds were 
released either by diffusion or degradation of the polymeric vehicle (Boateng 
et al. 2007). The use of polymeric formulations on broken wound tissue 
offered additional advantages with regard to maintaining and providing 
optimal healing conditions and concentrations of topical therapeutic agents.  
The properties of wound dressings depend on the materials used. 
Advantages and/or disadvantages are discussed, and categorised according to 
the materials from which modern dressings are prepared. Table 1.5 
summarizes the main characteristics of the most applicable and well known 
modern dressings based on exudate-holding capacity.  
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Table 1.5 Main characteristic of some modern dressings based on their ability 
to handle exudate (Adapted from Ayello and Cuddigan 2004) 
None Low Moderate Heavy 
 
Films 
Impermeable to water and microorganisms  
Used for wounds with little exudate  
Available as adhesive and non-adhesive  
Long wear times 
 
Hydrogels 
High water content 
Add moisture to wounds, used for dry or low exudative wounds  
Cooling and smoothing effect; good for burn and painful wounds 
Available as amorphous gels and sheets 
Need a secondary dressing to hold in place  
 
                         Hydrocolloids 
                         Maintain moist environment in partial thickness wounds 
                        Used in wounds with low or moderate amounts of exudate 
                        Flexible, mouldable, some are non-adhesive 
                        Available in many shapes and sizes 
                        Long wear times, 2-7 days 
 
                                     Alginates and Foams 
                                                 Absorb large amount of exudate 
                                        Provide thermal insulation 
                                     Used in infected wounds 
                                         Need a secondary dressing 
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1.14.1 Alginate dressings 
Alginic acid was discovered in 1882 by Stanford during extraction 
experiments with kelp seaweeds in Scotland (Blaine 1946).  Since then, the 
utilisation of haemostatic and non-toxic properties of alginate and its sodium 
and/or calcium salts in preparation of surgical dressings (Blaine 1946) initiated 
a new epoch of wound management. Additional conspicuous advantages of 
alginates such as moisture-holding capacity, biodegradability and compatibility 
with several antibacterial substances were originally observed by Blaine 
(1946). These favourable properties of alginates were embraced by the 
application of alginate dressings in a wide variety of wound types. In 
particular, alginates were most appreciated for their high absorbance capacity 
and their rapid and harmless transformation into gels when contacting wound 
fluids (Boateng et al. 2007; Agren 1996). The transformation of alginate fibres 
into gel occur via an exchange reaction between calcium ions present in 
wound exudate and sodium ions present in alginate fibres, which result in a 
crosslinked  sodium/calcium degradable gel (Boateng et al. 2007; Agren 
1996). Thus, the application of alginate materials has been more suitable in 
moderate/heavy exuding wounds rather than in dry or low exuding ones. 
Alginate dressings available in the UK market include antimicrobial free 
formulations such as ActiHeal® Alginate (MedLogic), Algisite® M, Algosteril® 
(Smith & Nephew), Kaltostat® (ConvaTec), Melgisorb® (Mölnlycke), SeaSorb® 
(Coloplast), Sorbalgon® (Hartmann) and antimicrobial loaded formulations 
such as Acticoat® Absorbent (Smith & Nephew) impregnated with silver and 
Alvigon® (Advancis) impregnated with medical grade manuka honey. 
The hydrophilic, non-toxic and haemostatic properties of alginates 
provide favourable moist conditions in the wound bed, desirable for 
epithelisation and eventually wound healing.  Furthermore, it was suggested 
that alginates may have a biological effect, acting as direct modulators of 
different cellular activities occurring during healing. Experimental studies 
undertaken with human histiocytic lymphoma cell lines U937, treated with 
several alginate-containing dressings, demonstrated that Kaltostat® 
(ConvaTec) induced a significant release of macrophage activator TNF-α 
(Thomas et al. 2000). Recent research studies conducted in wounded rats 
treated with alginates demonstrated that alginates increased expression of 
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collagen-I, while significantly suppressing expression of TGF-β1, fibronectin 
and vascular endothelial growth factor (VEGF) (Lee et al. 2009). This data 
indicated that some particular alginate dressings may possess the potential of 
inducing pro-inflammatory response by activating macrophages (Thomas et al. 
2000) and/or simultaneously act as cellular modulators in increasing collagen 
deposition in wounded tissue (Lee et al. 2009). It is difficult to conclude 
whether the physiological properties of alginates i.e. their properties as ideal 
dressings, or their effect on the physiology of wound healing, is more 
important. 
 
1.14.2 Hydrogel dressings 
Hydrogel dressings consist of insoluble synthetic or semi-synthetic 
polymers or an appropriate combination, which possess hydrophilic properties 
and moderate ability to absorb and retain fluids (swelling behaviour) (Thomas 
1990; Boateng et al 2007). Currently, there is a plethora of dressings 
available in the UK market including antimicrobial free and antimicrobial 
impregnated formulations. Some of the antimicrobial free dressings include 
ActiFormCool® (Activa), ActivHeal Hydrogel® (MedLogic), Coolie® (Tyco), 
IntraSite® Gel (Smith & Nephew) etc. Hydrogel dressings impregnated with 
antimicrobials include Iodoflex®, Iodosorb® (Smith & Nephew) prepared with 
0.9 % cadexomer iodine in a paste or ointment base, and Mesitran® 
(Mölnlycke) prepared with medical grade honey. 
Hydrogels fulfil many of the criteria that an ideal dressing should 
display. They are non-adherent, non-toxic, painless to remove and oxygen 
permeable. In vitro testing of Derma-Gel® and IntraSite Gel® has 
demonstrated that these particular hydrogels also possess bacteriostatic and 
fungistatic properties against S. aureus, P. aeruginosa and Candida albicans 
(Jones and Vaughan 2005). Although their ability to absorb fluids is limited 
due to the fact that hydrogels contain 70 - 90 % water, they provide a moist 
wound environment in dry and low exudative wounds (Boateng et al. 2007). 
In addition, their high water content can rehydrate the necrotic tissue, while 
promoting autolytic debridement in the devitalised tissue present in dry 
chronic wounds (Jones and Vaughan 2005). A recent review by Jones and 
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Vaughan (2005) based on the analysis of available published literature on 
clinical trials and case studies performed with hydrogel dressings since 1982, 
concluded that the use of hydrogels on burns was associated with soothing 
and cooling effects.  All the above properties possessed by hydrogels rank 
them as functional and applicable dressings for a wide variety of shallow and 
deep wounds including burns. Limitations of hydrogels are restricted to low 
absorbance capacity of fluids in moderate and heavy suppurating wounds, and 
with respect to allerginicity and maceration in long term wound care (Jones 
and Vaughan 2005; Boateng et al. 2007). 
 
1.14.3 Hydrocolloid dressings 
Hydrocolloids constitute the third major group of most practical and 
widely used dressings. As with alginates and hydrogels, hydrocolloids include 
both antimicrobial free and antimicrobial loaded dressings. Some of them 
available on the UK market are: Aquacel®, ConviDerm®, DuoDerm®, 
Granuflex®, Versiva® (ConvaTec), Contreet® (Coloplast), and Silvercel® (J & J) 
impregnated with silver.  
Hydrocolloids include a large variety of dressings, as they are produced 
from the combination of gel-forming materials such as carboxymethylcellulose 
(CMC) or other polysaccharides with elastomers and adhesives (Thomas 1990; 
Boateng et al. 2007). The amalgamation of different materials into a flexible 
and absorbent layer of either foams or films, enable hydrocolloids to suit a 
wide range of non-healing wounds. Although they adhere to both dry and 
moist surfaces, hydrocolloid dressings are mainly applied to low and 
moderately exuding wounds. Generally, hydrocolloids can be characterised as 
“multifunctional” dressings, as they help maintain moisture in the wound bed 
and facilitate autolytic debridement of dry, nectrotic tissue whilst promoting 
granulation. The permeability of hydrocolloids to water and oxygen increases 
with the amount of exudate produced and they can be designed to manage 
different volumes of exudate (Thomas et al. 1996; Boatang et al. 2007). 
Generally, hydrocolloids provide a moist wound bed, a protective barrier from 
the external environment, are user friendly and comfortable products.  
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A comparative in vivo study performed with wounded domestic swine 
demonstrated that different hydrocolloid dressings had dissimilar impacts on 
the treatment of full-thickness wounds that depended on their composition 
(Agren et al. 1997). The latter authors reported that the application of 
hydrocolloids showed different histological features, which were likely related 
to the different levels of adherence displayed. A randomised clinical trial 
performed with 31 patients suffering from venous ulcers helped evaluate the 
clinical efficacy of two hydrocolloid dressings. The results revealed significant 
differences in epithelialisation, adhesion, conformability, application and 
patient comfort for each hydrocolloid (Limova and Troyer-Caudle 2002). 
Testing of hydrocolloids is often controversial due to variations in wound 
aetiologies, selection of control groups and differences from one animal model 
to another. 
  
1.15 Advanced and innovative applications  
The complex nature of non-healing wounds has necessitated the 
employment of a wide variety of materials, including biomaterials such as 
collagen and hyaluronic acid (HA), which are physiologically involved in the 
construction of healthy tissue. This group of materials, also known as 
bioactive, constitute another category of dressings referred to as biological or 
advanced dressings (Boateng et al. 2007). Collagen and HA are thought to 
have a pharmacological role in wound healing. Other advantages attributed to 
bioactive materials include biocompatibility, biodegradability and lack of 
toxicity. Collagen in particular is though to be active in the healing process, 
stimulating fibroblast and macrophage production (Mian et al. 1992). In 
addition, collagen and HA can be used as carriers of different therapeutic 
compounds such as antimicrobials and/or growth factors (Boateng et al. 
2007). 
In the last two decades, there has been an increased interest in the 
investigation of pharmacological properties of either collagen or HA, or their 
binary combination, as carriers of therapeutic agents. The use of technologies 
such as freeze drying in the field of formulation science contributed to the 
formulation and combination of such materials. Park et al. (2003) have 
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investigated the role of collagen-HA matrices on human fetal dermal 
fibroblasts and their in vivo effect on wounded animals. Experimental data 
demonstrated that the presence of HA enhanced the proliferation of 
fibroblasts, but did not effect significantly their migration. In addition, the 
application of collagen and/or collagen-HA sponges on full-thickness wounds 
induced in guinea swine, increased epithelialisation, collagen synthesis and 
eventually wound healing, while the incorporation of HA did not significantly 
have an additional effect (Park et al. 2003). Recent in vitro and in vivo 
experiments performed with oligosaccharide-HA formulations on acute dermal 
wounds in small animal models, demonstrated that such formulations 
enhanced angiogenesis, granulation, fibroblast proliferation and collagen 
deposition. In addition, oligosaccharide-HA formulations promoted the repair 
of injured tissue (Gao et al. 2010). 
Other authors support that the application of collagen itself, may likely 
not promote healing in the presence of bacterial contamination, as collagen 
can rather serve as a substrate for pathogens, because it is in its essence a 
large protein (Kumar et al. 2010). As such, the incorporation of therapeutic 
compounds into collagen matrices could facilitate better healing rates. In vivo 
experiments performed with wounded mice demonstrated that the application 
of collagen films impregnated with human growth hormone (hGH) significantly 
reduced the wounded area after 21 days, while the application of either 
collagen film or powdered hGH alone, had no effect compared to the untreated 
controls (Maeda et al. 2001). Recent in vivo investigative data, performed in 
wounded albino mice, demonstrated that the incorporation of an antioxidant 
with antimicrobial properties, such as triphala, in collagen matrices can induce 
tissue regeneration, collagen deposition and faster wound closure, while also 
having an impact on reducing the activity of MMP-8 and MMP-9, compared to 
collagen and gauze controls.  
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1.15.1 Lyophilised wafers as innovative potential dressings 
The use of natural polymers, also known as biopolymers, in conjunction 
with the application of the freeze drying process in formulation of dressings 
possessing a high absorbency, led to innovative technologies in the field of 
wound management. Lyophilised wafers as a topical drug delivery system for 
the treatment and management of a wide range and types of non-healing 
exudative wounds have been developed by Matthews et al. (2005). The 
philosophy behind the design of wafers relies on the ability of a three-
dimensional, porous and regular matrix structure to turn into high viscosity, 
physical gels. The technology which supports the formulation of such 
structures is a sophisticated process, in terms of temperature and pressure, 
known as freeze drying or lyophilisation.  In other words, wafers are shape-
adaptive or mouldable formulations as they take shape from the containers 
where the gels are placed prior to lyophilisation.  
The term ‘wafer’ originated as the initial lyophilised polymers were 
relatively thin and porous. Lyophilised wafers can be suitable formulations for 
topical drug delivery on every moist biological membrane as they can be self-
adhesive. Adhesion at the site of delivery can provide targeted delivery of the 
appropriate therapeutic compounds. Porosity and hydrophilicity have been 
considered as the most dominant parameters which govern the swelling 
behaviour of drug-loaded, hydrophilic polymers as the drug is being released 
as the polymer swells (Vlachou et al. 2001). Lyophilised wafers can be 
considered as ideal carriers of therapeutic agents, including antimicrobials and 
therefore are thought to be efficient systems to deliver antimicrobial treatment 
on a wide range of suppurating chronic wounds.  
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1.16 Project design 
As outlined above, treatment of chronic non-healing wounds addresses 
major medical concerns with regard to selection of appropriate therapy, 
application of effective formulations and desirable quantities of therapeutic 
agents in a poly-contaminated site of infection.  As previously discussed, there 
are many factors that can result in non-healing, broken skin tissue. 
Undoubtedly, the presence of different types and populations of pathogens in 
an open skin injury stimulates inflammation, leading to persistent infection 
and inevitably to non-healing conditions. The topical delivery of antimicrobials 
on a contaminated chronic wound bed is considered an optimal choice of 
treatment. The application of such compounds via materials which can 
simultaneously absorb the excess exudate providing optimal moist conditions, 
sustained drug delivery while being self-adhesive, harmless and practical, 
present additional advantages. Contemporary formulations such as lyophilised 
wafers impregnated with broad spectrum antimicrobial compounds are thought 
to possess all the aforementioned properties.  
This project has therefore been designed to investigate formulations 
and microbiological issues that need to be considered in the development of a 
lyophilised antimicrobial wafer as a potential wound dressing for non healing 
exudating wounds. Additionally, the experimental work contained in this 
project, is multidisciplinary in nature, combining the disciplines of materials 
science, drug delivery, wound management and microbiology. Importantly, 
emphasis has been placed on attempting to mimic the contaminated and 
exuding profile of a chronic wound and to investigate the role of lyophilised 
antimicrobial wafers under those simulated conditions. 
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1.16.1 Aims 
1. To formulate cohesive lyophilised antimicrobial wafers using hydrophilic 
biopolymers which can be physically compatible with the embedded broad 
spectrum topical antimicrobial compounds.  
2. To evaluate the antimicrobial properties of lyophilised wafers using suitable 
in vitro wound models. 
3. To quantify the release of antimicrobials from lyophilised wafers under 
simulated condition of exuding wounds. 
4. To investigate the physicochemical and antimicrobial properties of gamma-
irradiated lyophilised wafers. 
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Chapter 2 
 Formulation of lyophilised antimicrobial wafers 
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2.1 Aim 
To formulate cohesive, non friable lyophilised antimicrobial wafers using 
hydrophilic biopolymers which are physically compatible with the embedded 
broad spectrum topical antimicrobial compounds.  
 
2.2 Introduction 
Natural polymers are materials which have been extracted from natural 
sources, such as plants, algae and/or bacterial biofilms. The exceptional 
properties, in terms of gelling in the presence of water and low cost, ranked 
them as broadly used thickeners, stabilisers or emulsifiers in the food industry. 
Simultaneously, the hydrophilic and non-toxic properties are also utilised in 
the pharmaceutical and cosmetic industries. Sodium alginate (SA) and 
xanthan gum (XG) are two of the most used biopolymers in both food and 
pharmaceutical manufacturing, while the use of karaya gum (KAG) and guar 
gum (GG) was initially restricted to food additives. Recently, there has been 
an increased interest in investigating their properties as drug delivery vehicles. 
Brannon-Peppas (1997) has characterised the ideal delivery system as 
the one which should be “inert, biocompatible, mechanically strong, 
comfortable for the patient, capable of achieving high drug loading, safe from 
accidental release, simple to administer and remove, and easy to fabricate and 
sterilise”. Interestingly, most of these properties have been found in materials 
displaying a polymeric nature. Although polymer gels are simply characterised 
as ‘soft’ and ‘wet’ materials (Kavanagh and Ross-Murphy 1998), their multi- 
clustered structure present different challenges in understanding their 
physicochemical behaviour in terms of gelling, swelling, flowing and interacting 
with other polymeric or non-polymeric compounds.  
In the present chapter, biopolymers such as XG (Xanthomonas 
campestris), GG (Cyamopsis tetragonolobus), SA and KAG (Sterculia urens) 
were selected for the formulation of lyophilised matrices, to contain clinical 
concentrations of selected, commonly used, broad spectrum topical 
antimicrobial compounds such as neomycin sulphate (NS), chlorhexidine 
digluconate (CHD), povidone iodine (PVP-I) and silver sulfadiazine (SS). 
Physicochemical properties of biopolymeric carriers will be investigated in 
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terms of biocompatibility, flow behaviour, lyophilisation and adhesive 
properties. 
 
2.3 Materials and methods  
2.3.1 Materials 
Neomycin trisulphate (powder), chlorhexidine digluconate (20 % w/v 
solution), silver sulfadiazine (SS) (98 % purity of powder), pluronic F68 (non-
ionic surfactant), sodium alginate, guar gum, karaya gum and xanthan gum 
were purchased from Sigma-Aldrich, Gillingham, UK. Povidone iodine (10 % 
w/v standardised aqueous solution) and 12-well polystyrene culture plates 
were purchased from Seaton Healthcare Group, Oldham and Costar Ltd., UK, 
respectively. Bacteriological agar was purchased from Oxoid Ltd., UK. 
 
2.3.2 Methods 
Initially, in order to establish a workable concentration for polymers and  
physical compatibility between the biopolymers and antimicrobials, 
combinations of different natural polymers and antimicrobial compounds were 
prepared as gels in distilled water at approximately 25 0C with continuous 
stirring at 1000 – 2000 rpm, using an overhead mechanical stirrer fitted with a 
70 mm (RZR 2102, Heidolph) propeller shaft. Clinical concentrations of 
antimicrobials used ranged from 0.5 % – 1 % (w/v or v/v depending on the 
nature of the antimicrobial) while concentrations of polymers ranged from 1.5 
– 5 % (w/v). Table 2.1 presents a summary of the antimicrobial gels 
prepared. 
 
2.3.3 Preparation of silver sulfadiazine (SS) gels 
Silver sulfadiazine was prepared as a suspension using 0.2 % (w/v) of a non-
ionic surfactant (pluronic F68). The suspension was prepared using a turbine 
mixer (DIAX 900, Heidolph) at maximum speed for 5 minutes.  Analysis of the 
particle size distribution of SS suspensions prepared with pluronic F68 was 
undertaken using a MastersizerS laser light scattering instrument. A 300 mm 
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lens focused the scattered beam ( = 633 nm) onto a multi diode detector. 
The size-range of the detector was 0.1 - 1000 m. The results of particle size 
distribution were obtained as the computed value for particle abundance (%) 
as a function of mean particle size, based on the statistics of polydisperse 
systems. The volume mean diameter D [4, 3] (derived from the statistical 
analysis of the distribution) was used, Figure 2.1. 
 
2.3.4 Binary gel synergies 
Binary polymer mixtures were prepared by the addition of small 
concentrations of powdered gums (XG, SA, GG and KAG) to distilled water 
warmed at approximately 25 0C and stirred continuously at 1000 - 2000 rpm. 
Gels were prepared by combining two polymer gels/solutions at concentrations 
ranging from 0.5 – 1.5 % for individual polymers. All possible combinations of 
two polymers were prepared.  Table 2.2 presents the rheological analysis of 
the flow properties of each polymer and their binary mixtures as analysed with 
the Herschel-Bulkley mode (Aulton 2002). 
 
2.3.5 Rheological measurements 
The analysis of flow and deformation of all polymeric gels prepared was 
investigated by rheological measurements. At least three fresh samples of 
each polymer solution (with and without antimicrobial) were characterised by 
continuous flow rheometry at 250C. A cone and plate geometry was used (40 
mm/2o steel) and flow measurements were conducted at continuous shear 
rates from 0 to 600 s-1 using a dynamic rheometer (AR1000, TA Instrument). 
Analysis of the descending flow curves was undertaken with the system 
software using the Herschel-Bulkley model, viz:  
 = n + 0 
 where,  = shear stress (Pa),  = viscosity coefficient or ‘consistency’ (Pa.s), 
 = shear rate (s-1), n = rate index of pseudoplasticity and 0 = yield stress 
(Pa), Figures 2.2-2.4 and Tables 2.3 - 2.4. 
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2.3.6 Freeze drying process 
Aliquots (1.5  0.02 g) of each batch of gel formulation were cast to the 
individual compartments of 12-well polystyrene culture plates and lyophilised 
in a laboratory-scale freeze drier (Virtis, Advantage 2.0) for 26 hours. Figure 
2.5 shows the temperature profile for sample and shelf during the 
lyophilisation cycle.  The lyophilisation process used was identical for all the 
wafer batches. Samples were slowly cooled to approximately –55 0C and then 
heated in a series of thermal ramps to room temperature under reduced 
pressure, ranging from 3525 mTorr to a minimum of 52 mTorr during the 
programmed cycle. Ice was removed by sublimation during the primary drying 
phase and residual non-freezing water was removed by desorption to the gas 
phase during the secondary drying cycle. The lyophilised wafers produced 
were stored in a dry place at room temperature in the sealed polystyrene 
plates in which they were cast. 
 
2.3.6.1 Batches of lyophilised formulations 
Two main groups of lyophilised wafers were prepared as presented in Table 
2.1 (grey boxes). The first group includes the combination of 3 % (w/v) 
solution of KAG with clinical concentrations of 0.5 % (w/v) NS, 0.5 % (v/v) 
CHD, 1.0 % (v/v) PVP-I and 1.0 % (w/v) SS. The second group of lyophilised 
antimicrobial wafers consists of three different polymer formulations, namely 
XG, SA, GG and the binary gel of SA-KAG in combination with 0.5 % (v/v) 
CHD. Control wafers (wafers with no antimicrobials added) were prepared for 
each group of antimicrobial wafers. For the KAG-SS wafer, an extra control 
wafer (KAG-F68) containing 0.2 % (w/v) pluronic F68 was included, as silver 
sulfadiazine was prepared as a suspension with pluronic F68 as surfactant.  
 
2.3.7 Thermogravimetric (TGA) analysis of the lyophilised wafers 
Thermogravimetric analysis was undertaken to determine the water content of 
the lyophilised wafers.  All wafer samples were manually compressed to fit on 
the pre-tarred platinum sample pan. Powder-free, latex gloves were worn to 
avoid external contamination form skin moisture/sweat. Mean sample weights 
of 9.8 ± 2.4 mg were used. The residual water content of lyophilised wafers 
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was analysed as the weight loss of the sample during a heating ramp from   
25 0C – 200 0C at a heating rate of 10 0C/min.  A TA Q500 Instrument was 
used for all measurements. Table 2.5 summarises the results of the 
thermogravimetric analysis for both control and antimicrobial KAG wafers. 
 
2.3.8 Scanning electron microscopy (S.E.M) 
A Leo S430 digital scanning electron microscope was used to image the 
microstructure of control and drug-loaded wafers. Samples for imaging were 
coated with gold and palladium for four minutes. Images of the wafer surfaces 
(top and bottom) were taken at magnifications of 200x and 500x, Figure 2.6 
and 2.7. 
 
2.3.9 In vitro determination of adhesive properties of lyophilised 
wafers to a model agar surface 
The adhesive properties of lyophilised wafers to a model surface were 
measured using a texture analyser with a 5 kg load cell attached (TA-XT2i, 
Stable Micro System Surrey, UK). A 0.8 % (w/v) agar plate was prepared 
using a salt solution (142 mmol.l-1 of sodium ions, 2.5 mmol.l-1 of calcium 
ions) representative of sodium/calcium levels found in wound fluid (Thomas 
2007). A wafer was attached to the base of an aluminium probe (20.0 mm) 
using double-sided adhesive tape and the probe fixed to the mobile arm of the 
texture analyser. The wafer was lowered at a rate 2.0 mm s-1 until contact 
with the moist agar surface was made. A contact force of 0.05 N was 
maintained for 30 seconds for KAG, NS, CHD, SS, F68, GG, XG and 90 
seconds for SA, SA/CHD, SA-KAG, SA-KAG/CHD, until approximately 1 mm of 
a gel layer was formed, after which the probe was withdrawn from the agar 
surface at a rate of 5.0 mm s-1. Clearly, wafers containing SA took slightly 
longer to swell. The peak detachment force was noted and the work of 
adhesion calculated using the area under the force/distance curve, Table 2.6 
and 2.7. The tensile stress (N cm-2) was calculated as the peak detachment 
force divided by the surface area of the wafer (approximately 3.463 cm2 at   
25 0C).  
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2.4 Statistical analysis 
Data are presented as the mean value of three samples ± standard error of 
the mean (SEM). Statistical analysis of adhesion data was performed using 
GraphPad Prism 4 software. The normality of data was analysed with the 
Skewness-Kurtosis Omnibus test for variable sampling plans. Normality of 
data was determined by 95 % confidence of the normal distribution of the 
data. When normal distribution was proven, a parametric test such as one way 
analysis of variance (ANOVA), followed by post hoc Tukey’s multiple 
comparison test was used to compare more than two groups. A nonparametric 
Mann-Whitney test was used for the comparison of two groups when the data 
did not show normal distribution. A p-value less than 0.05 was considered a 
significant difference.  
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2.5 Results 
Table 2.1 Qualitative analysis of physical compatibility (pre-lyophilisation) 
and friability (post-lyophilisation) between combinations of natural polymers 
and antimicrobials. NC- not compatible, C- compatible; +, ++, +++ indicate 
the visualised degree of friability and integrity for a disc of lyophilised polymer 
impregnated with antimicrobial compound. Formulated combinations are 
marked as grey boxes. 
 
Polymers 
(w/v) 
Antimicrobials 
NS 
(0.5 % w/v) 
CHD 
(0.5 % v/v) 
PVP-I 
(1.0 % v/v) 
SS 
(1.0 % w/v) 
KAG  
(3.0 %) 
pH = 4.5 
C C C C 
GG 
(2.0 %) 
pH = 6.1 
C+ C C+++ C 
XG 
(1.5 %) 
pH = 6.2 
NC C C++ C+ 
SA 
(5.0 %) 
pH = 8.3 
NC C C+++ C+ 
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Figure 2.1 Particle size distribution curve for 1.0 % (w/v) silver sulfadiazine 
suspension, prepared in distilled water with 0.2 % (w/v) non-ionic surfactant 
pluronic F68.  Mean particle size = 23.63 m. 
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Table 2.2 Viscosity coefficient or ‘consistency’,  (Pa.s) and yield stress o 
(Pa), for four natural polymers and their mixtures in aqueous solution as 
analysed with the Herschel-Bulkley model. Note the particularly large yield 
stress of the SA-KAG combination. 
 
Polymer 
(w/v) 
SA 
  
(o) 
XG 
  
(o) 
GG 
  
(o) 
KAG 
  
(o) 
SA (1.5 %) 
0.61  
(0.00) 
- - - 
XG (0.5 %) 
2.00  
(0.00) 
0.17  
(6.09) 
- - 
GG (0.5 %) 
6.89  
(0.00) 
2.35 
(21.29) 
0.16  
(4.58) 
- 
KAG (1.5%) 
9.03 
(96.45) 
0.94 
(20.38) 
3.15 
(22.60) 
0.50 
(0.00) 
 
 
 
Figure 2.2 Rheological analysis of pre-lyophilised gels. Flow curves of 1.5 % 
SA, 1.5 % KAG and the combination of SA-KAG (1:1) ratio.  
(____) ascending, (----) descending. 
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Figure 2.3 Rheological analysis of flow curves of KAG control and 
antimicrobial gels; (____) ascending, (----) descending. 
 
Table 2.3 Viscosity coefficient of 3 % (w/v) KAG in combination with clinical 
concentrations of antimicrobials as obtained using the Herschel-Bulkley model. 
Values represent the mean value of three samples ± the standard error of 
mean (n=3, SEM) 
 
Pre-lyophilised gel 
( 3.0 % KAG w/v) 
Viscosity coefficient 
(Pa.s) 
Control (3.0 % KAG) 12.89 ± 0.93 
0.5 % NS   1.56 ± 0.10 
1.0 % PVP-I   4.09 ± 0.34 
0.5 % CHD   3.79 ± 0.30 
1.0 % SS (0.2 % F68)   6.48 ± 0.33 
0.2 % F68   7.40 ± 0.55 
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Figure 2.4 Rheological analyses of pre-lyophilised control gels. Below [Figures (a), (b), (c) and (d)]: Flow curves of control 
gels (____) and 0.5 % CHD (____); (a) 2.0 % GG, (b) 1.5 % XG, (c) 5.0 % SA and (d) binary gel synergy of SA-KAG; Note the 
difference in scale of the ‘y’ axis. (____) ascending, (----) descending.                                                    
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(a) (b) 
 
(c)                                                                                     (d) 
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Table 2.4 Viscosity coefficients and yield stresses of pre-lyophilised gels 
(controls) and 0.5 % CHD-containing gels of 2 % GG, 5 % SA, 1.5 % XG and 
the binary mixture of SA-KAG, as obtained with the Herschel-Bulkley model. 
Values represent the mean value of three samples ± the standard error of 
mean (n=3, SEM) 
 
Pre-lyophilised gels (w/v) 
(η’ ) Viscosity coefficient (Pa.s) 
[(σ0 ) Yield stress ( Pa)] 
Control 0.5 % (v/v) CHD 
2 % GG 
 
82.21 ± 5.41 
 
(95.87 ± 2.31) 
 
65.49 ± 6.64 
 
(93.63 ± 9.50) 
5 % SA 
 
18.17 ± 0.70 
 
(00.00 ± 0.00) 
 
43.36 ± 6.48 
 
(00.00 ± 00.00) 
1.5 % XG 
 
2.86 ± 0.12 
 
(23.61 ± 0.68) 
 
2.56 ± 0.37 
 
(31.71 ± 2.43) 
1.5 % - 1.5 % 
SA - KAG 
 
7.75 ± 0.64 
 
     (86.34 ± 5.19) 
 
13.71 ± 0.8 
 
(155.43 ± 12.08) 
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Figure 2.5 Temperature profile of the freeze-drying process 
 
Table 2.5 Thermogravimetric analysis (TGA) of water content of KAG 
lyophilised wafers. 
Wafers Water content (%) 
KAG 15.22 
NS 16.77 
CHD 16.12 
PVP-I 13.87 
SS 15.54 
F68 18.49 
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Figure 2.6 Scanning electron microscopy (S.E.M) images of wafer matrices 
top surfaces taken at 200x magnification. Image A – GG, B – GG-CHD;C - XG,    
D – XG-CHD; E – SA, F – SA-CHD; G – SA-KAG, H – SA-KAG-CHD. 
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Figure 2.7 (a) S.E.M images taken at 200x magnification, A – KAG (control 
wafer) B – KAG-NS, C – KAG-CHD and D – KAG- PVP-I. 
(b) S.E.M images of KAG/SS. Images A and C taken at 200x magnification, 
B and D taken at 500x magnification. Images A and B - top surface of the 
wafer, C and D - bottom surface of the wafer. (Note the differences in pore 
size and shape between the top and bottom surfaces).
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(b) 
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Table 2.6 Adhesion properties (peak detachment force and work of adhesion) 
of KAG lyophilised wafers impregnated with clinical concentrations of 
antimicrobial compounds. Statistical analysis of data was performed using 
one-way analysis of variance (ANOVA), followed by Tukey’s post hoc test.  A p 
< 0.05 was considered a significant difference. (n = 3, SEM) (* p< 0.05, ** 
p<0.01, *** p<0.001) 
 
Lyophilised wafers 
Peak detachment 
force (N) 
Work of adhesion    
(N. mm) 
KAG (Control) 0.88 ± 0.018 0.33 ± 0.023 
NS  0.68 ± 0.026* 0.30 ± 0.010 
PVP-I     0.36 ± 0.035*** 0.31 ± 0.009 
CHD     0.52 ± 0.049*** 0.27 ± 0.016 
SS  0.78 ± 0.038 0.30 ± 0.026 
F68 (Control for SS)  0.78 ± 0.048 0.37 ± 0.022 
 
Table 2.7 Adhesion properties (peak detachment force and work of adhesion) 
of lyophilised wafers prepared with different biopolymers impregnated with 
clinical concentrations of CHD. Statistical analysis of data was performed using 
a two-tailed, nonparametric Mann-Whitney test. A p < 0.05 was considered a 
significant difference.   (n = 3, SEM)  
 
Lyophilised 
wafers 
Peak detachment force (N) Work of adhesion (N. mm) 
Control 0.5 % CHD Control 0.5 % CHD 
GG 0.86 ± 0.032 0.82 ± 0.028 0.48 ± 0.037 0.41 ± 0.009 
XG 0.93 ± 0.077 0.79 ± 0.034 0.55 ± 0.028 0.49 ± 0.028 
SA 1.05 ± 0.101 0.90 ± 0.024 0.45 ± 0.044 0.32 ± 0.023 
SA-KAG 0.56 ± 0.026 0.31 ± 0.003 0.18 ± 0.004 0.12 ± 0.014 
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Figure 2.8 Tensile stress of KAG lyophilised wafers, control and antimicrobial-
loaded, was calculated as the stress applied over the contact surface area of 
the wafer. The effect of embedded antimicrobials in the KAG matrix was 
compared to the control (KAG) matrix. Statistical analysis was performed 
using one way analysis of variance (ANOVA) followed by Tukey’s post hoc test. 
A p < 0.05 was considered a significant difference. (n=3, SEM)  (* p< 0.05, 
** p<0.01, *** p<0.001) 
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Figure 2.9 Tensile stress of GG, XG, SA and SA-KAG lyophilised wafers was 
calculated as the stress applied over the contact surface area of the wafer. The 
effect of embedded 0.5 % CHD in lyophilised matrices of different biopolymers 
was compared to the control. Statistical analysis was performed using a 
nonparametric Mann-Whitney test. A p < 0.05 was considered a significant 
difference. (n=3, SEM)  
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2.6 Discussion  
The formulation and physicochemical characterisation of novel 
antimicrobial wafers containing clinical concentrations of the broad spectrum 
topical antimicrobials neomycin sulphate (NS), chlorhexidine digluconate 
(CHD), povidone iodine (PVP-I) and silver sulfadiazine (SS) form the basis of 
this chapter. Several issues are discussed with regard to the utilisation of 
natural polymers such as sodium alginate (SA), xanthan gum (XG), guar gum 
(GG), karaya gum (KAG) and the binary combination of SA-KAG used as 
carrier of the selected antimicrobials.  
  Based on the results obtained from the qualitative assessment of 
physical compatibility between polymers and antimicrobials (Table 2.1), only 
certain combinations were selected for further development as cohesive and 
non friable antimicrobial wafers. KAG was the biopolymer which was found 
physically compatible with all of the antimicrobials and produced intact 
lyophilised wafers. In addition, CHD was miscible with all the polymers tested, 
also producing cohesive lyophilised wafers. As a result, two main groups of 
lyophilised antimicrobial wafers were prepared. This led to the investigation 
and evaluation of carrier (KAG) loaded with different antimicrobial compounds 
and different carriers loaded with the same antimicrobial compound (CHD). 
A brief investigation was also undertaken on the analysis of the 
rheological properties of binary combinations of biopolymeric gels presented in 
Table 2.2. In the present study, rheological investigation has clearly shown 
that several binary combinations of biopolymers demonstrated a notable 
increase in viscosity and yield stress compared to the respective homopolymer 
gels. A distinctive example of this synergistic interaction is the combination of 
KAG with SA in a 1:1 ratio. Figure 2.2 clearly shows that the gel mixture of 
SA-KAG exhibits different and improved flow behaviour with regards to 
increased viscosity (9.03 Pa.s), yield stress (96.45 Pa) and thixotropy 
(reversible isothermal transformation of gels induced by applied stress), 
compared to homopolymers of SA (0.61 Pa.s) and KAG (0.5 Pa.s). This may 
be due to interactive interconnections between polymeric chains of KAG and 
SA and formations of hyperentanglement. The water soluble salt of alginic 
acid, sodium alginate, is weakly basic (pH = 8.3) while KAG has free 
carboxylic acid groups (pH = 4.5). The synergistic interaction exhibited by the 
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combination of SA with KAG is likely to be attributed to the overriding acidic 
effect of karaya residues upon sodium alginate. However, further investigation 
will be required to explain the complex intermolecular interactions between 
both materials. This novel synergistic combination between KAG and SA has 
been used in this project as a lyophilised matrix impregnated with 0.5 % CHD 
and appears to be original. 
Analysis of the flow behaviour (rheology) of the pre-lyophilised gels 
(miscible complexes of biopolymers with antimicrobials) was performed under 
controlled conditions of geometry and temperature. Rheological 
characterization of pre-lyophilised gels plays an essential role in quantification 
of flow properties of the gels (antimicrobial-loaded and/or antimicrobial-free).  
Flow properties of pre-lyophilised gels provide necessary information with 
regards to performance and flow behaviour (expansion) of the re-hydrated 
lyophilised wafers. Rheological analysis of 3 % (w/v) KAG gels (antimicrobial-
free and antimicrobial-loaded) indicated pseudoplastic flow behaviour with no 
yield stress as presented in Figure 2.3. However, the rheological behaviour of 
pre-lyophilised KAG gel mixed with antimicrobials demonstrated decreased 
viscosity compared to the control KAG gel.   
Flow curves of pre-lyophilised KAG gels (Figure 2.3) clearly display the 
effect of each antimicrobial on the polymer network of KAG. Table 2.3 
summarises the values of viscosity coefficients of all KAG gels, as analysed 
with the Herschel-Bulkley model. The viscosity coefficient or consistency for 
KAG pre-lyophilised gels ranged from 1.56 – 12.89 Pa.s, where KAG-NS had 
the lowest value of consistency and KAG control gel revealed the highest. 
Apparently, the presence of antimicrobials such as NS and CHD had a major 
influence on the consistency of KAG gel, as they reduced the consistency of 
KAG gel by approximately 8 and 3.4 times, respectively.  
Gelation of a branched, partly acetylated biopolymer such as KAG is 
complex. Silva et al. (2003) have reported that Sterculiaceae forms a gel 
network mainly due to opposite ionic interconnections between galacturonic 
acid residues of the main chain and glucuronic acid branching residues. In 
addition, junction zones may also form from hydrogen bonding created 
between rhamnose segments. The later authors suggest that interaction 
between homogalacturonic residues between different chains (the ‘egg-box 
model’) may also occur, however, to a small extent. De Brito et al. (2005) 
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have analysed the flow behaviour of karaya gum in aqueous solution and have 
shown that the presence of salt, such as NaCl (0.1 M), decreased the gel 
strength of karaya. The latter authors suggest that the presence of salt may 
partition the ionic strength of KAG and decrease cross-linking between 
polymer chains. It is proposed that disruption of junction zones is more likely 
to happen for counter ion interaction between galacturonic and glucuronic acid 
segments (De Brito et al. 2005; Silva et al. 2005). Therefore, it is very likely 
that the presence of antibacterial compounds such CHD, NS, PVP-I and SS 
may disrupt the gel network of karaya, resulting in a reduced gel consistency. 
However, further investigation is required to elucidate the drug-polymer 
interactions occurring and the effect of specific ions having a detrimental 
influence in the gel network of KAG. 
Rheological analysis was also undertaken for pre-lyophilised gels 
(control and 0.5 % CHD-loaded) of GG, XG, SA and SA-KAG (Figure 2.4, Table 
2.4). Different rheological behaviours of pre-lyophilised control gels were 
attributed to inherent differences in the molecular configuration of biopolymer 
chains. Rheological analysis of 2 % GG and 1.5 % XG gels displayed plastic 
flow behaviour with a clear yield stress, while the gel prepared with 5 % SA 
demonstrated pseudoplastic flow properties with no apparent yield stress. In 
addition, the gel prepared with SA-KAG (1:1 ratio) demonstrated plastic and 
thixotropic flow behaviour with high values of yield stress. Incorporation of 
cationic CHD notably affected the flow behaviours of XG, SA and SA-KAG. 
Complexes of SA and SA-KAG with CHD both displayed a substantial increase 
in consistency and yield stress. CHD enhanced the consistency of SA gel by 
approximately 2.4 times and doubled the yield stress of SA-KAG gel.  The 
consistency of XG was not affected considerably by the addition of CHD, 
whereas the yield stress was increased from 23.61 – 31.71 Pa. The non-ionic 
polymeric structure of GG did not exhibit notable qualitative alterations to its 
rheological behaviour in the presence of CHD, however, the analysis of the 
flow curves of GG gels showed a slightly decreased yield stress and 
consistency. In conclusion, the antimicrobials NS and CHD incorporated in 
KAG, SA, XG and SA-KAG gel networks, influenced the rheological properties 
of the gels and would be expected to influence the in vitro performance of 
reconstituted wafers. 
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Disc-shaped, lyophilised wafers were produced by casting gels in the 
circular wells of polystyrene plates and freeze drying. The freeze drying 
process consists of a triple-stage operation, starting with freezing, followed by 
primary drying and secondary drying. All stages play a definitive role in the 
quality, micro and macro morphology of the final lyophilised product. During 
freezing, materials are cooled to low temperatures (e.g. -60 0C). The high 
water content of the gel will result in ice crystals, the size of which will depend 
on the cooling rate, while the polymers will form highly concentrated solutions 
that display amorphous and glassy properties below their glass transition 
temperature (Tg). Consequently, the freezing gel will yield a combination of an 
amorphous and a crystalline phase. On freezing, the pressure is reduced and 
primary drying begins. During primary drying, the ice is removed by 
sublimation and the endothermic phase transition from solid to gas is driven 
by a gradual increase in the process temperature. Water vapour is collected as 
ice on a condenser that is at a lower temperature than the sample. It is 
important that during this stage, the freeze concentrate is maintained at a 
process temperature below its glass transition temperature (Tg) to maintain 
the cast shape. Upon complete removal of ice, residual amounts of non-
freezing water contained within the freeze concentrate, must be removed by 
desorption. This is achieved by a careful increase in the process temperature 
under continuous low pressure/high vacuum conditions. As the non-freezing 
water is removed, the Tg of the freeze concentrate increases (Beddu-Addo 
2004).  
The temperature profile of the freeze drying process presented in Figure 
2.5 demonstrates that the mean sample temperature followed the shelf 
temperature with an approximate +15 – 20 0C difference. The recorded 
difference of the mean sample temperature was attributed to the insulating 
properties of the polystyrene plates used as moulds. In addition, the freeze 
drying cycle used for the lyophilisation of the biopolymeric gels (with or 
without antimicrobials), involved a slow cooling rate of approximately           
10 0C/2.5 hours (Figure 2.5), whereas the lowest temperature reached by the 
sample was approximately -55 0C.  The freezing cycle is decisive for the 
morphology of the lyophilised product, in particular the size of the pore formed 
by the ice crystals. It is observed that the freezing rate influences the mean 
size of the ice crystals. A rapid freezing process develops small and numerous 
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crystals, whereas slow freezing develops large and less numerous ice crystals, 
affecting the microstructure and the appearance of the matrix of the final 
lyophilised formulation (Faydi et al. 2001). 
Such micro structural dissimilarities were observed between top and 
bottom surfaces of lyophilised wafers. Although, the cast gel had a depth of 
approximately 5 mm, there was an apparent variance in the cooling rate of the 
bulk. S.E.M pictures taken at two magnifications (200x and 500x) presented in 
Figure 2.7(b) show the distinctive micro structure of top and bottom surfaces 
of a KAG-SS wafer. The top surface of KAG-SS (Images A and B) is notably 
different from that of the bottom surface (Images C and D), the pore size of 
the top surface being much larger (≈ 100 µm) than that of the underside (< 
50 µm). These differences can be attributed to different crystal sizes resulting 
from bulk variations in cooling rate during the freezing process. 
The network microstructure of KAG-NS, KAG-CHD and KAG-SS (Figure 
2.7 (a) Images B, C and Figure 2.7 (b) Image A, respectively) did not display 
distinctive morphological differences compared to the control (KAG) matrix, 
Figure 2.7 (a) Image A. However, notable alterations were presented in the 
matrix morphology of KAG-(PVP-I) (Figure 2.7 (a) Image D) as the matrix 
microstructure of KAG impregnated with 1 % PVP-I demonstrated a two-fold 
reduced pore size and semi-formed pore shapes compared to the control 
(KAG). It appears that the incorporation of PVP-I, which was used as a 
standardized liquid formulation (containing: 100 mg/g PVP-I, glycerol, 
nonoxynol-9, sodium phosphate, sodium hydroxide, potassium iodate, citric 
acid and water), affected the thermal properties of the KAG-(PVP-I) mixture. 
Although it is difficult to precisely conclude which of the ingredients of the 
PVP-I solution affected the micro morphology of the KAG-(PVP-I) formulation, 
the presence of compounds possessing cryoprotective properties such as 
glycerol may be the more likely candidate. The presence of glycerol molecules 
during the freezing stage of lyophilisation have a strong effect on ice formation 
in the bulk, resulting in partial ice nucleation (Inaba and Anderson 2007). 
Therefore, the development of semi-formed, non-maturated ice crystals in the 
presence of small amounts of glycerol within the bulk of KAG-(PVP-I) mixture 
likely led to the formation of small and rounded pore morphologies in the final 
lyophilised structure. 
                                                       
68 
 
The microstructures of lyophilised polymers impregnated with 0.5 % 
CHD were also observed and compared to the control samples. S.E.M analysis 
of CHD-polymer lyophilised complexes presented in Figure 2.6 demonstrate 
similarities between controls and CHD impregnated wafers, indicating that the 
presence of CHD had no apparent effect on the morphology of the lyophilised 
matrix. The same was also true of wafers formed from GG, XG and SA-KAG 
(Images A, B, C, D, G and H). CHD incorporated in SA wafers did not appear 
to affect the microstructure. The matrix morphology of lyophilised SA 
appeared to form a denser interconnected network with an elongated, ‘melted-
looking’ porous structure (Figure 2.8, Images E and F). The microstructure of 
a SA wafer is similar to the one reported recently by Boateng et al. (2010). 
The matrix morphology of SA wafers might be attributed to the process 
temperature exceeding the Tg of SA during the primary or secondary drying 
cycles. Thermal analysis of the freeze/thaw behaviours of polymer gels could 
give a definitive explanation of ‘melt-back’ in terms of the Tg of the glassy 
freeze concentrate, however, the notoriously weak nature of these thermal 
events made detection extremely difficult. Despite many efforts to detect this 
weak but critical thermal event using differential scanning calorimetry (DSC), 
no clear transition in the frozen state were unambiguously detected. The small 
amounts of polymer contained in the frozen gels relative to the amount of 
water requires a much larger gel sample than is commonly possible with the 
standard aluminium pans. As a result, chances of detecting the Tg of 
polymer/antimicrobial freeze concentrates may require the use of large 
volume steel sample pans. Alternatively, use of modulated DSC may enhance 
the resolution (Flikkema et al. 1998).  
The determination of residual moisture in a lyophilised formulation is 
important for two main reasons: firstly, to assess the quality of the final 
lyophilised product and secondly, to establish the appropriate storage 
conditions, in terms of moisture content, for the lyophilised articles (Franks 
1990). Thermogravimetric analysis (TGA) of KAG wafers showed that the 
residual water content varied from 13.87 – 18.49 %, where the KAG-(PVP-I) 
wafer exhibited the lowest percentage and KAG-F68 the highest (Table 2.5). 
Equilibrium moisture content (EMC), post-lyophilisation, is related to the 
hygroscopicity (affinity to water) of both polymer and contained compounds. 
EMC will generally vary with changes to temperature and relative humidity. A 
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typical example is the incorporation of minimal amounts of highly hygroscopic 
surfactant such as pluronic F68, which is highly hydrophilic and contributes to 
a slightly increased moisture content. Also, the moisture content of KAG-NS 
and KAG-CHD wafers were slightly increased compared to the antimicrobial-
free control (KAG), indicating the likely hygroscopic nature of NS and CHD. It 
is difficult to precisely determine the exact quantity of moisture, as external 
parameters such as storage temperature and percentage of room humidity on 
the day of examination have an effect on the final water content.    
Lyophilised wafers (with and without antimicrobial compounds), 
intended for topical application on damaged and exuding skin, were further 
analysed for adhesive properties in vitro using a model exuding surface. The 
method used to mimic this environment was a soft, moist agar gel prepared 
with the same concentrations of electrolytes as found in wound exudate. 
Adhesion in its essence is an interfacial phenomenon resulting from chemical 
and mechanical attraction (or repulsion) of molecules of dissimilar materials in 
contact (Peppas and Buri 1985). Attractive forces usually consist of Van der 
Waals interactions, hydrogen bonding and polymeric chain entanglement that 
develops during hydration of the formulation from the moist surface with 
which it is in contact.  At this polymer-polymer interface, penetration of 
polymer chains from the formulation to the substrate and vice versa occurs 
(Bredenberg and Nystrom 2003). The breakdown of these bonds, also known 
as debonding behaviour, is usually calculated as the work of adhesion, where 
the peak detachment force represents the maximum force required to 
disconnect the tested article from the interacting surface. 
Tensile stress (ratio of maximum force with the contact surface area) 
values generated from the analysis of KAG wafers, impregnated with clinical 
concentrations of antimicrobial compounds, demonstrated that the 
incorporation of 0.5 % NS (p < 0.05), 1.0 % PVP-I (p < 0.001) and 0.5 % 
CHD (p < 0.001) had a significant effect. The incorporation of an iodophore, 
such as PVP, into the matrix of KAG would generally be expected to improve 
adhesion properties of the formulation; however, other authors have reported 
the ‘anti-tack’ action of PVP. Karavas et al. (2006) have demonstrated that 
PVP displayed in vitro a negligible mucoadhesive force equal to 0.006 N/cm2. 
In addition, dynamic adhesive evaluation of lyophilised nasal formulations 
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prepared with 1 % PVP showed that the incorporation of PVP significantly 
reduced bioadhesion (McInnes et al. 2007).  
Although the incorporation of 1.0 % SS prepared as a suspension with 
0.2 % pluronic F68 decreased the tensile stress of the lyophilised formulation, 
it didn’t apparently affect it significantly (Figure 2.8). However, while the 
adhesive properties of antimicrobial wafers displayed a tendency for a 
decreased tensile stress, compared to control samples (KAG), the work of 
adhesion showed similar values for all the KAG wafers tested. This paradox 
may be related to the wettability of antimicrobial wafers. Although the 
interfacial contact time was similar (30 seconds) for all the lyophilised 
formulations tested, the presence of antimicrobials may restrain the hydration 
ability of lyophilised matrices. In addition, other dispersive forces such as 
polymeric chain entanglement, apart from hydrogen bonding, were likely 
developed during contact of KAG with the agar surface, and this increases the 
difficulty of precisely interpreting the debonding behaviour of lyophilised 
formulations. 
The incorporation of CHD into biopolymer matrices with different 
rheological behaviours, demonstrated a small and insignificant decrease in 
tensile stress and work of adhesion compared to CHD-free wafers (Figure 2.9). 
It is apparent, however, that different polymeric materials displayed different 
adhesive properties. The work of adhesion of CHD-free wafers ranged from 
0.18 – 0.55 N.mm, where the dual synergistic wafer of SA-KAG was the least 
adhesive and XG the most. The peak detachment force of CHD free wafers 
ranged from 0.56 – 1.05 N, where the matrix of SA-KAG had the lowest and 
SA the highest. Generally, the SA-KAG matrix (antimicrobial free or loaded) 
exhibited weak adhesive properties with respect to both work of adhesion and 
tensile strength. However, with the exception of SA-KAG, the peak 
detachment force of different biopolymeric wafers was not proportional to the 
work of adhesion, as wafers displaying increased values of work of adhesion 
displayed moderate values of detachment force.  This phenomenon is likely 
related to different polymer hydration abilities. In addition, the incorporation 
of CHD influenced negatively the adhesive properties of biopolymeric wafers. 
Further investigations are required to elucidate the molecular behaviours of 
miscible compounds. 
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While the examination of the physicochemical characteristics of different 
natural polymers as lyophilised carriers of antimicrobials was undertaken, the 
antimicrobial activity of these formulations was also tested in vitro against 
selected and common pathogens of chronic, non-healing wounds. Chapter 3 
describes the effect of antimicrobial compounds released upon swelling of the 
wafers. In addition, the influence of the rheological and adhesive properties of 
antimicrobial wafers on their flow behaviour is further discussed.   
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Chapter 3 
In vitro evaluation of the efficacy of lyophilised 
antimicrobial wafers 
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3.1 Aim 
To evaluate the antimicrobial properties of lyophilised wafers using a modified 
disc diffusion assay and an antimicrobial diffusion cell (ADC) to simulated 
conditions of an exuding wound. 
 
3.2 Introduction 
  Bacterial infection is considered a common reason for impaired wound 
healing. The presence of diverse types and populations of pathogens, often 
assembled in the form of biofilms, represent a major difficulty in controlling 
contamination and/or infection in the wounded skin. As previously mentioned 
(Chapter 1), an optimal treatment of infection is considered to be the topical 
application of broad spectrum antimicrobials such as silver, iodophores, 
chlorhexidine etc. Despite the plethora of commercially available antimicrobial 
formulations, the complex nature of non-healing infected wounds with regards 
to microbial flora, tissue pathophysiology and surface abnormalities, present a 
real challenge in establishing a universal in vitro antimicrobial wound assay.  
Generally, in vitro testing of antimicrobial formulations has been 
performed using different assays, which were essentially based on the 
established method of diffusion of antimicrobials within an agar substrate. For 
instance, Bhende and Spangler (2004) have tested, in vitro, the antimicrobial 
activity of chlorhexidine gluconate impregnated foam, against common 
pathogens associated with wound infections, using inoculated agar plates. 
Grzybowski et al. (1996) modified the use of an agar substrate by creating 
circular wells for bacteria carriers, where formulations to be tested were 
placed on top of the agar surface. Recently, Bowler et al. (2010) modified 
further the agar surface to represent a shallow wound microbial model.  
A paper disc wetted with an antimicrobial solution and placed on the 
inoculated agar surface, also known as the disc diffusion technique, has been 
used successfully to determine bacterial susceptibility to soluble antimicrobial 
compounds. The antimicrobial diffuses from the saturated disc, which 
represents a drug reservoir, resulting in the formation of a clear and visible 
circular area, known as the zone of inhibition. The inhibition zone is formed 
from the synchronised events of drug diffusion and bacterial growth, until the 
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accumulation of the antimicrobial within the agar substrate reaches a critical 
inhibitory concentration. Consequently, the diameter of the inhibition zone 
reflects the degree of susceptibility of the tested bacterium against the drug, 
when all other variable parameters are kept constant (i.e. drug concentration, 
bacterial density, depth of agar, diameter of paper disc, temperature) (Barry 
1986). One major limitation of the method is considered to be that the 
diffusion rate of the drug depends on the molecular weight, solubility and the 
likelihood of drug interacting with the agar; factors that should be considered 
when interpreting and comparing any data obtained. 
The assessment of the antimicrobial activity of formulations 
impregnated with antimicrobial, designed for application in a suppurating 
wound bed, represents another challenge, in terms of interference occurring 
between antimicrobial compounds and organic matter present, such as serum, 
blood and pus. Previous investigations have shown that many antimicrobial 
compounds are reversibly bound to serum proteins, as structures of proteins 
possess several interactive groups. Albumin, in particular, has approximately 
100 acidic and 86 basic groups ionised at pH 7.4 (Craig and Suh 1986). The 
interaction of organic matter with antimicrobials can lead to substantial 
alterations to the antimicrobial activities of certain antimicrobial compounds.  
The experimental work summarised in this chapter is undertaken in 
order to investigate, in vitro, the performance of antimicrobial formulations, 
such as lyophilised antimicrobial wafers, using an inoculated agar surface. In 
addition, an antimicrobial diffusion cell assay was developed and optimised in 
order to assess the activity of released antimicrobials from the slowly re-
hydrating matrix of lyophilised formulations. Moreover, emphasis has been 
given in assessing the activity of released antimicrobials in the presence of 
electrolytes (e.g. Na+, Ca2+ and Cl-) and protein, present in chronic wound 
exudate. 
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3.3 Materials and Methods 
3.3.1 Materials  
Antimicrobial wafers prepared as described in Chapter 2 (2.2.2) were used. 
Neomycin trisulphate (powder), chlorhexidine digluconate (20 % w/v 
solution), silver sulfadiazine (SS) (98 % purity of powder) were purchased 
from Sigma-Aldrich, Gillingham, UK. Povidone iodine (10 % w/v standardised 
aqueous solution) was purchased from Seaton Healthcare Group. Nutrient agar 
and broth were purchased from Oxoid, UK. Phosphate buffer tablets (PBS), 
bovine serum albumin (BSA), sodium chloride (NaCl), calcium chloride (CaCl2) 
were purchased from Sigma-Aldrich, Gillingham, UK. Cellulose membrane (12-
14 kDa) was obtained from Medicell Int. Ltd., UK. Triple vented Petri dishes of 
90 mm diameter and sterile syringes and needles were purchased from Fisher 
Scientific. Franz diffusion apparatus was purchased from Copley Scientific and 
a Spectrophotometer Cecil CE 3021 was used to determine the optical 
densities of the bacterial strains used. 
National Collection of Type Culture (NCTC) methicillin-resistant Staphylococcus 
aureus (11940), methicillin-sensitive Staphylococcus aureus (6571), 
Escherichia coli (4174) and Pseudomonas aeruginosa (6750) strains, were 
used for microbiological assays. 
 
3.3.2 Methods 
3.3.2.1 Bacterial storage and preparation 
The bacterial stock cultures of methicillin-resistant S. aureus (MRSA), 
methicillin-sensitive S. aureus (MSSA), E. coli and P. aeruginosa were stored 
at -80 0C using Protect Bacterial Preservation beads (Technical Service 
Consultants Ltd., Haywood, UK). Fresh bacterial cultures were prepared at    
37 0C by transferring a single bead unit to 10 ml of nutrient broth and 
incubating for 24 hours. A loop full of bacterial culture was streaked onto a 
nutrient agar plate and incubated at 37 0C for 24 hours to yield separate 
colonies. The plates were subsequently stored in a refrigerator (4  0C) and agar 
plates sub-cultured weekly using a representative single colony. 
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Broth cultures were prepared by inoculating 100 ml of a nutrient broth 
in a 250 ml flask with one discrete colony and incubating with orbital agitation 
(100 rpm) at 37 0C for 24 hours. Overnight bacterial cultures (40 ml) were 
centrifuged at 4000 rpm for 10 minutes in an MSE Centaur 1 centrifuge. The 
sitting supernatant was discarded and the bacterial pellet re-suspended in 20 
ml of sterile 0.9 % (w/v) NaCl solution. Bacterial density was determined 
spectrophotometrically by measurement of a dilute suspension at a 
wavelength of 500 nm. 
 
3.3.2.2 Determination of minimum inhibitory concentration (MIC) and 
minimum bactericidal concentration (MBC) of antimicrobials 
Antimicrobial susceptibly of MRSA, MSSA, E. coli and P. aeruginosa were 
determined by establishing the MIC using a standard 2-fold macro-broth 
dilution method in 10 ml volumes of nutrient broth inoculated with 5 × 105 
cfu/ml. Suitable controls incorporating a non-inoculated bottle of nutrient 
broth (negative) and an inoculated bottle of nutrient broth (positive) were 
included in all assays. After 24 hours incubation at 37 0C, the presence or not 
of bacterial growth was determined optically comparing each dilution to the 
negative and positive controls.  
The MBC values were determined by plating duplicate samples of 100 μl 
(20 μl x 5 volumes) taken from each MIC dilution on agar plates and incubated 
at 370 C for further 24 hours. The absence of bacterial colonies was 
determined as the MBC value of the tested antimicrobial against the bacterial 
strains. All MIC/MBC determinations for each antimicrobial were performed 
twice in duplicate. 
 
3.3.2.3 Modified disc diffusion assay as a simple model of an exuding 
surface 
  A modified disc diffusion assay was used to determine initially the 
bacterial susceptibility to the antimicrobial compounds incorporated within the 
matrix structure of lyophilised wafers. The method was optimized according to 
the protocol of the National Committee of Clinical Laboratory Standards 
(NCCLS) and Barry (1986). Triple vented sterile Petri dishes (90 mm) were 
                                                       
77 
 
prepared by pouring 20 ml of molten nutrient agar (1.5 %) containing yeast 
extract (20 g/l), peptone (5.0 g/l), sodium chloride (5.0 g/l). Each plate was 
inoculated with 5 x 105 cfu/ml of either MRSA, MSSA, E. coli or P. aeruginosa. 
Individual circular (diameter  20 mm) antimicrobial wafers, including controls, 
were placed onto solidified, seeded agar plates and incubated at 37 0C for 24 
hours. The diameter of inhibition of the antimicrobial wafers was measured 
from one edge of the circular zone of inhibition to the other (Figure 3.1). 
Zones of inhibition (calculated from the average of two measurements of the 
diameter of the inhibition zone taken at intervals of 00 and 900) and the 
swollen diameter of wafers (Dt) were measured after incubation using a rigid 
steel engineering rule (Mitutoyo). The initial diameters of the wafers (D0) were 
measured with a digital calliper (Mitutoyo) prior to being placed on the centre 
of the seeded agar plate. Wafer expansion was calculated as the ratio of Dt/D0 
(Matthews et al. 2005). Antimicrobial activity was determined as an inhibition 
ratio IR = Di/D0, where Di = mean diameter of inhibition zone. 
 
 
Figure 3.1 Aerial view of disc diffusion measurements 
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3.3.2.4 In vitro assessment of the efficacy of antimicrobial wafers 
using a diffusion cell 
The use of a Franz diffusion apparatus was altered in order to assess 
the antimicrobial activity of loaded wafers as they slowly rehydrated in contact 
with the dissolution medium. For the purposes of this project the modified and 
optimised method is referred to as an antimicrobial diffusion cell (ADC). This 
original term is used to characterize the precise use of the diffusion apparatus, 
as both chambers (donor and receptor) were filled with media inoculated with 
known concentrations of MRSA (Figure 3.2). 
The effective diffusion area of the receptor chamber was 3.46 cm2, 
matching perfectly with the surfaces of lyophilised formulations and had a total 
volume of 20 ml. The receptor chamber kept at 25 ± 0.5 0C was inoculated to 
yield a final bacterial cell density of 5×105 cfu/ml of MRSA.  An antimicrobial 
wafer was placed on top of a cellulose membrane (12 - 14 kDa) in contact 
with the inoculated medium. The system was sealed in order to maintain a 
continuous volume of medium in the receptor chamber (20 ml) and to keep 
the membrane and wafer constantly hydrated.  A maximal volume of 200 µl 
was withdrawn at each time point in order to minimize the introduction of 
untreated bacterial cells into the receptor chamber. The sample was 
withdrawn using a sterile syringe and needle. Samples (200 µl) of the 
dissolution medium were taken at 0, 2, 4, 6, 8 and 24 hour intervals and each 
diluted to sub-inhibitory levels, ten-fold down to 10-5, in 0.9% (w/v) NaCl 
solution. Dilutions were plated in duplicate on nutrient agar plates (5 µl × 20 
volumes) and incubated at 37 0C for 24 hours. After incubation, bacterial 
colonies were counted and the original cell count (cfu/ml) calculated.  The 
lowest detectable limit of the method was 100 cfu/ml. 
Different dissolution media were used and inoculated with the same 
MRSA densities, in order to compare the activity of released antimicrobials 
from the re-hydrated matrices of antimicrobial wafers. The dissolution media 
of the chambers were stirred at 1200 rpm and consisted of either:  
a) phosphate buffer solution (PBS) containing 0.2 % potassium chloride (KCl) 
and 0.8 % sodium chloride (NaCl) (pH 7.4),  
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b) sodium/calcium chloride solution (pH 6.5) containing 142 mmol/litre of 
sodium ions (0.82 %) and 2.5 mmol/litre of calcium ions (0.027 %), typical of 
those found in wound exudate Thomas (2007), 
c)  pseudo-exudate containing sodium/calcium chloride solution enriched with 
3 % (w/v) BSA (pH 7.4), similar to protein levels found in wound exudate 
(Clought  and Noble 2003).  
 
 
 
Figure 3.2 Schematic of antimicrobial diffusion cell (ADC) assembly used for 
in vitro determination of antimicrobial measurements 
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3.4 Statistical analysis 
Data are presenting as the mean value of three samples ± standard error of 
the mean (SEM). Statistical analysis of data obtained from the expansion and 
inhibition ratios was performed using GraphPad Prism 4 software. The 
normality of data was analysed with the Skewness-Kurtosis Omnibus test for 
variable sampling plans. Normality of data was determined by 95 % 
confidence of normal distribution. When normal distribution was proven, a 
parametric test such as one way analysis of variance (ANOVA), followed by 
post hoc Tukey’s multiple comparison test was used to compare more than 
two groups. A p-value less than 0.05 was considered a significant difference.  
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3.5 Results 
Table 3.1 MIC and MBC values of antimicrobial compounds tested against a 
bacterial density of 5 × 105 cfu/ml. PVP-I* is used as a standardised aqueous 
formulation containing 100 mg/g PVP-I, where the exact concentration of 
antimicrobial iodine compound is not given. Silver sulfadiazine was poorly 
soluble in distilled water and the determination of MIC /MBC values for this 
antimicrobial compound was not possible (ND – not determined). 
  
Bacterial 
strains 
Antimicrobials 
MIC – MBC (μg/ml) 
NS CHD PVP-I* SS 
 
MRSA 
 
3.0 – 6.0 0.2 – 0.4 625 
 
ND 
 
MSSA 
 
2.0 – 6.0 0.2 – 0.4 625 ND 
 
E. coli 
 
6.0 - 18 0.6 - 14 1256 ND 
 
P. aeruginosa 
 
8.0 - 20 4.0 - 20 1256 ND 
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Figure 3.3 Expansion ratio (ER) of 3 % (w/v) KAG wafers prepared with 0.5 
% (w/v) NS, 1.0 % (v/v) PVP-I, 0.5 % (v/v) CHD, 1.0 % (w/v) SS, 0.2 % 
(w/v) pluronic F68. Data were statistically analysed using one way analysis of 
variance (ANOVA), followed by Tukey’s post-hoc test. Statistical analysis was 
performed comparing the same formulation tested against four different 
bacterial strains, and also comparing different antimicrobial formulations to 
the control (KAG). A p < 0.05 was considered a significant difference (n=3, 
SEM). (Please note that the large error bars are due to the small scale of the y 
axis). 
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Figure 3.4  Inhibition ratio (IR) of 3 % (w/v) KAG wafers prepared with 0.5 
% (w/v) NS, 1.0 % (v/v) PVP-I, 0.5 % (v/v) CHD, 1.0 % (w/v) SS. Control 
wafers (KAG) and 0.2 % (w/v) pluronic F68, did not show zones of inhibition. 
Data were statistically analysed using one way analysis of variance (ANOVA), 
followed by Tukey’s post-hoc test. A p < 0.05 was considered a significant 
difference (n=3, SEM). (*p<0.05, **p<0.01, ***p<0.001) 
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Figure 3.5 Expansion ratios of wafers prepared with different biopolymers 
[guar gum (GG), xanthan gum (XG), sodium alginate (SA) and blend of SA 
with karaya gum (KAG) (1:1) ratio] impregnated with 0.5 % (v/v) CHD. 
Measurements were taken testing lyophilised wafers against P. aeruginosa 
NCTC 6750. (n=3, SEM). 
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Figure 3.6 Inhibition ratios of wafers prepared with different biopolymers 
[guar gum (GG), xanthan gum (XG), sodium alginate (SA), karaya gum (KAG) 
and blend of SA with KAG (1:1) ratio], impregnated with 0.5 % CHD, tested 
against P. aeruginosa NCTC 6750. Data were statistically analysed using one 
way analysis of variance (ANOVA), followed by Tukey’s post-hoc test. (n=3, 
SEM). (*p<0.05, **p<0.01, ***p<0.001) 
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Figure 3.7 Correlation of ER/IR for 0.5 % CHD impregnated wafers. 
Significant linear regression between ER and IR values of CHD wafers is 
apparent. (---) represent 95 % confidence intervals. (n=3, SEM) 
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Figure 3.8 Viability of MRSA in the antimicrobial diffusion cell (ADC) 
suspended in PBS, containing 0.02 % KCl and 0.8 % NaCl, adjusted to the 
same pH of the nutrient agar/broth medium (pH 7.4). The experiment was 
performed over 24 hours, however, the above graph presents the viability of 
MRSA over 8 hours. There is a natural > 2-log powers decrease in the number 
of cells (control) in this period. NS killed all MRSA cells at 24 hours, while the 
antimicrobial profile of SS remained constant.  The values represent the mean 
of three independent experiments ± standard error of mean. (---) represent 
the loss of viability of MRSA populations at each log division, in percentage 
terms, compared to the initial MRSA population (n=3, SEM). 
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Figure 3.9 Viability of MRSA in the antimicrobial diffusion cell (ADC) 
suspended in NaCl-CaCl2, containing 0.027 % CaCl2 and 0.82 % NaCl, (pH 
6.5). The experiment was performed over 24 hours, however, the above graph 
presents the viability of MRSA over 8 hours. There is a natural > 2-log powers 
decrease in the number of cells (control) in this period. NS killed all MRSA cells 
at 24 hours, while antimicrobial profile of SS remained constant. The values 
represent the mean of three independent experiments ± standard error of 
mean. (---) represent the loss of viability of MRSA populations at each log 
division, in percentage terms, compared to the initial MRSA population (n=3, 
SEM). 
 
 
 
                                                       
89 
 
 
Figure 3.10 Viability of MRSA in the antimicrobial diffusion cell (ADC) 
suspended in NaCl-CaCl2 enriched with organic material, containing 0.027 % 
CaCl2, 0.82 % NaCl and 3 % (w/v) BSA, (pH 7.4). The prepared solution 
simulates chronic wound exudate. The presence of one model protein does not 
necessarily reflect an infected wound. The values represent the mean of four 
independent experiments ± standard error of mean. (---) represent the loss of 
viability of MRSA populations at each log division, in percentage terms, 
compared to the initial MRSA population (n=4, SEM). 
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3.6 Discussion 
Initially, the minimum inhibitory and bactericidal concentrations, MIC 
and MBC, respectively, of selected topical antimicrobial compounds were 
determined for known densities of common bacterial strains found associated 
with infected, non healing wounds. Table 3.1 summarises the obtained values 
of MICs and MBCs. It is apparent that CHD displayed, in vitro, the lowest 
inhibitory/bactericidal concentration against all bacterial strains, in particular 
against MRSA and MSSA (0.2 - 0.4 µg/ml).  E. coli and P. aeruginosa showed 
3 times and 20 times increased MIC values, respectively compared to S. 
aureus strains. MBC values of CHD against E. coli and P. aeruginosa were 23 
times and 5 times higher, respectively than MIC values. The antimicrobial 
activity of NS tested against all bacterial strains demonstrated moderately 
increased values of MIC compared to CHD, whereas the MBC concentrations of 
NS against E. coli and P. aeruginosa were similar to those of CHD. MBC values 
for NS and CHD against E. coli and P. aeruginosa were notably higher than the 
respective MICs, indicating that the growth of such strains can be easily 
inhibited, but a considerably higher lethal concentration of drug is required. 
PVP-I demonstrated equal values for both MIC and MBC against all 
bacterial strains tested, indicating that this compound possessess a rapid 
lethal mechanism of action, however, E. coli and P. aeruginosa demonstrated 
a higher tolerance to the activity of PVP-I (1256 µg/ml) compared to MRSA 
and MSSA (625 µg/ml). Previous research studies have also reported the 
tolerant nature of Pseudomonas spp against iodophoric solutions, whereas the 
production of a protein coat from such species was the most likely explanation 
for the inefficacy of PVP-I (Berkelman et al. 1984). A decade later, Hardegger 
et al. (1994) proved by using molecular techniques that P. aeruginosa 
produces a 16-kDa extracellular protein, encoded by the pra gene present in 
P. aeruginosa genome. These data suggest that the antimicrobial activity of 
PVP-I is challenged in the presence of organic matter. It is apparent that the 
inhibitory/bactericidal concentrations demonstrated by PVP-I, against tested 
pathogens, were notably higher compared to NS and CHD. Although PVP-I is 
generally reported as one of the broadest spectrum, rapidly acting bactericidal 
antimicrobial compounds (Burks 1998), in vitro, under certain circumstances, 
PVP-I displayed relatively high values for MIC/MBC. This paradox most 
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probably results from a combination of factors related to both instability of this 
formulation and antimicrobial deactivation of PVP-I occurring during in vitro 
testing conditions. 
  The macro dilution assay undertaken to determine the MIC/MBC 
values of antimicrobials, including PVP-I, was performed at 37 0C, using a 
nutrient broth as a culture medium. However, the 10 % aqueous standardised 
formulation of PVP-I is stable at temperatures ≤ 25 0C, as suggested by the 
manufacturer. The elevated temperature, 12 0C above the stability 
requirements during the 24 hours of examination, led to decreased activity of 
the antimicrobial compound (iodine). Simultaneously, the presence of organic 
material such as peptone and/or beef extracts in the growth medium acted as 
quencher for PVP-I resulting in decreased antimicrobial activity and increased 
values of MIC/MBC. Messager et al. (2001) have also reported the neutralising 
capacity of organic matter such as bovine albumin (1 g/l) to antimicrobial 
activity of 2 % (w/v) PVP-I. 
Silver sulfadiazine (SS) is a non-ionised antimicrobial compound which 
is poorly soluble in water (White and Cooper 2005). Despite the numerous 
efforts of investigating SS solubility in other solvents, harmless to 
microorganisms, the insoluble nature of this compound made it unfeasible to 
determine the MIC/MBC values, using the macro dilution assay. Previous 
studies conducted by Hamilton-Miller and Shah (1996) have assessed the 
susceptibility of clinical isolates against SS. The latter authors tested the MIC 
of SS, prepared as a suspension, and demonstrated that the inhibitory levels 
of suspended SS against MRSA isolates were notably higher (32 - 128 mg/ml) 
compared to E. coli and P. aeruginosa (16 - 32 mg/ml). It is clear that in vitro, 
Gram-negative strains are more sensitive to the antimicrobial activity of SS, 
than Gram-positive ones; however, the MIC values of SS were relatively high 
for a powerful and effective, in vivo, antimicrobial compound.  
It has been suggested that the oligodynamic antimicrobial profile of SS 
shown in vitro can be enhanced in vivo by the presence of electrolytes and/or 
thiol groups of proteins that biological fluids (e.g. wound exudate) contain. 
The continuous contact of SS molecules with wound fluids leads to 
solubilisation of silver sulfadiazine, therefore release of sulfadiazine and 
additional antimicrobial activity (White and Cooper 2005). Tsipouras et al. 
(1995) have investigated the solubility of SS in a synthetic electrolyte solution 
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(containing NaCl, NaHCO3, Na2HPO4 and Na2SO4), artificial exudate and human 
serum. They demonstrated that the disassociation of SS was greatly increased 
in the presence of biological fluids containing chlorides, peptides and proteins. 
The assessment of antimicrobial activity of antimicrobial wafers was 
undertaken, in vitro, using a slightly modified disc diffusion method. The 
nutritional, polymeric surface inoculated with known densities of bacteria, 
represented a suitable in vitro wound model for the initial assessment of 
antimicrobial properties of lyophilised wafers. In addition, the application of 
circular antimicrobial formulations on a moist surface was indicative of the 
swelling during rehydration of the specimens, which was calculated as the 
ratio of expansion. Figure 3.3 presents the expansion ratios of KAG wafers 
tested against MRSA, MSSA, E. coli and P. aeruginosa. The decreased 
consistency of KAG (Table 2.3, Chapter 2) induced from the incorporation of 
clinical concentrations of drugs into the biopolymeric matrix, would generally 
be expected to increase the expansion of antimicrobial formulations. However, 
such a trend was not observed. The expansion ratio of KAG wafers varied from 
1.05 – 1.15, where a non significant intra-batch variation was noted (Figure 
3.3) for all antimicrobial/polymer combinations.  
While the expansion of wafers resulted from the flow properties of the 
rehydrated polymer on a moist surface, the inhibition zone was the effect of 
diffused antimicrobial within the inoculated agar substrate during hydration. 
As such, the visible, clear and circular area of inhibition observed depended on 
the susceptibility of the bacterial strain tested against selected antimicrobials. 
However, other secondary parameters may influence the inhibition zone 
formed from the diffusion of antimicrobial compounds. Molecular weight of the 
tested drugs, solubility and the degree of interaction between the diffused 
drug and the agar substrate are considered as the main secondary parameters 
which may influence the rate of diffusion of antimicrobial compounds. 
Consequently, these parameters will likely affect, indirectly, the zone of 
inhibition obtained for an antimicrobial compound against a selected 
bacterium. 
Figure 3.4 presents the antimicrobial activity of tested antimicrobial 
formulations, calculated as the inhibition ratio (IR), where the control wafer of 
plain KAG or KAG impregnated with 0.2 % (w/v) F68 (control for the SS 
wafer) did not demonstrate inhibition zones. The antimicrobial activity of 
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loaded wafers was compared between the bacterial species, as the 
antimicrobial compounds tested possess different molecular weights and 
solubility profiles. Diffused CHD demonstrated the largest IR against MRSA and 
MSSA, whereas the susceptibility of S. aureus strains to CHD was significantly 
higher compared to E. coli and P. aeruginosa (p < 0.001). The antimicrobial 
effect of diffused CHD appeared to be lower against E. coli and P. aeruginosa; 
however, there was no significant difference for CHD between Gram-negative 
strains.  
Diffused neomycin sulphate (NS) demonstrated a similar antimicrobial 
activity to CHD when tested against MRSA, MSSA, E. coli and P. aeruginosa. 
NS showed a similar IR against Gram-positive strains of MRSA and MSSA and 
a significantly higher IR compared with E. coli and P. aeruginosa (p < 0.001). 
The antimicrobial activity of NS was reduced when tested against Gram-
negative strains. In addition, P. aeruginosa appeared to be more susceptible to 
NS than E. coli (p < 0.01). Moreover, it is worth noting that although NS is a 
broad spectrum topical antibiotic, its antimicrobial activity, in vitro, calculated 
as the IR, appeared to be notably higher compared to the broad spectrum, 
rapidly lethal antiseptic compounds of PVP-I and SS.   
The antimicrobial activity of PVP-I varied between the bacterial strains 
tested. Similar to NS and CHD, PVP-I appeared to be more effective against 
Gram-positive strains of MRSA and MSSA. The IR with both S. aureus strains 
was similar, but significantly greater than those with E. coli (p < 0.05, p < 
0.01) and P. aeruginosa (p < 0.01). P. aeruginosa demonstrated the highest 
tolerance to PVP-I compared to all antimicrobials and bacterial strains tested. 
The antimicrobial activity of PVP-I against P. aeruginosa obtained from the 
disc diffusion assay, was in agreement with previous research studies, already 
discussed, indicating the deactivation of antimicrobial properties of iodophors 
by Pseudomonas spp. In addition, other factors such as the temperature 
exceeding the stability requirements of PVP-I and the presence of organic 
matter (e.g. peptone/beef extract) in the cultivated nutrient can affect the size 
of the inhibition area created over 24 hours for this antimicrobial. 
Antimicrobial wafers impregnated with 1.0 % of SS (w/v) prepared as a 
suspension with 0.2 % (w/v) pluronic F68, were also tested using the 
inoculated, moist agar surface. Interestingly, all species were similarly 
susceptible to the small, soluble amount of SS diffused from the hydrated 
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matrix of KAG. P. aeruginosa demonstrated slightly increased susceptibility to 
SS, however not significantly different compared to MRSA, MSSA and E. coli. 
In addition, SS showed reduced antimicrobial activity, in general, compared to 
NS, CHD and PVP-I, indicating that the poor solubility of this compound 
probably had a major effect on the diffusion of SS particles within the agar 
substrate. 
 The disc diffusion assay was used as a simple model surface for exuding 
wounds for assessment of the antimicrobial activity of CHD-loaded wafers 
prepared with different biopolymers (e.g. GG, XG, SA and SA-KAG). The 
expansion properties were investigated along with the antimicrobial activity of 
wafers when tested against P. aeruginosa. Expansion of CHD-free specimens 
was compared to CHD-loaded lyophilised formulations. Figure 3.5 presents the 
expansion profiles of controls and CHD-loaded lyophilised wafers calculated as 
the expansion ratio (ER). It is apparent that the incorporation of CHD into the 
biopolymeric matrices generally decreased the expansion of re-hydrated 
wafers compared to controls.  SA-CHD matrix, in particular, demonstrated the 
most notable decrease in ER compared to respective control specimen by 
approximately 1.5 times. 
The antimicrobial-free matrix of SA displayed the highest value of ER, 
indicating that the re-hydrated SA wafer extended its diameter 1.51 ± 0.03 
times the original diameter. These results are in total agreement with 
Matthews et al. (2005), where the lyophilised wafers (D0 = 34 mm) prepared 
with 5 % of a low viscosity grade SA displayed an ER of 1.6 ± 0.01 within 24 
hours. The addition of CHD into the SA matrix induced a notable decrease in 
the expansion ratio. The decreased ER of SA-CHD wafers was likely to be due 
to a considerable increase in consistency induced from the incorporation of 
CHD in the gel network of SA, reported in Chapter 2 (Table 2.4, Figure 2.4). 
Earlier work by Matthews et al. (2005) had produced a similar decrease in the 
ER of SA wafers by the addition of small amounts of methylcellulose (MC) 
which acted as a viscosity modifier. It was suggested that the viscosity of pre-
lyophilised gels determined the flow behaviour of re-hydrated wafers. These 
observations were based on truly pseudoplastic flow behaviour i.e. no 
apparent yield stress. 
In the case of formulations prepared with gels displaying pseudoplastic 
flow with an apparent yield stress (e.g. GG and XG), the expansion behaviour 
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of re-hydrated wafers, appeared to be more complex. It is apparent that such 
polymers show a restricted expansion; however, it is not clear if the increased 
yield stress is proportionally related to decreased expansion of the respective 
re-hydrated formulations. For instance, the expansion ratio of XG was smaller 
than GG; however, the pre-lyophilised gel of GG demonstrated a higher 
viscosity and yield stress than XG (Table 2.4, Chapter 2). Therefore, the 
degree of wettability may play a primary role in the expansion behaviour of 
polymers displaying a plastic flow.  
The phenomenon of expansion of a swollen polymer becomes more 
complicated and indecipherable when the drug incorporated into the polymer 
network acts as a ‘viscosity modifier’. As reported in Chapter 2 (Table 2.4, 
Figure 2.4), the combination of CHD with biopolymers notably affected the 
rheological behaviour of pre-lyophilised gels. The CHD-impregnated wafers of 
GG, XG and SA demonstrated similar expansion behaviours, where the 
expansion ratio varied from 1.02 - 1.07, indicating slightly increased swollen 
diameters and no appreciable flow. On the other hand, the wafer prepared as 
a dual synergistic carrier of SA-KAG, did not expand within 24 hours of re-
hydration, whereas the diameter of CHD-loaded SA-KAG specimens displayed 
a decreased diameter conducive with shrinkage. 
It is difficult to precisely conclude which factors have a primary 
influence in the expansion/shrinkage behaviours of re-hydrated wafers, either 
alone or as carriers of antimicrobial compounds, as this behaviour is strongly 
related to both external factors such as temperature and humidity conditions 
created within the Petri dish, and internal factors such as the inherent 
hydrophilic properties of individual biopolymers. In other words, expansion 
and/or shrinkage of each specimen is the result of an equilibrium during water 
uptake (rate of re-hydration) and water restraint (rate of evaporation), where 
hydrophilic properties of individual biopolymers most probably play the key 
role. However, other external factors such as adhesive, polymeric chain 
entanglements developed at the polymeric interface between polymeric 
carriers and the agar surface may also have an additional impact (Shenoy et 
al. 2005). 
The antimicrobial activity of CHD-loaded wafers was measured after 24 
hours of re-hydration when in contact with a nutrient agar surface inoculated 
with known densities of P. aeruginosa. The inhibition zones were calculated as 
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the inhibition ratio (IR) and are presented in Figure 3.6. It is apparent that 
although antimicrobial wafers were prepared with an equal concentration of 
CHD, i.e. similar weights of drug (7434 ± 98.0 µg), the inhibition ratios were 
significantly different. GG, XG and KAG demonstrated significantly higher 
values of IR compared to SA and/or SA-KAG (p < 0.001, p < 0.01 and p < 
0.05). Plotted values of ER versus IR of antimicrobial wafers (Figure 3.7) 
indicated that there is a significant, yet moderate correlation (R2 = 0.5882) 
between the expansion and inhibition ratios resulting within 24 hours of 
swelling. The data obtained indicate that for inhibition zones developed during 
gradual expansion of re-hydrated wafers, the bigger the expansion the larger 
the inhibition area. Although inhibition ratios were calculated as the ratio of 
the diameter of the inhibition zone (Di) to the initial diameter of the wafer 
(D0), these estimations do not characterise the absolute antimicrobial activity 
of CHD-loaded formulations.  In addition, the significant correlation between 
ER vs. IR indicated that the diffusion of CHD is part of a dynamic process, 
where the diameters of the saturated discs are variable with time. It was 
concluded that the disc diffusion assay is a reliable, yet semi-quantitative 
control method for the initial investigation of the flow and antimicrobial 
properties of antimicrobial wafers.   
It is not a simple matter to quantify the antimicrobial efficacy of 
formulations intended for topical application in a variety of suppurating 
wounds. The complex nature of infected non-healing wounds with regards to 
both polycontamination and continuous production of exudate represent a 
complex environment to mimic in vitro. The efficacy of antimicrobial dressings 
in terms of determining the killing rates of released antimicrobials during 
hydration of the formulation has normally been undertaken using the 
conventional kill-time assay (Ip et al. 2006; Rossi et al. 2007). However, 
under such conditions, the formulation under test will eventually totally 
disintegrate and dissolve in the presence of substantial amounts of dissolution 
medium. Usually, contemporary formulations prepared for topical drug 
delivery in exuding wounds aim to absorb the exudate while maintaining a 
swollen intact state. Therefore, testing the antimicrobial properties of 
dressings using time-kill studies, is likely to demonstrate the accelerated rate 
of killing of antimicrobials released from their carriers, possibly a desirable 
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property for effective topical application. Importantly, however, it does not 
resemble the real conditions of exuding wounds. 
The antimicrobial diffusion cell (ADC) was developed in order to quantify 
the effect of antimicrobials released slowly from the matrices of KAG wafers as 
the antimicrobial formulations continuously hydrated and swelled, but did not 
disintegrate. These conditions were mediated by placing the antimicrobial 
formulation in permanent contact with a wetted hydrophilic membrane. The 
antimicrobial effect of released antimicrobials was tested against planktonic 
cells of MRSA, a common pathogen of chronic wounds. In addition, in order to 
overcome the potential quenching affect of organic matter present in nutrient 
agar/broth, bacterial cells were initially suspended in phosphate buffer solution 
(PBS) containing  KCl (0.02 %) and NaCl (0.8 %), adjusted to pH 7.4. Figure 
3.8 presents the killing behaviour of the tested antimicrobials against MRSA 
over 8 hours. Although PBS buffer was adjusted to a similar pH to the growth 
medium, the lack of nutrition led to gradual death of MRSA cells by 
approximately 1-log power (90 %) within 8 hours and 2-log powers (99 %) at 
24 hours.  
The data obtained demonstrated that all the antimicrobials decreased 
the viability of MRSA by approximately 2-log powers (99 %) over 4 hours. At 
that stage the untreated cells (control) were still at a considerable and viable 
density. The release of iodine from its PVP carrier showed the fastest killing 
rate, where this potent antimicrobial killed all the MRSA cells within 6 hours. 
CHD demonstrated the second fastest killing rate against MRSA as there were 
no detectable bacterial cells within 8 hours. NS demonstrated a slower killing 
rate compared to PVP-I and CHD, however the release of NS decreased by > 
2-log powers (> 99 %) the viability of MRSA over 8 hours, and totally killed 
the presence of the bacterium at 24 hours. SS demonstrated a similar killing 
pattern to NS within 8 hours, however in the case of SS, its sparing solubility 
should also be considered. The SS particles entrapped in the lyophilised matrix 
of KAG, were unable to pass through the cellulose membrane, resulting in a 
slower, yet considerable decrease of MRSA population. However, the change in 
colour from white to light purple-blue for the SS wafer, at 24 hours, consistent 
with the formation of silver chloride, indicated that the chloride ions present in 
the PBS solution enhanced the solubilisation of the silver salt producing 
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sulfadiazine. These results are in agreement with previous studies on 
solubilisation of silver sulfadiazine undertaken by Tsipouras et al. (1995).  
The antimicrobial activity of antimicrobials released from the swollen 
matrix of KAG was further assessed by suspending similar densities of MRSA 
cells in a salt solution containing 142 mmol/l NaCl (0.82 %) and 2.5 mmol/l 
CaCl2 (0.027 %), typical values to those found in wound exudate (Thomas 
2007). This experimental condition aimed to investigate the antimicrobial 
activity of selected antimicrobial compounds only in the presence of certain 
electrolytes such as Na+, Ca2+ and Cl- at a lower pH. The pH of the prepared 
solution was slightly acidic (pH 6.5) and the absence of nutrients led to 
considerable reduction of untreated MRSA cells (Figure 3.9). There was a 
notable decrease in the viability of MRSA cells [(> 1-log power, (> 90 %)] 
over 4 hours, suggesting that the salt solution did not present a suitable niche 
for the viability of planktonic cells. The killing rate of PVP-I and CHD were 
faster than in PBS, however, this was probably due to a reduced MRSA 
population in the NaCl-CaCl2 solution, rather than potentiation of CHD and/or 
iodine in the presence of Na+, Ca2+ and Cl- electrolytes. On the other hand, the 
antimicrobial effect of released NS and SS upon the viability of MRSA was 
notably inhibited compared to the untreated control, despite the apparent 
reduction of the MRSA population in the control medium. This paradox was 
likely related to inhibited antimicrobial activity of NS in a slightly acidic 
environment. NS is a bactericidal, antimicrobial compound which induces 
lethal reaction in bacteria by inhibiting protein synthesis. However, the 
antimicrobial effect of this aminoglycoside depends on the extracelluar pH. It 
has been reported that antimicrobial activity of NS is reduced significantly in 
the presence of cations (e.g. Ca2+ and Mg2+) and in solutions of pH ≤ 6.5 
(www.greatvistachemicals.com).  
The antimicrobial activity of SS upon the viability of MRSA was also 
reduced compared to the antimicrobial-free control (KAG) wafer. Although it 
has been reported that the anionic content of exudate, in particular chloride 
ions, influence the solubility of sulfadiazine salt and increase its antimicrobial 
activity (Tsipouras et al. 1995) the effect of chloride ions, present in the 
prepared salt solution, was probably inhibited by the slightly acidic pH 
displayed. White and Cooper 2005 have also reported that disassociation of 
silver salts is a pH dependent reaction.  The results obtained indicated that the 
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pH of the environment where antimicrobial compounds are released plays a 
decisive role in antimicrobial activity. 
To simulate further the conditions existing in exudates of infected, non 
healing wounds, the salt solution of NaCl-CaCl2, containing similar values of 
electrolytes to those found in human exudates, was enriched with 3 % w/v 
bovine serum albumin (BSA). The concentration of protein varies with wound 
aetiology and clinical healing stage, however, the selected concentration of 
BSA represents an average value of protein found in exudates of chronic 
wounds (Clought and Noble 2003). Figure 3.10 presents the antimicrobial 
effect of antimicrobial compounds released in the presence of BSA over 24 
hours. The antimicrobial profiles of topical antimicrobials released from the 
swollen KAG matrix were notably altered in the presence of BSA. The BSA 
supplement increased the pH of the solution to 7.4 and provided sufficient 
nutrient for a viable population of MRSA to survive over 24 hours, maintaining 
the initial bacterial density. Under these conditions, the comparison of 
antimicrobial effect to the untreated control was more meaningful.  
The presence of BSA totally deactivated the antimicrobial effect of 
iodine released from its carrier. These results are in agreement with previous 
research studies indicating the quenching activity of BSA upon the 
antimicrobial activity of PVP-I (Messager et al. 2001). The presence of organic 
matter appeared to inhibit moderately the antimicrobial activity of CHD, as the 
CHD released decreased the viability of MRSA by less than 1-log power (< 90 
%) after 4 hours. In contrast, the same antimicrobial led to more than a 2-log 
powers (> 99 %) reduction of MRSA cells in the absence of organic mater, at 
similar pH values, in PBS. Pitten et al. (2003) has also reported the inhibition 
effect of organic matter such as 10 % albumin, 10 % sheep blood or 1% 
mucin on the antimicrobial activity of chlorhexidine and/or PVP-I.  
While the presence of organic material represents a challenge for the 
antimicrobial activity of PVP-I or CHD, for other topical antimicrobials such as 
SS and NS, the presence of BSA acts as a potentiatior. SS decreased the 
viability of MRSA by 1-log power (90 %) after 4 hours. The viability of 
bacterial cells was further decreased after 24 hours by >1-log power (> 90 
%), however, not considerably compared to SS wafers in the presence of PBS. 
Fox and Modak (1974) and Tsipouras et al. (1995) have also indicated that 
dissociation of SS is similar in both electrolyte solutions containing chloride 
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ions and in the presence of human serum. Solubility of the sulfadiazine salt of 
silver appeared to be moderate in such solutions, where the addition of protein 
does not enhance significantly the antimicrobial activity of SS (Fox and Modak 
1974). 
 In contrast, the presence of BSA and the elevated pH of the pseudo-
exudate enhanced notably the antimicrobial activity of NS. Under such 
conditions, NS released showed a maximum antimicrobial activity and the 
fastest killing rate by decreasing the viability of MRSA cells more than 3-log 
powers (> 99 %) within 8 hours. It is difficult to precisely identify the 
enhanced effect of BSA upon the antimicrobial properties of NS in a complex 
solution such as the pseudo exudate. However, a plausible interpretation may 
be achieved by elucidating the interaction occurring between the molecules 
present in the medium. Although it is well know that the majority of proteins 
of human serum bind to antimicrobials/antibiotics and deactivate their 
antimicrobial effect, recently, it has been reported that NS binds weakly to 
BSA (Keswani et al. 2010). In addition, it has been reported that small ions 
such as Na+ and Ca2+ do appreciably bind to the structures of BSA (Doremus 
and Johnson 1958). This favourable interaction between BSA and Na+ and 
Ca2+  results in two simultaneously favourable effects towards enhancement of 
the antimicrobial activity of NS; elevated values of pH (from 6.5 to 7.4) and 
the elimination of free Ca2+ inhibitors of NS.  
In conclusion, it is apparent that the use of the ADC represented a 
superior in vitro microbiological assay, compared to disc diffusion, for 
evaluating the efficacy of antimicrobial formulations, such as antimicrobial 
wafers, intended as topical delivery systems for suppurating, non healing 
wounds. There are several advantages of the ADC to conventional time-kill 
studies and disc diffusion. Firstly, ADC represents an in vitro model that 
resembles relatively well the swollen yet intact state of dressings when applied 
in moderately exuding wound beds. Secondly, it demonstrates the 
antimicrobial effect, with time, of sustained release of antimicrobials from 
slowly re-hydrating wafers upon the common bacterial population present in 
chronic wounds. Thirdly, the different media used either alone, or enriched 
with organic material, provide a picture of how antimicrobial activity of well-
known and widely used antimicrobial compounds can be considerably altered 
by the presence of electrolytes and proteins found in wound exudates. In 
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addition, interaction between topically applied antimicrobials and compounds 
present in human serum should be elucidated prior to application of any 
antimicrobial formulation to suppurating wound beds, as inhibition of the 
antimicrobial effect can lead to poor therapy and perhaps to an increased 
likelihood of acquired bacterial resistance. 
Limitations of the developed ADC model are recognised, two main 
drawbacks being apparent. Firstly, the use of an inert, hydrophilic membrane 
would be considered a better choice, as cellulose was reported recently to 
favourably interact with cationic compounds such as chlorhexidine (Gimenez-
Martin et al. 2009); however, these recent facts were not known at the time of 
experimentation. Secondly, samples taken at 2-hour intervals introduced 
untreated planktonic MRSA cells from the donor chamber into the receptor 
chamber (Figure 3.2). However, this untreated bacterial population was 
calculated to be a maximum of 5 % of the total volume of the receptor 
chamber and did not exceed 1 ml over 24 hours. 
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Chapter 4 
Release studies of chlorhexidine digluconate 
(CHD) from lyophilised wafers and gels  
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4.1 Aim  
To analyse the release profiles and to quantify released CHD from lyophilised 
and pre-lyophilised gels prepared with biopolymers displaying different flow 
behaviours. 
 
4.2 Introduction 
Lyophilised antimicrobial wafers intended for targeted drug delivery in 
contaminated and exuding non healing wounds, were analysed for the ability 
to release a broad spectrum antimicrobial compound such as CHD. 
Quantification of the amount of delivered antimicrobial compound in a poly-
contaminated niche, such as the non-healing chronic wound bed, is an 
important parameter for the efficacy of an antimicrobial formulation. It is well 
known that quantities of antimicrobial delivered must exceed the MIC/MBC 
values for selected bacteria for the treatment to be effective. In contrast, sub-
inhibitory antimicrobial concentrations of active agents will lead to continued 
growth of pathogens in a wound bed, persistent infection and poor control of 
bacterial bioburden.  
The quantification of released antimicrobial compound from a polymeric 
antimicrobial dressing is not a simple matter, as many factors can influence 
the release of the drug from its carrier. Factors such as the rate of exudate 
production from the damaged skin (external factor) and the degree of water 
uptake of the polymeric carrier (internal factor) are two of the most important. 
There is restricted information with regards to quantification of exudate 
produced from non healing wounds as exudation varies with wound aetiology 
and clinical healing stage. Different levels of suppuration are difficult to 
reproduce in vitro, however, in the present study, an enclosed dissolution 
apparatus that roughly resembles the exuding wound environment is used to 
quantify and further understand the release profiles of CHD from lyophilised 
polymeric carriers. In addition, the release profiles of CHD from lyophilised 
wafers have been compared to those of pre-lyophilised gels.  
The release of CHD from the biopolymeric vehicles was assessed in a 
dissolution medium containing 142 mmol/litre of sodium ions and 2.5 
mmol/litre of calcium ions, similar values of electrolytes found in wound 
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exudate (Thomas 2007).  The same dissolution medium is used to assess 
moisture vapour permeability, fluid handling properties and absorbance 
capacity of commercial polymeric dressings (www.dressings.org).  Additional 
water uptake estimations were undertaken for re-hydrated antimicrobial 
wafers, under the conditions created in the enclosed dissolution apparatus. 
Kinetics of release profiles of CHD from both wafers and gels were also 
analysed using an appropriate diffusion model.  
The in vitro simulated conditions of an exuding environment were 
facilitated by placing antimicrobial formulations (wafers and/or gels) on a 
constantly hydrated cellulose membrane. Recently, published studies revealed 
that chlorhexidine digluconate is absorbed by cellulosic fibres (Gimenez-Martin 
et al. 2009). The experiments performed for the purposes of this chapter were 
scheduled and undertaken, prior the publication of this information, however, 
the sorption of chlorhexidine on cellulose will be taken into account during 
discussion of the obtained data. 
 
4.3 Materials and methods 
4.3.1 Materials 
Gels and wafers were used and produced as previously described in Chapter 2 
(2.2.2). Sodium chloride (NaCl) and calcium chloride (CaCl2) were purchased 
from Sigma-Aldrich, Gillingham, UK. Cellulose membrane (12-14 kDa) was 
obtained from Medicell Int. Ltd., UK. UV spectrophotometer Cecil CE 3021 was 
used. Quartz cuvettes (3 ml volume) were purchased from Fischer Scientific 
Ltd. UK.  The free standing dissolution raft was designed by the author and 
constructed by the workshop engineers of the Robert Gordon University.  
 
4.3.2 Methods 
4.3.2.1 In vitro release of CHD from lyophilised wafers and gels 
Six identical free standing dissolution rafts (FSDR) were constructed as 
indicated in Figure 4.1. CHD lyophilised wafers and freshly prepared CHD gels 
(1.5 ± 0.2 g) were placed on top of the cellulose membrane (12-14 kDa) in 
contact with the dissolution medium for 24 hours at 36 ± 0.5 0C. The FSDR 
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was placed in 20 ± 2 ml of dissolution medium (NaCl-CaCl2) in a glass 
container topped with a lid to avoid evaporation during the experiment. The 
enclosed dissolution system was placed in an agitating water bath (Fischer 
Scientific) at 145 rpm. Samples (3 ml) were taken, analysed and returned to 
the glass container at hourly intervals for eight hours and after 24 hours, in 
order to maintain a constant volume of dissolution medium with time. The 
presence of CHD was detected by UV analysis at 254 nm and the 
concentration determined from the regression equation generated from the 
calibration curve in NaCl-CaCl2 solution (y = 0.0306x, R
2 = 0.9995). 
Two controls containing known amounts of CHD in the dissolution 
medium were included.  The first contained 46 µg/ml of CHD and was placed 
under the same conditions with the tested CHD-polymeric carriers (36 ± 0.5 
0C). The second control contained 30 µg /ml CHD, and a dissolution raft with 
no CHD-wafers/gel was placed at 20 ± 0.5 0C. Samples (3 ml) were taken 
every hour for 8 hours and at 24 hours and analysed as described above. The 
absorbance indicated the amount of CHD in the solution over 24 hours. 
 
 
Figure 4.1 Configuration of the free standing dissolution raft (FSDR)  
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4.3.2.2 Calculation of the water uptake capacity (WUC) (%) for 
lyophilised wafers in NaCl-CaCl2  dissolution medium  
The water uptake capacity of different lyophilised controls and CHD loaded 
wafers when placed on top of a constantly hydrated cellulose membrane for 24 
hours, as presented in Figure 4.1, was determined. Wafer weights were 
recorded prior to being placed on the membrane (W0) and after 24 hour of 
water uptake (Wt), using an analytical balance, Mettler AE 50. Water uptake 
(WU) was calculated in percentage terms (%) using the simple formula: WU = 
(Wt/ W0) x 100, where Wt = weight of swollen wafer after 24 hours of 
hydration and W0 = weight of lyophilised wafer at time zero. 
 
4.3.2.3 Analysis of drug release kinetics 
The kinetics of CHD released from re-hydrated wafers and gels in NaCl-CaCl2 
dissolution media were determined by analysing the curves based on a simple, 
yet comprehensive model of Korsmeyer-Peppas [Equation (1)], which is based 
on the Higuchi theory of diffusion (Lao et al. 2011).  
                                    Mt/Minf = kt
n                          (1) 
                         log10(Mt/Minf) = log10 (kt
n)              (2) 
                         log10(Mt/Minf) = nlog10t + log10k     (3) 
                       
Mt = the concentration of CHD released at a given time (t), Minf = the 
concentration of CHD present initially, k = constant of structural and 
geometrical characteristic of the formulation and n = the diffusion exponent. 
The diffusion exponent (n) was calculated as the slope of the linear regression 
line, by plotting the mean value of three samples [log10 (Mt/Minf)] against 
(log10t) [Equation (2) and (3)]. Table 4.1 presents the values of the release 
exponent (n) and drug release mechanism of the polymeric delivery system 
formulated as a cylindrical shape (Lao et al. 2011). 
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Table 4.1 Values of the diffusion exponent (n) and solute drug release 
mechanism of cylindrical shaped polymeric systems (Lao et al. 2011; Cox et 
al. 1999; Tang et al. 2009). 
Diffusion exponent (n)   Drug release mechanism 
≤ 0.45 Fickian diffusion 
0.45 < n < 0.89 Anomalous (non-Fickian) transport 
0.89 Case-II transport 
n > 0.89 Super case-II transport 
 
4.4 Data analysis 
Data are presented as the mean value of three samples ± standard error of 
the mean (SEM). Regression analysis of the data was performed using 
GraphPad Prism 4 software.  
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4.5 Results 
 
Figure 4.2 Determination of UV wavelengths of CHD solution, using a 
ThermoSpectronic Biomate 5 spectrophotometer. Note that CHD has two peak 
maxima in the wavelength region at 231 and 254 nm. UV measurements for 
the purposes of this project were undertaken at 254 nm. 
 
 
Figure 4.3 Standard UV calibration curve of CHD in NaCl-CaCl2 solution at 254 
nm (R2 = 0.9995). 
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Table 4.2 Control solutions of CHD containing 46 and 30 µg/ml CHD, 
respectively, tested at 36 ± 0.5 and 20 ± 0.5 0C. Please, note that there is a 
decrease in the concentration of CHD (control 1) at 36 ± 0.5 0C by 
approximately 4 %, indicating degradation of CHD after 24 hours incubation. 
CHD solution tested at 20 ± 0.5 0C remained at a steady concentration, 
indicating that the presence of cellulose membrane did not affect the 
concentration of CHD. 
 
Time 
(Hours) 
Control 1 (36 ± 0.5 0C) Control 2 (20 ± 0.5 0C) 
CHD 
(µg/ml) 
CHD 
(%) 
CHD 
(µg/ml) 
CHD 
(%) 
0 46.30 100 29.68 100 
1 45.57 98 30.76 104 
2 45.74 99 30.05 101 
3 45.98 99 30.66 103 
4 45.49 98 29.76 100 
5 46.05 99 29.74 100 
6 46.32 100 29.67 100 
7 46.16 100 29.42 99 
8 46.33 100 - - 
24 44.29 96 30.16 102 
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Figure 4.4 Release profiles of CHD- impregnated biopolymeric carriers (pre-
lyophilised gels  and lyophilised wafers) in NaCl-CaCl2 dissolution medium, 
(a) gels (b) wafers (n = 3, SEM) 
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Table 4.3 Accumulation of CHD (%) in NaCl-CaCl2 dissolution medium, from 
gels and wafers impregnated with clinical concentrations (0.5 % v/v) CHD, at 
24 hours (n = 3, SEM). 
 
Polymer type 
(w/v) 
Accumulation of CHD (%) in NaCl-CaCl2 
Gel Wafer 
 
2.0 % GG 
 
8.5 ± 1.15 4.2 ± 0.21 
 
1.5 % XG 
 
7.5 ± 0.97 7.6 ± 0.66 
 
3.0 % KAG 
 
14.7 ± 2.59 17.4 ± 0.39 
 
5.0 % SA 
 
10.7 ± 2.07 3.5 ± 0.04 
1.5 % - 1.5 % 
SA-KAG 
5.5 ± 0.21 3.5 ± 0.01 
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Figure 4.5 Water uptake capacity (WUC) (%) of re-hydrated wafers within 24 
hours, placed on the FSDR. (n=3, SEM). 
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Figure 4.6 Linear regression of released CHD from polymeric systems in 
NaCl-CaCl2, as analysed with the Korsmeyer-Peppas model; (a) gels (b) 
wafers  
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Table 4.4 Values of the release exponent (n) and the correlation coefficient 
(R2) of CHD released from gels and wafers, in NaCl-CaCl2, as analysed with the 
Korsmeyer-Peppas model; F (Fickian diffusion), NF (non-Fickian diffusion). 
 
Polymeric 
systems 
impregnated 
with CHD 
(w/v) 
n 
(R2) 
Gel Wafer 
 
GG 
 
0.0 
(0.0359) 
0.36F 
(0.9974) 
 
XG 
 
0.37F 
(0.9791) 
0.65NF 
(0.9981) 
 
KAG 
 
0.39F 
(0.9413) 
0.41F 
(0.9752) 
 
SA 
 
0.39F 
(0.9819) 
0.36F 
(0.9974) 
 
SA-KAG 
 
0.31F 
(0.9914) 
0.33F 
(0.9935) 
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4.6 Discussion 
Antimicrobial loaded biopolymers, studied either as lyophilised wafers or 
pre-lyophilised gels, showed varied release profiles (Figure 4.4). The 
concentrations of CHD detected in NaCl-CaCl2 after eight hours varied from 
15.5 ± 1.250 µg/ml for SA-KAG gel to 35.5 ± 4.934 µg/ml for GG gel.  The 
accumulated CHD after eight hours released from rehydrating wafers varied 
from 8.1± 0.183 µg/ml for SA and 22.3 ± 0.958 µg/ml for KAG. The rate of 
released CHD after eight hours varied between gel types, where GG > KAG > 
XG > SA > SA-KAG, where the synergistic combination showed the lowest rate 
of release and GG the highest, respectively. The release patterns of CHD from 
rehydrating wafers differ between wafers, where KAG > XG > GG > SA-KAG > 
SA. It is apparent that the rate of released CHD was not similar for polymeric 
carriers consisting of the same biopolymer in the pre-lyophilised or lyophilised 
state; however, generally SA and SA-KAG (gel and/or wafer) showed the 
slowest rate of release. The apparent decrease of CHD, from 8-24 hours, 
observed in the case of GG gels, was attributed to degradation of CHD with 
time, at 36 ± 0.5 0C (Table 4.2). 
The diffusion of a soluble compound from a polymeric network is 
mediated via complex mechanisms that depends on both external (nature of 
the aqueous environment) and internal (inherited properties of polymeric 
molecules) factors.  Hydrophilic biopolymers ‘biohydrogels’ used as carriers of 
a cationic antimicrobial compound, CHD, are large molecules, linear and/or 
branched, ionic and/or non-ionic, which possess an inherent ability to form a 
three-dimensional, cross-linked network in the presence of water. Cross-
linking of such molecules is facilitated through ionic, hydrogen bonds, van der 
Waals forces and/or physical entanglements (Singh et al. 2010). The 
compartments formed within the 3-D polymeric network are filled with water, 
which contains the soluble molecules of CHD. Solute transport within the 
biohydrogels occurs, initially, within the water-filled areas in the structure 
depicted by the polymeric chains. Alteration in space of these regions will 
eventually influence the movement of the entrapped solute. The main factors 
that effect the diffusivity of solute entrapped in  compartments between 
polymeric chains include, solute concentration, solute size in relation to the 
size of compartments created between polymeric chains, degree of swelling, 
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molecular weight between crosslinks, degree of crystallinity, pore size, 
mobility of polymeric chains and drug-polymer interactions (Amsden 1998).  
The amount of CHD within the polymeric carriers was similar and the 
weight of drug was estimated at 7434.4 ± 98.0 µg per 1.5 ± 0.02 g of gel 
(pre-lyophilised and/or lyophilised). However, the polymer concentration 
varies from 1.5 - 5 % (w/v), where XG had the lowest and SA the highest 
concentration. The slower diffusivity of CHD from the SA gel, compared to that 
from the XG gel, may simply be due to an increased polymer concentration for 
SA. According to Amsden (1998) “the diffusivity of a solute through a 
physically cross-linked hydrogel decreases as cross-linked density increases”. 
However, based on the rheological results, XG appear to be more prone to 
forming a weak gel network (with a yield stress) than SA (with no yield stress, 
even at 5 % w/v). The release of CHD from GG however, does not appear to 
fit this picture. 
As previously mentioned (Chapter 2), the presence of CHD in the 
biopolymer network induced notable changes to the flow properties of the 
gels. Rheological analysis of CHD-loaded gels demonstrated that the addition 
of CHD increased the values of consistency and/or yield stress for SA, XG and 
SA-KAG, while GG gel showed negligible alterations (Table 2.4, Figure 2.4). 
These results indicate that the entrapment of CHD in the water-filled 
compartments of cross-linked biohydrogels was likely interacting with the 
surrounding polymeric chains.  Drug-polymer interactions led to permanent 
entrapment of drug within the cross-linked network, and restrained diffusivity 
through the gel network. It is apparent that most gels and/or wafer samples 
released CHD at a decreasing rate, indicating that the developed interactions 
between CHD and polymer carriers played a key role in the delivery of the 
antimicrobial compound.   
GG gel demonstrated a different pattern of CHD release compared to all 
other gels. Diffusivity of CHD from GG gel showed a burst release that reached 
a maximum concentration of 40.7 ± 2.922 µg/ml at 2 hours. This pattern of 
release of CHD from the pre-lyophilised gel of GG was clearly dissimilar 
compared with release of CHD from the lyophilised wafer of GG. These results 
suggest that this lyophilised wafer can deliver in a sustained release manner; 
however, the rate of delivery of impregnated compounds varies with nature of 
the biopolymeric carrier.  The total accumulated concentrations of CHD at 24 
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hours (Table 4.3) provide a rough indication of such influence, however, these 
values  do not represent absolutely the accumulated concentration at 24 
hours, as some of CHD is degraded (approximately 4 %). Although it was 
reported that CHD interacts with cellulose fibres, this interaction did not play a 
considerable effect on the total accumulation of CHD in the dissolution medium 
(Table 4.2).   
The total accumulation of CHD at 24 hours varied from 3.5 ± 0.01 % to 
17.4 ± 0.39 % for wafers, where SA-KAG and KAG demonstrated the lowest 
and the highest accumulation, respectively. The accumulation of CHD from 
gels was slightly increased compared to wafers and ranged from 5.5 ± 0.21 % 
to 14.7± 2.59 % for SA-KAG and KAG, respectively. Although the 
concentration of accumulated CHD from biopolymeric carriers is minimal and 
did not exceeded 17.5 %, the accumulated concentrations of CHD from gel 
and wafers were generally similar, except in the case of GG and SA. It is 
apparent that the amount of CHD released from GG gels was 2-times higher 
than from GG wafers. Interestingly, both gels and wafers of XG and KAG 
released similar amounts of CHD within 24 hours. Although wafers of SA and 
SA-KAG released similar amounts of CHD at 24 hours, these gels increased the 
release of CHD by 3 and 1.5 times respectively. This data indicates that 
lyophilised wafers can provide a controlled release of the impregnated 
therapeutic compound. 
The majority of polymeric systems (gels and/or wafers), displayed 
similar patterns of release of CHD. Although the pre-lyophilised gels were 
expected to show a faster release of CHD compared to the respective wafers, 
this was only apparent for GG gel. The mechanism of drug transport through a 
polymeric gel is governed by the rules already discussed, however in the case 
of water absorbent formulations the level of water uptake will also have an 
impact on the pattern of release of the incorporated drug. According to 
Vlachou et al. (2001) “the overall delivery rate from a polymeric specimen is 
expected to be a function of both swelling and disintegration (erosion)”. In the 
case of rehydrated lyophilised wafers, water uptake only led to swelling of the 
matrix. 
Water uptake capacity (WUC) of lyophilised wafers, (antimicrobial-free 
or loaded) varied from 492 ± 56.65 % to 1161 ± 87.55 %, where GG showed 
the lowest and SA the highest water uptake capacity, respectively (Figure 
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4.5). These results suggest that lyophilised wafers can absorb and retain a 
substantial amount of water, approximately 5 - 11 times their initial weight; 
however, the ability to absorb water will depend on the inherent 
hygroscopicity of each polymer. The equilibrium swelling will be a balance 
between available water, relative humidity and temperature. All these 
biopolymers will have a particular water uptake capacity in the conditions 
created in the FSDR. Antimicrobial-free wafers demonstrated a slightly 
increased water uptake capacity, compared to CHD-loaded wafers. XG-CHD 
wafers in particular demonstrated approximately 2 times decreased WUC, 
compared to XG CHD-free control. The decreased capacity to retain water is 
due to altered properties of the gels mediated from the CHD-polymer 
interactions. 
Water uptake capacity of CHD-loaded wafers varied with biopolymer 
type in the following order SA > KAG > SA-KAG > XG > GG, where SA had the 
highest water uptake and GG the lowest. Diffusion of CHD from swelling 
wafers, however was in the order KAG > XG > GG > SA-KAG > SA. It is 
apparent that diffusion of CHD was not proportional to water uptake capacity 
as the most swollen wafer (SA) released the lowest quantity of CHD. This 
paradox may be explained by consideration of the polymer content (solid 
content) of individual wafers. Presumably, increased polymer content 
determines the water uptake capacity. SA (5 % w/v) has a much higher 
capacity than XG (1.5 % w/v). Diffusion of CHD on the other hand, is 
determined by polymer-drug interactions. 
Kinetic analyses of diffused solute were undertaken using a 
comprehensive model of Korsmeyer-Peppas in order to understand further the 
drug release mechanism from cylindrical shaped matrices (Figure 4.6). This 
model is thought to represent the kinetics of drug/solute released as 
controlled by polymer swelling, where the value of the release exponent (n) is 
indicative of the mechanism of diffusion. The amorphous polymer matrix is 
initially in a glassy state, but as the lyophilised system absorbs water, the 
glass transition temperature (Tg) of the matrix is reduced, as water acts as a 
plasticiser for the polymer network. The swollen lyophilised matrix possesses 
an increased mobility of polymeric chains, which eventually lead to diffusion of 
the solute and an increased matrix volume (Perrie and Rades 2010). Diffusion 
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of solute from a swollen polymeric carrier can be explained by four 
mechanisms, depending on the diffusion exponent value (Table 4.1). 
Fickian diffusion represents steady-state diffusion that occurs due to a 
chemical potential gradient, where the flux goes from regions with high 
concentration to regions with low concentration (Lao et al. 2011). Anomalous 
(non-Fickian) transport refers to the abridgement of both diffusion and 
dissolution of released solute (Reza et al. 2003). Case II and super case II 
transport generally refer to solute release mechanisms associated with state-
transitions in hydrophilic, glassy matrices which swell in water or biological 
fluids (Cox et al. 1999).  This state presents polymer disentanglement and 
erosion (Danarao et al. 2011). Table 4.4 presents the release exponents (n) 
and correlation coefficients (R2) for CHD diffused from both rehydrated wafers 
and gels. It is apparent that the Korsmeyer-Peppas model was generally a 
good-fit for the diffused CHD within 8 hours of dissolution, as the majority of 
R2 values ranged from 0.9413 to 0.9981. The only exception was the case of 
burst release of CHD from GG gel. 
The release mechanism of CHD from polymeric carriers was generally 
Fickian, indicating that gel structures in pre-lyophilised form or swollen wafers 
were not completely relaxed at 8 hours. In the majority of cases, the diffusion 
mechanism was the same for gels and rehydrated wafers. XG gels 
demonstrated Fickian diffusion of CHD, while re-hydrated wafers showed non-
Fickian transport of CHD, indicating that the presence of electrolytes likely had 
an effect on the XG network. Samples of KAG, SA and SA-KAG all 
demonstrated Fickian diffusion of CHD, indicating that drug-polymer 
interactions played a key role in the diffusivity of the incorporated drug from 
the polymeric matrix. 
It is very difficult to precisely elucidate the mechanism of drug diffusion 
from a polymeric carrier as many factors interplay during transportation of 
solute. Interestingly, the majority of both gel and re-hydrated wafers had 
similar patterns of diffusivity of CHD. The rehydrated matrices absorbed a 
substantial amount of water, which did not reach the initial amount of water in 
the pre-lyophilised gel, mainly due to equilibrium conditions created in the 
enclosed FSDR. Clearly, gels or re-hydrated wafers of GG, XG, SA, KAG and 
SA-KAG did not result in complete relaxation of polymer chains hence the 
diffusion of CHD was governed by considerable drug-polymer interactions. 
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However, further research is required to decipher the intermolecular 
interactions taking place within the biopolymer network.  
As mentioned previously, the quantification of a released antimicrobial 
compound is essential for effective treatment and therapy of bacterial 
infection. Applied antimicrobial concentrations which exceed the MIC/MBC 
values at the site of application against common pathogens are considered to 
be effective for the treatment of bacterial contamination. Although CHD is a 
broad spectrum antimicrobial, the estimated values of MIC and MBC against 
common pathogens of chronic wounds varied with the type of bacterial strain 
(Chapter 3, Table 3.1). MRSA and MSSA showed the lowest values of MIC and 
MBC (0.2 - 0.4 µg/ml) indicating that low concentrations of CHD are required 
to kill the growth of S. aureus. CHD demonstrated moderate values of MIC 
(0.6 µg/ml) and MBC (14 µg/ml), when tested against E. coli, where the MBC 
was 23 times higher than MIC, indicating that increased doses of CHD are 
required to totally kill the viability of such a pathogen. In vitro antimicrobial 
activity of CHD against P. aeruginosa demonstrated increased values of both 
MIC/MBC, indicating that the latter pathogen can withstand the antimicrobial 
activity of CHD below 20 µg/ml. Estimated values of MIC (4 µg/ml) and MBC 
(20 µg/ml) indicated that a concentration of CHD higher than 20 µg/ml is 
required to totally kill the viability of P. aeruginosa. 
The release profiles of CHD-containing wafers and gels demonstrated 
that the bulk of the antimicrobial compound remained in the gel network. All 
gels released quantities of CHD greater than the MBC of all bacterial strains 
tested. All wafers released CHD in a sustained fashion, where the 
concentration of CHD accumulated from XG, GG, SA and SA-KAG did not 
exceed 15.4 ± 1.218 µg/ml within 8 hours. Quantities of CHD released from 
wafers of GG, SA and SA-KAG at 24 hours were still lower (15.13 ± 0.738 
µg/ml) than the estimated MBC value of CHD against P. aeruginosa.  
It is well known that suppurating chronic wounds have a mixed 
polymicrobial flora, where more than one species of pathogen can contaminate 
the wound bed. Although it was clear from these measurements that most of 
the antimicrobial remains within the swollen biopolymer network, that in itself 
did not undermine the utility of antimicrobial wafers to be used as effective 
antimicrobial dressings. Antimicrobial wafers are formulations intended to 
provide controlled and sustained delivery of therapeutic compounds, by 
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adhering to a suppurating wound bed. This includes the ability to absorb 
wound fluids and maintain a moist wound bed. It has been reported that the 
exudate of infected chronic wounds contains a variety and high densities of 
common bacterial species (White and Cutting 2006). Dressings with a high 
absorbance capacity are able to absorb and retain bacteria within their matrix 
(Newman et al. 2006). Walker et al. (2003) have visualized the encapsulation 
and immobilisation of P. aeruginosa and S. aureus in alginate and 
carboxymethyl cellulose dressings (Aquacel®). Recently, Newman et al. (2006) 
examined the antimicrobial activity of Hydrofyber® dressings where bacterial 
populations of S. aureus and P. aeruginosa were entrapped. They concluded 
that the ability of polymeric dressings to sequester and immobilise bacterial 
pathogens may provide a beneficial environment for wound healing. In 
addition, antimicrobial-loaded dressings, containing ionic silver, killed the 
entrapped microorganism, demonstrating a favourable behaviour for dressings 
which aim to control wound bioburden.  Moreover, minimal release of broad 
spectrum antimicrobials may prove less cytotoxic for skin cells. 
Porous, adhesive and absorptive formulations, such as lyophilised 
wafers, are very likely to encapsulate bacterial species within their swollen 
structure. However, it is currently unknown how entrapped pathogens will 
behave within the swollen network of antimicrobial free and/or loaded 
biopolymers. Additional research is required to quantify the microorgnisms 
absorbed by wafers and to investigate the antimicrobial activity of swollen 
antimicrobial wafers containing entrapped pathogens associated with chronic 
wounds. 
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Chapter 5 
Physicochemical and antimicrobial properties of 
gamma-irradiated lyophilised wafers 
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5.1 Aim 
To investigate the physicochemical and antimicrobial properties of gamma-
irradiated lyophilised wafers prepared with different natural polymers and 
clinical concentrations of broad spectrum topical antimicrobial compounds. 
 
5.2 Introduction 
Medical products, including dressings, which aim to provide protection 
and treatment of injured and infected skin, must be prepared as sterile 
products. Based on the constituent materials, dressings have been sterilised 
by different methods including autoclaving, dry heat, ethylene oxide and 
ionising radiation (Ford 2004). Gamma irradiation in particular, is broadly 
utilised for the sterilisation of pharmaceutical products and surgical materials 
including polymeric and antimicrobial dressings. This sterilising method has 
been usually the choice for heat-sensitive materials and/or compounds, as 
there is only a minimal increase in temperature during the sterilising process 
performed with gamma-rays. However, gamma-irradiation has been reported 
to affect the structures of some polymeric materials. Structural alterations of 
polymers are due to either chain scission or cross-linking which ultimately lead 
to decreased and/or increased molecular weight, respectively. Matthews et al. 
(2006) has reported both phenomena occurring on irradiated biopolymers 
such as xanthan gum and sodium alginate by analysing the rheological 
properties post-irradiation. In addition, increased doses of gamma-irradiation 
have been reported to induce colour alteration in alginate solutions, turning 
them brown (Lee et al. 2003). 
The present chapter includes work undertaken to investigate the 
rheological properties of gamma-irradiated, selected natural polymers (SA, 
KAG, GG and XG) and the structural stability of broad spectrum antimicrobial 
compounds (NS, CHD, PVP-I and SS). In addition, the performance of 
lyophilised wafers with and without antimicrobial, were also investigated, in 
terms of expansion and inhibition ratios. Moreover, antimicrobial release 
properties and swelling properties will be assessed for some of the irradiated 
formulations and compared to non-irradiated lyophilised wafers. 
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5.3 Materials and methods 
5.3.1 Materials 
Neomycin trisulphate (powder), chlorhexidine digluconate (20 % w/v 
solution), silver sulfadiazine (98 % purity of powder), pluronic F68 (non-ionic 
surfactant) karaya gum, sodium alginate, guar gum and xanthan gum, 
deuterium oxide (99.9 % D2O) and triflouroacetic acid deuterated (TFA-d) 
were purchased from Sigma-Aldrich, Gillingham, UK. Povidone iodine (10 % 
standardised aqueous solution) and 12-well polystyrene culture plates were 
purchased from Seaton Healthcare Group and Costar Ltd., UK, respectively. 
Tryptone soya agar and sabouraud dextrose agar were purchased from Oxoid, 
Ltd. UK.  
 
5.3.2 Methods 
5.3.1 Gamma-irradiation sterilisation of lyophilised wafers 
Irradiation sterilisation of lyophilised wafers was carried out by Isotron Ltd. 
UK, using gamma rays generated from a radioactive Cobalt-60 source with an 
approximate dose rate of 5 kGy/hour. Two lots from each batch of formulated 
wafers (antimicrobial loaded and antimicrobial free) were irradiated with 25.0 
kGy ± 10 % and 40.0 kGy ± 10 % doses, respectively. Lyophilised wafers 
were sterilised within the polystyrene plates in which they were cast. 
Polystyrene is reported to have excellent radiation resistance (Isotron Ltd, 
UK). Samples of raw polymers and antimicrobials were irradiated within glass 
vials under the same conditions. The prescribed doses of irradiation are 
typically used for sterilising medical devices (Matthews et al. 2006). 
 
5.3.2 Microbiological validation of sterility of irradiated products 
Validation of the sterility of irradiated polymeric products was undertaken 
using aseptic microbiological examination of a minimum number of samples 
taken from each irradiated lot. Samples were placed on tryptone soya agar 
(TSA) and sabouraud dextrose agar (SDA) plates, incubated at 37 0C for 24 - 
48 hours and at 25 0C for 4-5 days, respectively. TSA plates were composed of 
15 g/l tryptone, 5 g/l soyapeptone, 5 g/l sodium chloride and 15 g/l agar to 
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test for the presence of aerobic bacterial species and SDA plates were 
composed of 10 g/l mycologicalpeptone, 40 g/l glucose and 15 g/l agar to test 
for the presence of fungi. Both growth media were autoclaved at 121 0C for 15 
minutes prior to use to ensure sterility. Controls of non-irradiated samples 
were also included and were tested under the same conditions. Growth and/or 
absence of either bacterial or fungal species was recorded after 48 hours and 
5 days incubation, respectively. The presence of visible growth was recorded 
as ‘+’ and the lack of growth was recorded as ‘-‘. 
 
5.3.3 Structural validation of antimicrobial compounds 
A 400 MHz nuclear magnetic resonance (NMR) spectrometer (Bruker, 
Biospin UK) was used to investigate the chemical configuration of irradiated 
antimicrobial compounds. NS (80 mg) and CHD (50 µl of 20 % stock aqueous 
solution) were dissolved in deuterium oxide, D2O (0.5 ml). SS (30 mg) was 
dissolved in deuterium trifluoroacetic acid, TFA-d, (0.5 ml). Changes in the 
positioning or ordering of resonances detected may indicate changes to the 
chemical configuration induced by gamma-irradiation. 
Both proton (1H) and/or carbon 13 (13C) NMR were used to characterise 
irradiated and non-irradiated PVP-I, with no success. This was essentially due 
to the presence of additives such as glycerol, nonoxynol-9, sodium phosphate, 
sodium hydroxide, potassium iodate and citric acid, which complicated the 
spectra in the 10 % (w/v) standardised solution (obtained commercially), the 
complex structure of the iodophor(e) arguably being the main reason. 
 
5.3.4 Rheological analysis of irradiated polymers and lyophilised 
formulations as reconstituted gels 
Rheological characterisation of gels prepared from irradiated raw polymers 
was performed as previously described in Chapter 2, Section 2.3.5. 
Rheological analysis was also performed for irradiated lyophilised wafers as 
reconstituted gels.  Lyophilised formulations (with and without antimicrobial) 
were reconstituted to gels by adding precise volumes of distilled water until 
reaching the pre-lyophilised weight of the initial cast gels (1.5 ± 0.02g). The 
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rheological properties of at least three samples for each prepared gel were 
analysed with the Herschel-Bulkley model.  
For the purposes of this project the gels prepared from irradiated raw 
polymers will be referred to as pre-lyophilised irradiated gels. The gels 
prepared from reconstituted irradiated wafers will be referred to as post-
lyophilised irradiated gels. The gels prepared from non-irradiated raw 
polymers and/or reconstituted wafers will be referred to as pre-lyophilised gels 
and post-lyophilised gels, respectively. 
 
5.3.5 Antimicrobial properties of irradiated lyophilised formulations 
A modified disc diffusion method (as previously described in Chapter 3, 
Section 3.3.2.3) was used to investigate the performance and antimicrobial 
properties of irradiated wafers. Measurements of the of initial diameter of the 
wafers (D0), the swollen diameter of the wafers (Dt) and diameter of the 
inhibition zone (Di) were taken at intervals of 0
0 and 900 using a digital calliper 
and steel engineering ruler (Mitutojo). Only in the case of karaya (KAG) wafers 
(with and without antimicrobial), was the swollen diameter (Dt) and diameter 
of the inhibition zone (Di) measured in one direction as indicated in Figure 5.1-
B, due to  a total erosion of the disc shape of KAG wafers after 24 hours 
incubation at 37 0C. Expansion and inhibition ratios were calculated as ER = 
Dt/Do and IR = Di/D0, respectively. 
 
 5.3.6 Release profile, swelling properties and kinetics of CHD release 
from gamma-irradiated SA-CHD wafers 
Release profiles of irradiated wafers of sodium alginate (SA) impregnated with 
clinical concentrations of chlorhexidine digluconate (CHD) were investigated 
using the free standing dissolution raft (FSDR) as previously described in 
Chapter 4 (Section 4.3.2.1). The same diffusion model and associated formula 
were used to calculate the diffusion mechanism of CHD from irradiated wafers 
of SA-CHD. In addition, the same formula as indicated in Chapter 4 (Section 
4.3.2.1), was used to calculate the water uptake (WU) of swollen wafers at 24 
hours in the conditions created in the FSDR. 
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Figure 5.1 Typical images taken after 24 hours incubation of karaya (KAG) 
wafer impregnated with 1 % (w/v) silver sulfadiazine (SS), tested against 
bacterial strains using a modified disc diffusion assay. A - Non-irradiated and 
B - irradiated antimicrobial wafer. The same behaviour was observed for all 
KAG loaded and non-loaded, irradiated wafers. 
 
5.4 Data analysis 
Data are presented as the mean value of three samples ± standard error of 
the mean (SEM). Regression analysis of data was performed using GraphPad 
Prism 4 software.  
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5.5 Results 
Table 5.1 Microbiological validation of raw polymers tested for the presence of 
bacterial and/or fungal contamination. (+) presence of bacterial/fungal 
growth, (-) lack of bacterial/fungal growth. 
 
Raw 
polymers 
Bacterial growth Fungal growth 
Non-
irradiated 
Irradiated doses 
Non-
irradiated 
Irradiated doses 
0 kGy 25 kGy 40 kGy 0 kGy 25 kGy 40 kGy 
KAG - - - - - - 
GG + - - - - - 
XG + - - + - - 
SA - - - - - - 
 
 
Table 5.2 Microbiological validation of control (antimicrobial free) lyophilised 
wafers tested for the presence of bacterial and/or fungal contamination.  
(+) presence of bacterial/fungal growth, (-) lack of bacterial/fungal growth. 
 
Control 
wafers 
Bacterial growth Fungal growth 
Non-
irradiated 
Irradiated doses 
Non-
irradiated 
Irradiated doses 
0 kGy 25 kGy 40 kGy 0 kGy 25 kGy 40 kGy 
KAG - - - - - - 
GG - - - - - - 
XG + - - + - - 
SA - - - - - - 
SA-KAG - - - - - - 
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Table 5.3 Microbiological validation of KAG (3 % w/v) lyophilised antimicrobial 
wafers tested for the presence of bacterial and/or fungal contamination.  
(+) presence of bacterial/fungal growth, (-) lack of bacterial/fungal growth. 
 
KAG 
antimicrobial 
wafers 
Bacterial growth Fungal growth 
Non-
irradiated 
Irradiated doses 
Non-
irradiated 
Irradiated doses 
0 kGy 25 kGy 40 kGy 0 kGy 25 kGy 40 kGy 
0.5 % (w/v) 
NS 
- - - - - - 
0.5 % (v/v) 
CHD 
- - - - - - 
1.0 (v/v) 
PVP-I 
- - - - - - 
1.0 % (w/v) 
SS 
- - - - - - 
0.2 % (w/v) 
F68 
+ - - - - - 
 
Table 5.4 Microbiological validation of lyophilised antimicrobial wafers 
prepared with the incorporation of a clinical concentration of CHD (0.5 % v/v) 
into matrices of different biopolymers. (+) presence of bacterial/fungal 
growth, (-) lack of bacterial/fungal growth. 
 
CHD 
lyophilised 
wafers 
Bacterial growth Fungal growth 
Non-
irradiated 
Irradiated doses 
Non-
irradiated 
Irradiated doses 
0 kGy 25 kGy 40 kGy 0 kGy 25 kGy 40 kGy 
2 % GG - - - - - - 
1.5 % XG - - - - - - 
5.0 % SA - - - - - - 
SA-KAG 
(1:1) 
- - - - - - 
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Figure 5.2 13C NMR spectra of chlorhexidine digluconate (CHD) diluted in D2O. (—) non-irradiated compound, (—) irradiated 
with 25.0 kGy ± 10 % and (—) irradiated with 40.0 kGy ± 10 %. 
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Figure 5.3 UV analysis of gamma-irradiated chlorhexidine digluconate (CHD) 
aqueous solutions containing the same concentrations of CHD (40 µg/ml), 
using a ThermoSpectronic Biomate 5 spectrophotometer. Note that both 
chromophores (chlorobenzene rings) are visible at identical wave lengths (231 
and 254 nm) for all solutions; however the intensity of absorbance is lower in 
the irradiated samples by approximately 15 %. (a) Non-irradiated sample, (b) 
Irradiated sample with 25.0 kGy ± 10 %, (c) Irradiated sample with 40.0 kGy 
± 10 % 
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Figure 5.4 13C NMR spectra of neomycin sulphate (NS) dissolved in D2O. (—) non-irradiated compound, (—) irradiated with 
25.0 kGy ± 10 % and (—) irradiated with 40.0 kGy ± 10 %. 
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Figure 5.5 1H NMR spectra of silver sulfadiazine (SS) dissolved in TFA-d. (—) non-irradiated compound, (—) irradiated with 
25.0 kGy ± 10 % and (—) irradiated with 40.0 kGy ± 10 %. Below (a): 13C-1H heteronuclear single quantum coherence 
(HSQC) NMR spectrum of SS. 
 (a) 
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Figure 5.6 Plots of natural logarithm (ln) of shear stress (σ) as a 
function of ln shear rate (γ) for pre-lyophilised gels prepared from 
non-irradiated and irradiated (25 kGy and 40 kGy) polymers. (a) 2 % 
w/v GG, (b) 3 % KAG w/v, (c) 5 % w/v SA, (d) 1.5 % w/v XG and (e) 
SA-KAG (1:1 ratio). (Note the major decrease in viscosity for 
irradiated samples of GG, KAG, SA and SA-KAG, but not for XG). 
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Table 5.5 Viscosity coefficients and yield stresses of pre-lyophilised gels 
prepared with irradiated (25 kGy and 40 kGy) and non-irradiated polymers, as 
analysed with the Herschel-Bulkley model (n=3, SEM). 
 
Raw polymers 
Non irradiated 
 
η’ 
 
(σ0) 
 
Irradiated doses 
 
η’ 
 
(σ0) 
 
0 kGy 25 kGy 40 kGy 
 
2 % w/v  
GG 
 
 
82.21± 5.41 
 
(95.87 ± 2.31) 
  
0.49 ± 0.17 
 
(0.00 ± 0.00) 
 
0.22 ± 0.01 
 
(0.00 ± 0.00) 
 
 
1.5 % w/v  
XG 
 
 
2.86 ± 0.12 
 
(23.61 ± 0.68) 
 
 
1.40 ± 0.06 
 
(19.96 ± 0.33) 
 
 
2.50 ± 0.32 
 
(22.16 ± 3.41) 
 
 
5.0 % w/v  
SA 
 
 
18.17 ± 0.70 
 
(0.00 ± 0.00) 
 
 
0.09 ± 0.01 
 
(0.00 ± 0.00) 
 
 
0.05 ± 0.01 
 
(0.00 ± 0.00) 
 
 
3.0 % w/v 
KAG 
 
 
12.89 ± 0.93 
 
(0.00 ± 0.00) 
 
 
0.06 ± 0.01 
 
(0.00 ± 0.00) 
 
 
0.02 ± 0.00 
 
(0.00 ± 0.00) 
 
 
SA-KAG (1:1) 
 
 
7.75 ± 0.64 
 
(86.34 ± 5.19) 
 
 
0.48 ± 0.03 
 
(0.00 ± 0.00) 
 
0.74 ± 0.10 
 
(0.00 ± 0.00) 
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Figure 5.7 Plots of natural logarithm (ln) of shear stress (σ) as a function 
of ln shear rate (γ) of post-lyophilised 3 % w/v KAG gels containing 
different antimicrobials, non-irradiated and irradiated (25 kGy and 40 
kGy). (a) 3 % w/v KAG (control antimicrobial free), (b) 0.5 % w/v NS, (c) 
0.5 % v/v CHD, (d) 1.0 % v/v PVP-I, (e) 1.0 % w/v SS and (f) 0.2 % w/v 
Pluronic F68. (Note the different degrees of degradation for antimicrobial 
gels, in particular impregnated with CHD and PVP-I, compared to 
antimicrobial free matrix of KAG). 
 
 
 141 
 
 
 
 
 
 142 
 
Table 5.6 Viscosity coefficient (η’) of KAG pre-lyophilised antimicrobial gels 
and reconstituted post-lyophilised wafers irradiated and/or non-irradiated, as 
analysed with the Herschel-Bulkley model (n=3, SEM). 
 
3.0 % w/v 
KAG wafers 
Non-irradiated Irradiated wafers 
Pre-
lyophilised 
gels 
Post-
lyophilised 
gels 
25 kGy 40 kGy 
KAG 12.89 ± 0.93 15.26 ± 1.81 0.09 ± 0.01 0.03 ± 0.00 
NS 1.56 ± 0.10 2.19 ± 0.94 0.01 ± 0.00 0.01 ± 0.00 
CHD 3.79 ± 0.30 3.71 ± 1.53 0.72 ± 0.13 0.04 ± 0.02 
PVP-I 4.09 ± 0.34 2.82 ± 0.15 0.50 ± 0.05 0.10 ± 0.03 
SS 6.48 ± 0.33 11.36 ± 0.44 0.04 ± 0.00 0.01 ± 0.00 
F68 7.40 ± 0.55 17.80 ± 2.61 0.07 ± 0.01 0.02 ± 0.00 
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Figure 5.8 Plots of natural logarithm (ln) of shear stress (σ) as a function of 
ln shear rate (γ) for post-lyophilised gels (non-irradiated and/or irradiated with 
25.0 kGy ± 10 % and 40.0 kGy ± 10 %): (a) 5 % w/v SA (CHD-free), (b) 5 % 
w/v SA-CHD, (c) 1.5 % w/v XG (CHD-free) and (d) 1.5 % w/v XG-CHD. 
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Table 5.7 Rheological properties, viscosity coefficient (η’) and yield stress (σ0) 
of reconstituted, post-lyophilised irradiated (25 kGy and 40 kGy) and non-
irradiated antimicrobial-free wafers, prepared from different biopolymers, as 
analysed using the Herschel-Bulkley model (n=3, SEM). (Post-lyophilised non-
irradiated samples of GG did not produce a homogenous gel, rendering 
rheological measurements infeasible). 
 
 
 
 
 
 
 
 
Control 
wafers 
Non irradiated 
 
η’ 
 
(σ0) 
 
Irradiated doses 
 
η’ 
 
(σ0) 
 
0 kGy 25 kGy 40 kGy 
 
2.0 % w/v 
GG 
 
- 
 
- 
0.18 ± 0.03 
 
(0.00 ± 0.00) 
0.05 ± 0.01 
 
(0.00 ± 0.00) 
 
1.5 % w/v 
XG 
 
2.42 ± 0.32 
 
(20.58 ± 1.25) 
 
1.23 ± 0.29 
 
(15.94 ± 0.27) 
 
 
1.82 ± 0.42 
 
(22.67 ± 4.36) 
 
 
5.0 % w/v 
SA 
 
10.95 ± 1.73 
 
(0.00 ± 0.00) 
0.083 ± 0.026 
 
(0.00 ± 0.00) 
0.06 ± 0.01 
 
(0.00 ± 0.00) 
 
SA-KAG 
(1:1) 
 
12.69 ± 0.34 
 
(148.9 ± 4.33) 
0.49 ± 0.03 
 
(0.00 ± 0.00) 
0.24 ± 0.03 
 
(0.00 ± 0.00) 
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Table 5.8 Rheological properties, viscosity coefficient (η’) and yield stress (σ0) 
of post-lyophilised irradiated (25 kGy and 40 kGy) and non-irradiated 0.5 % 
v/v CHD antimicrobial gels, prepared from different biopolymers, as analysed 
with the Herschel-Bulkley model (n=3, SEM). (Post-lyophilised non-irradiated 
samples of GG did not produce a homogenous gel, rendering rheological 
measurements infeasible). 
 
 
 
 
 
 
 
 
CHD  
(0.5 % v/v) 
antimicrobial 
wafers 
Non irradiated 
 
η’ 
 
(σ0) 
 
Irradiated doses 
 
η’ 
 
(σ0) 
 
0 kGy 25 kGy 40 kGy 
 
2.0 % w/v 
GG 
 
- 
 
- 
0.18 ± 0.03 
 
(0.00 ± 0.00) 
0.04 ± 0.01 
 
(0.00 ± 0.00) 
 
1.5 % w/v 
XG 
 
2.46 ± 0.192 
 
(26.5 ± 1.41) 
 
1.66 ± 0.41 
 
(34.25 ± 4.59) 
 
     
1.50 ± 0.08 
 
(26.51 ± 2.97) 
 
 
5.0 % w/v 
SA 
 
44.03 ± 9.72 
 
(0.00 ± 0.00) 
0.95 ± 0.35 
 
(0.00 ± 0.00) 
0.52 ± 0.01 
 
(0.00 ± 0.00) 
 
SA-KAG 
(1:1) 
 
10.34 ± 0.59 
 
(170.41 ± 7.76) 
2.09 ± 0.36 
 
(0.00 ± 0.00) 
0.61 ± 0.03 
 
(0.00 ± 0.00) 
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Figure 5.9 Expansion and inhibition ratios of irradiated (25 ± 10 kGy and 
40 ± 10 kGy) KAG antimicrobial wafers tested with a modified disc diffusion 
assay against common bacterial strains of infected, non-healing wounds. 
(n=3 SEM)  
(a), (b) Expansion and inhibition ratio of KAG wafers tested against MRSA 
(c), (d) Expansion and inhibition ratio of KAG wafers tested against MSSA 
(e), (f) Expansion and inhibition ratio of KAG wafers tested against E. coli 
(g), (h) Expansion and inhibition ratio of KAG wafers tested against P. aeruginosa  
(KAG and pluronic F68 control wafers did not demonstrated inhibition zones) 
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Figure 5.10 Images of irradiated KAG wafers impregnated with clinical 
concentrations of broad spectrum antimicrobials, tested against MRSA in the 
modified disc diffusion assay, after 24 hours incubation at 37 0C. A-KAG 
impregnated with 0.5 % w/v NS, B-KAG impregnated with 0.5 % v/v CHD, C- 
KAG impregnated with 1.0 % v/v PVP-I and D-KAG impregnated with 1.0 % 
w/v SS. Note the white residue visible in the case of KAG wafers impregnated 
with CHD (Image B), which was visible for all irradiated CHD impregnated 
wafers. 
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Figure 5.11 Linear regression analysis of inhibition ratio (IR) vs. expansion 
ratio (ER) of KAG wafers containing (0.5 % w/v) of NS, irradiated at 25.0 kGy 
and 40.0 kGy ± 10 %. (a) MRSA, (b) MSSA, (c) E. coli and (d) P. aeruginosa. 
(ns)- non significant correlation, (s)- significant correlation 
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Figure 5.12 Linear regression analysis of inhibition ratio (IR) vs. expansion 
ratio (ER) of KAG wafers containing (0.5 % v/v) of CHD, irradiated at 25.0 
kGy and 40.0 kGy ± 10 %. (a) MRSA, (b) MSSA, (c) E. coli and                    
(d) P. aeruginosa. 
(ns)- non significant correlation, (s)- significant correlation 
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Figure 5.13 Linear regression analysis of inhibition ratio (IR) vs. expansion 
ratio (ER) of KAG wafers containing (1.0 % v/v) of PVP-I, irradiated at 25.0 
kGy and 40.0 kGy ± 10 %. (a) MRSA, (b) MSSA, (c) E. coli and                   
(d) P. aeruginosa. 
(ns)- non significant correlation, (s)- significant correlation 
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Figure 5.14 Linear regression analysis of inhibition ratio (IR) vs. expansion 
ratio (ER) of KAG wafers containing (1.0 % w/v) of SS, irradiated at 25.0 kGy 
and 40.0 kGy ± 10 %. (a) MRSA, (b) MSSA, (c) E. coli and (d) P. aeruginosa. 
(ns)- non significant correlation, (s)- significant correlation 
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Figure 5.15  Expansion and inhibition ratios of irradiated (25.0 kGy ± 10 % 
and/or 40.0 kGy ± 10 %) wafers prepared with a clinical concentration of CHD 
(0.5 % v/v) incorporated within different biopolymer matrices, tested in a 
modified disc diffusion assay against P. aeruginosa (n =3, SEM).  
(a) Expansion ratio of controls (CHD-free) lyophilised wafers,  
(b) Expansion ratio of CHD-loaded lyophilised wafers and  
(c) Inhibition ratio of CHD-loaded wafers. 
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Figure 5.16 Linear regression analysis of inhibition ratio (IR) vs. expansion 
ratio (ER) of CHD wafers (irradiated and non-irradiated) prepared with 
different biopolymers, when tested against P. aeruginosa on modified disc 
diffusion assay. (a) GG-CHD, (b) XG-CHD, (c) SA-CHD and (d) SA-KAG-CHD. 
(ns) – not significant correlation, (s) – significant correlation 
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Figure 5.17 Release profiles of SA wafers (irradiated and non-irradiated) 
impregnated with a clinical concentration of CHD (0.5 % v/v) in NaCl-CaCl2 
dissolution medium (n=3, SEM). 
 
 
Figure 5.18 Water uptake (%) of rehydrated SA-CHD wafers (irradiated and 
non-irradiated) at 24 hours, placed on the FSDR (n=3, SEM). 
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Figure 5.19 Linear regressions of CHD released from irradiated and non-
irradiated SA-CHD matrices in NaCl-CaCl2, as analysed with the Korsmeyer-
Peppas model. 
 
Table 5.9 Accumulation of CHD (%) in NaCl-CaCl2 dissolution medium as 
released from SA-CHD wafers, impregnated with a clinical concentration of 
CHD (0.5 % v/v) at 24 hours. Values of the release exponent (n) and the 
correlation coefficient (R2) of CHD released from irradiated and non-irradiated 
wafers. All wafers demonstrated Fickian (F) diffusion. 
Gamma-Irradiated 
polymeric wafers of 
SA-CHD (w/v) 
Accumulation of CHD 
(%) in NaCl-CaCl2 
(pH = 6.5) 
Release exponent  
(n) 
Correlation coefficient 
(R2) 
0 kGy 3.5 ± 0.04 
0.36F 
(0.9974) 
25 kGy 6.2 ± 0.41 
0.28F 
(0.9721) 
40 kGy 6.3 ± 0.21 
0.29F 
(0.9746) 
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5.6 Discussion 
Gamma-rays are high energy electromagnetic waves emitted from a 
radionucleotide source such as Cobalt-60 or Cesium-137. They are used 
commercially to sterilise medical polymers and are attractive for their ability to 
penetrate packing and destroy endotoxins. Sterilisation by gamma-irradiation 
involves stable temperatures and easy validation. However, one major 
limitation of gamma-irradiation is the formation of radiolytic products that 
usually lead to degradation, alteration in colour and odour for some materials.  
The presence of water molecules in the gamma-irradiated material is 
associated with the production of H3O
+ and OH- radicals. According to Zagorski 
(2004) ”radiolytic products of water can be considered as reagents towards 
added solutes, because in the case of diluted solutions radiation interacts 
practically with water only, not with solutes”. It has been reported that 
hydroxyl radicals are the main water radiolysis species which interact with 
polymers and lead to the formation of intermediate reactive compounds. Free 
radicals, if favourably positioned, can react with each other and form new 
cross links between separated polymer chains (Rosiak et al. 1995). If not, the 
final product of irradiated macromolecules will be degraded polymer chains, 
which is associated with decreased molecular weight. Hydroxyl radicals cause 
irreversible DNA damage due to a strong oxidant effect and it is this effect that 
destroys viable bioburden (Silindir and Ozer 2009). Generally doses of 25 - 35 
kGy are sufficient to achieve a sterility assurance level (SAL) of 10-6 (6-log 
powers reduction of microbial population) and simultaneously these irradiation 
doses ensure that either cross-linking or degradation of irradiated polymeric 
materials will dominate (Baloda et al. 2008; Rosiak et al. 1995).  
The validation process for gamma-irradiated products is important as 
both the level of sterility (absence of viable microorganisms) and the integrity 
of the final irradiated product are ensured. Microbiological validation of 
irradiated biopolymers in these studies was performed on TSA and SDA media 
for the detection of contamination by bacterial and fungal populations, 
respectively (Table 5.1). It is apparent that the irradiation doses of 25.0 kGy 
± 10 % and 40.0 kGy ± 10 % were sufficient for elimination of microbial flora 
present in the polymeric powders of GG and XG. Interestingly, non-irradiated 
samples of KAG and SA powders did not promote the growth of 
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microorganisms. This result is likely associated with the pH values of KAG and 
SA gels. It has been reported that KAG has a high uronic acid content which 
generates a low pH (4.4 – 4.7) when dispersed in water (Verbeken et al. 
2003). This range was verified with pH measurements undertaken in a 3.0 % 
w/v gel of the KAG batch used in this project (Table 2.1, Chapter 2). The gel 
of the sodium salt of a low viscosity grade alginic acid, prepared in distilled 
water (as previously described in Chapter 2, Section 2.5, Table 2.1) generated 
a slightly basic pH (8.3), which does not present a desirable environment for 
the growth of microorganisms. A neutral nutritional environment (pH 7.2 ± 
0.2) is considered a favourable environment for the growth of the majority of 
bacterial and fungal species.  In addition, it has been reported that polymers 
of SA and KAG were found to reduce the adhesion of Streptococcus salivarius 
by 98.7 % and 97.9 % respectively (Wilson and Harvey 1989), indicating that 
the polymeric habitat of either SA or KAG does not present a favourable niche 
for several bacterial species. 
Irradiated wafers maintained their initial cylindrical shape. 
Microbiological validation of the sterility of non-medicated wafers 
demonstrated that there was no growth of microorganisms (Table 5.2). Non-
irradiated antimicrobial free wafers of KAG, SA, GG and SA-KAG did not 
present growth of either bacterial or fungal populations. It was apparent that 
non-irradiated samples of KAG and SA did not demonstrate growth of 
microorganisms (bacterial and/or fungi) either as raw material or lyophilised 
wafers. Non-irradiated samples of XG, raw powder and lyophilised wafers, 
promoted the growth of both bacteria and fungal species. Non-irradiated 
samples of raw GG showed bacterial contamination, but non-medicated 
lyophilised wafers of 2 % (w/v) GG did not support the growth of bacterial 
populations.  
Lyophilisation is a common method used to preserve and store 
collections of microbial cultures; however the freezing rate, storage conditions 
and moisture content of the lyophilised product can affect the viability of 
microorganisms. Although the majority of bacteria, yeast and spore-forming 
fungi can resist the detrimental effect of freezing, the survival rates of 
lyophilised microorganisms depend on the species and density (Miyamoto-
Shinohara et al. 2010; Miyamoto-Shinohara et al. 2008). For example, it has 
been reported that freeze-dried Gram-positive bacteria demonstrate better 
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survival rates than Gram-negative strains, due to a thicker cell wall 
peptidoglycan layer (Miyamoto-Shinohara et al. 2008). All wafers were 
produced and stored under the same conditions. However, the lack of 
information about the type and amount of bacterial contaminates present in 
raw polymers can only lead to speculation with regards to the absence of 
bacterial contamination of non-irradiated GG wafers. In addition, further 
investigations are required to examine the effect of considerable amounts of 
residual water (15 - 20 %) present in lyophilised wafers upon the viability of 
different bacterial and fungal species. 
Microbiological validation of irradiated antimicrobial wafers was 
undertaken under the same nutritional media and growth conditions (Table 5.3 
and 5.4). As expected, there was no growth of microorganisms apparent for 
irradiated and non-irradiated antimicrobial wafers. The non-irradiated, control 
wafer containing 0.2 % (w/v) pluronic F68 demonstrated bacterial growth. 
This is probably associated with bacterial contaminants present in the powder 
of the non-ionic surfactant, as the raw KAG powder did not present either 
bacterial or fungal contamination. 
Potential changes to the chemical configuration of antimicrobial 
compounds were assessed with NMR spectroscopy (1H and/or 13C) as 
presented in Figures 5.2, 5.4 and 5.5. Irradiated samples of antimicrobials as 
received were compared to non-irradiated ones. Nuclear configuration of CHD, 
NS and SS demonstrated that there did not appear to be major structural 
differences between irradiated samples and non irradiated ones. These results 
generally suggest that the structural integrity of selected antimicrobial 
compounds remained unaffected by gamma-irradiation and antimicrobial 
agents potentially still possess their initial antimicrobial properties.      
Previous studies conducted on antimicrobial activity of gamma 
irradiated (25.0 kGy) common antibiotics that included neomycin sulphate 
(NS) (Muszynski et al. 2002), revealed that there was a minimal increase of 
the MIC value for the irradiated antibiotics, the authors concluding that the 
antimicrobial activity of NS was generally preserved by 96.26 %. (Muszynski 
et al. 2002). 13C NMR and UV spectrophotometry were essentially inconclusive 
as to whether there had been any degradation of CHD following gamma-
irradiation. The NMR spectra (Figure 5.2) appeared to be the same for 
irradiated and non-irradiated CHD as no notable shifts in the main resonance 
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signals were apparent. However, the spectra were very noisy and the 
appearance of weak resonances due to degradation products may be lost in 
the background. The UV spectra (Figure 5.3) indicated a slight decrease in the 
absorbance intensity at the same concentration of both irradiated CHD 
samples compared with the non-irradiated CHD samples. 
It is difficult to conclude if the energy uptake from gamma-rays does or 
does not influence the antimicrobial activity of such compounds. It has been 
reported that irradiated, coated-catheters containing small quantities of 
chlorhexidine, were found less efficacious at preventing bacterial 
contamination in patients in intensive care units when compared to pre-
sterilised chlorhexidine–coated catheters (Sherertz et al. 1996). The latter 
authors suggested that gamma-rays were likely to have a negative effect on 
the antimicrobial properties of CHD; however additional experimental studies 
were required in order to clarify the potential effect of irradiation on the 
antimicrobial activity of CHD. 
Figure 5.4 is the 13C NMR spectra of irradiated and non-irradiated NS. 
Although of better signal quality than CHD, it is still uncertain if any changes 
to the chemical configuration of NS have occurred. However, at a glance, it 
may be safe to conclude that no major changes were apparent. 
NMR analysis of SS demonstrated that the structural integrity of this 
compound remained unaffected by gamma-ray treatment and potentially, the 
antimicrobial activity of SS is not considerably altered by gamma-irradiation. 
Reference to Figure 5.5 indicates the downfield regions of the 1H NMR spectra 
of irradiated and non-irradiated SS in TFA-d. All the aromatic protons are 
clearly distinguishable and numbered 1 - 4 (see chemical structure). 
Assignment of these resonances was possible from the HSQC 13C - 1H 
heteronuclear spectrum positioned above [Figure 5.5 (a)]. The 13C NMR 
component of this HSQC spectrum has three unassigned carbon atoms (not 
numbered in figure). 
Nho et al. (2009) have recently reported that cross-linked hydrogels of 
PVA/PVP/glycerin/antimicrobial, cross-linked by gamma-rays (25.0 kGy), 
containing 1.0 % silver sulfadiazine (SS) demonstrated slightly decreased 
antimicrobial activity compared to non-irradiated samples. The latter authors 
concluded that gamma-rays had a minor effect on the antimicrobial properties 
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of cross-linked hydrogels impregnated with either silver salts or sodium 
sulfadiazine. 
Although the effect of gamma-rays on the antimicrobial properties of 
antimicrobial compounds remains ambiguous, it is well known that the 
absorbance of gamma-irradiation by polymeric materials will instantly lead to 
chain scission and cross-linking. Both reactions happen simultaneously within 
the polymeric bulk; however one will usually predominate and result in either 
degradation or inter-connection of adjacent polymeric chains. Configurational 
and conformational changes in gamma-irradiated polymer will alter the 
network structure and affect both swelling and rheological properties. 
Rheological measurements of irradiated polymers are therefore an essential 
and reliable gauge of the net effect of ionising radiation on the flow properties 
of biopolymeric materials. 
Rheological analysis of pre-lyophilised irradiated gels was undertaken 
and compared with pre-lyophilised gels, as presented in Figure 5.6 and Table 
5.5.  It is apparent that irradiation doses of 25.0 kGy ± 10 % and 40.0 kGy ± 
10 % decreased considerably the viscosity of GG, KAG, SA and the binary 
mixture of SA-KAG. The higher the irradiative dose the greater the reduction 
in viscosity. The viscosity of XG, however, was not considerably affected. 
These data suggest that chain scission and degradation dominated within the 
bulk of GG, KAG and SA which was associated with a dramatic decrease in 
consistency and yield stress of irradiated biopolymers, while cross-linking 
reactions were dominant for XG, which was manifest as a slight increase in 
yield stress.  It was evident that pre-lyophilised irradiated gels of GG, KAG and 
SA, lost their initial ability to form a strong gel network, as samples 
demonstrated generally Newtonian flow. These results are in agreement with 
King and Gray (1993), who have reported the degradation of GG and KAG 
irradiated with a range of gamma-rays < 10 kGy. Lee et al. (2003) have also 
reported that the effect of increased doses of irradiation on alginate polymers 
is associated with increased degradation and decreased values of viscosity. In 
addition, degradation of sodium alginate was enhanced in irradiated polymeric 
solutions and there was also an associated colour change compared to 
irradiated samples in the solid state (Sen et al. 2010; Nagasawa et al. 2000), 
indicating that the presence of water enhances the degradation effects of 
gamma-rays upon sodium alginate. 
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Although the binary mixture of SA-KAG prepared with samples of pre-
lyophilised irradiated gels of SA and KAG displayed a notable decrease in 
consistency (Figure 5.6-e), it is apparent that the viscosity of this synergistic 
mixture displayed a smaller reduction than the homopolymers. These results 
indicate that the mechanism of interactions between biopolymers was likely to 
be unaffected by gamma-irradiation. Degradation of SA and KAG raw 
materials was increased with increased doses of irradiation. The binary 
mixture of pre-lyophilised irradiated gels of SA and KAG displayed a higher 
viscosity at 40.0 kGy than it did at 25.0 kGy. It is difficult to precisely interpret 
such synergistic behaviour between degraded but interacting polymers, 
however, a plausible scenario would be that increased amounts of radiolytic 
products may produce an increased likelihood of increased branching of lower 
molecular weight fractions of degraded biopolymers. Additional investigations 
are required to elucidate the effect of gamma-rays on binary polymeric 
systems. 
Rheological properties of post-lyophilised irradiated gels (with and 
without antimicrobial) were analysed and compared with post-lyophilised gels. 
Particular attention was given to the antimicrobial impregnated samples as the 
cascade of events occurring between radical polymer species and antimicrobial 
compounds are unknown. It is apparent that gamma-irradiation dramatically 
decreased the viscosity of post-lyophilised irradiated gels of KAG containing 
antimicrobials (Figure 5.7, Table 5.6). Rheological analysis of post-lyophilised 
irradiated gels of KAG exhibited Newtonian flow behaviour compared to non-
irradiated samples, which were pseudoplastic with no apparent yield stress. 
However, it was extremely difficult to extrapolate conclusions on the behaviour 
of irradiated polymer-antimicrobial systems from the calculated values of 
viscosity coefficient, especially when it is appreciated that incorporation of 
antimicrobial compounds was already associated with a notable decrease in 
the viscosity of KAG gels (Chapter 2).  
Analysis of rheological continuous flow data as a plot of ‘ln (σ) as a 
function of ln (γ)’ permits straightforward and accurate comparison of flow 
curves in terms of the gradient of the straight line (equivalent to the rate 
index of pseudoplasticity) and the displacement of the line from the origin, as 
indicated by the intersect with the ln (σ) or ‘y-axis’ i.e. the consistency or 
viscosity coefficient (η’). The higher the line on the graph the ‘more viscous’ 
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the sample. Generally, increased doses of gamma-rays increased the 
degradation of post-lyophilised gels. Interestingly, the degree of degradation 
between polymer matrices with or without antimicrobial was different. This 
was particularly true for post-lyophilised irradiated gels of KAG containing CHD 
and PVP-I, which were degraded to a lesser extent than the KAG control 
(without antimicrobial). Considering that the inclusion of antimicrobial e.g. 
CHD, naturally decreased the consistency of KAG gel (Chapter 2), these 
results indicate that drug polymer interactions occurring between CHD and 
KAG, were not affected by gamma-rays, as CHD is generally able to withstand 
irradiation. On the other hand, chain scission and degradation dominated 
within the bulk of KAG, and degradation of KAG causes the production of 
radiolysis products, which may generally consist of ‘chopped’ branches and/or 
broken backbone residues. Plausibly, free radicals were still able to interact 
with CHD, where interactions between CHD and degraded KAG hold together 
the broken branched KAG network resulting in a smaller reduction in 
consistency. 
In the case of irradiated KAG-(PVP-I) systems, a plausible interpretation 
may be slightly different and more complex, as more than one polymer and 
additional compounds such as of glycerol, monoxynol-9, sodium phosphate, 
sodium hydroxide, potassium iodate and citric acid, are also involved. Lugao et 
al. (2002) have reported that irradiation causes cross-linking between PVP 
chains, where the physicochemical properties of the polymerised PVP network 
will depend on the presence of additives and irradiation dose. Other authors 
have also reported the ability of PVP to form of a cross-linked gel network by 
using a range of gamma-irradiation doses (Benamer et al. 2006; Rosiak et al. 
1990; Rosiak 1994). In addition, it has been reported that gamma-irradiation 
induces cross-linking between PVP and acrylic acid and/or poly (vinyl alcohol) 
(Abd Alla et al. 2007; Nho et al. 2009). Moreover, gamma-rays can induce the 
diffusivity of inorganic compounds within a polymeric matrix (Mathakari et al. 
2010). Gamma-irradiation has also been recently utilised for the inclusion of 
compounds, including antimicrobial compounds, in an expanded polymeric 
network by radiation grafting (Puiso et al. 2011; Gasaymeh et al. 2010; Nho 
et al. 2009). Abad et al. (2003) have used gamma-rays to synthesise new 
hydrogels containing blends of PVP and biopolymers such as kappa carrageean 
(KC). The latter authors suggested that PVP-KC hydrogels result from cross-
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linking of PVP and grafting of KC to PVP, where degraded KC was also 
physically entangled in the cross-linked PVP network. 
Similar to gamma-irradiated blends of PVP-KC, gamma irradiation of 
KAG-(PVP-I) wafers would result simultaneously in cross-linking of PVP, 
degradation of KAG and perhaps grafting of KAG to PVP. The combination of 
these processes may form a KAG-PVP gel network where degraded KAG is 
physically entangled within the cross-linked PVP and grafted KAG into the PVP 
backbone. The overall effect could influence the gel fraction (the ratio of 
weight of swollen gel/ initial weight of polymer) and therefore the swelling 
behaviour of KAG-(PVP-I) wafer. Abad et al. (2003) demonstrated that a 
higher gel fraction is obtained when pure PVP was irradiated. They suggested 
that a decreased gel fraction is achieved with increasing concentration of KC, 
indicating that KC acts as a cross-link inhibitor. In the case of irradiated KAG-
(PVP-I) wafers, it is apparent from plot of ‘ln (σ) as a function of ln (γ)’ Figure 
5.7 (d) that gamma rays induced cross-linking of the  iodophore (PVP), and 
KAG is physically entangled as a semi-interpenetrating polymer network and 
perhaps grafted to cross-linked PVP. More experiments are needed to 
elucidate the phenomena taking place. 
Rheological analysis of post-lyophilised irradiated gels was undertaken 
as presented in Figure 5.8, Tables 5.7 and 5.8. It is apparent that chain 
scission and degradation dominated within the matrices of GG, SA and SA-
KAG. Interestingly, although gamma-rays induced a total degradation of post-
lyophilised irradiated gel of SA (Figure 5.8-a), the incorporation of CHD in the 
SA matrix reduced notably the degree of degradation for SA-CHD. These 
results are in agreement with the behaviour of the KAG-CHD systems 
previously discussed. In addition, the rheological behaviour of the XG-CHD 
matrices further supports this scenario, indicating that the presence of CHD 
immobilises the polymeric chains and/or radiolytic products. Immobilisation of 
polymeric chains and/or radicals results in a reduction of either polymeric 
cross-linking and/or chain scission. This phenomenon is apparent in CHD 
loaded systems of SA and XG compared to CHD-free matrices (Figure 5.8). 
The performance of irradiated antimicrobial wafers was tested on a 
modified disc diffusion assay, previously described (Chapter 2), where the 
expansion and inhibition ratios of irradiated wafers were compared to non-
irradiated specimens. Figure 5.9 presents the data obtained from expansion 
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and inhibition ratios of KAG antimicrobial wafers tested against MRSA, MSSA, 
E. coli and P. aeruginosa. It is apparent that all KAG irradiated wafers 
expanded more than the non-irradiated ones. The degraded polymeric matrix 
of KAG was reflected by the increased flow of the re-hydrated wafers, which 
was associated with total erosion of the cylindrical shape of the lyophilised 
formulation after 24 hours incubation (Figure 5.10). Interestingly, irradiated 
wafers impregnated with CHD and PVP-I demonstrated both the lowest and 
highest expansion ratios, compared to other irradiated antimicrobial loaded 
KAG wafers. The expansion behaviour demonstrated by irradiated CHD-loaded 
KAG wafers reflects the rheological behaviour of the KAG-CHD system 
mentioned above, where the incorporated drug holds together the degraded 
KAG matrix. The high expansion displayed by the rehydrated matrices of KAG-
(PVP-I) is complex to interpret, however such behaviour supports the 
development of a PVP-I cross-linked system within the degraded KAG matrix. 
The polymerised, hydrophilic iodophore of PVP-I, swells when placed on the 
moist agar surface, while the degraded KAG matrix erodes from the outside. 
Both phenomena occur simultaneously resulting in an increased expansion of 
irradiated KAG-(PVP-I) discs. 
It is apparent that increased inhibition ratios of irradiated KAG wafers 
are associated with increased expansion ratios of the formulations tested 
(Figure 5.9-b-d-f-h). Linear regression analysis of expansion ration (ER) vs. 
inhibition ratio (IR) for each antimicrobial tested against every bacterial strain 
(Figures 5.11-14) demonstrated that there was a trend for such a correlation, 
in some cases. The correlation between ER vs. IR was more evident in the 
case of SS and PVP-I rather than NS and CHD, indicating that the antimicrobial 
activity of SS and PVP-I was probably not affected by gamma-irradiation, 
while NS and CHD lost some of their initial antimicrobial potency. White 
residues observed around the swollen rehydrated matrices of all CHD-
impregnated irradiated wafers support this hypothesis; however, it is difficult 
to precisely interpret the linear regression analyses of ER vs. IR, as gamma-
rays may also have altered the diffusivity and release profiles of drugs 
embedded in degraded matrices. In addition, drug-polymer interactions, which 
apparently also influence the expansion ability of the swollen matrix, may also 
play a key role.  
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Expansion and inhibition ratios of irradiated CHD-impregnated matrices 
of GG, XG, SA and SA-KAG demonstrated a different behaviour compared to 
CHD impregnated wafers of KAG (Figure 5.15). The expansion ratios of 
antimicrobial-free irradiated wafers showed similar expansion profiles to non-
irradiated specimens. This expansion behaviour was particularly expected for 
XG wafers, rheological properties of which were not altered considerably, 
however degraded polymers of GG, SA and SA-KAG were expected to 
demonstrate increased flow on the moist agar surface. This paradox is difficult 
to interpret as several factors may be at play.   
It has been reported that gamma irradiated tablet formulations 
consisting of polyethylene oxide (PEO) lost the ability to swell and to form a 
gel layer during dissolution. In addition, irradiated PEO formulations dissolved 
rapidly decreasing their initial dimensions, while the ability to release the 
impregnated drug in a sustained manner was totally lost. This behaviour of 
PEO tablets was associated with considerable chain scission and overall 
degradation of the polymer matrix by gamma-rays (Maggi et al. 2004). Desai 
and Park (2006) have reported a similar behaviour for gamma-irradiated 
chitosan microparticles. The latter authors indicated that increased irradiation 
doses decreased the swelling capacity and increased the release rate of 
impregnated drug from irradiated chitosan microparticles. 
Depolymerisation of GG, SA and SA-KAG is likely to lead to an inability 
of the irradiated matrix to swell and form a weak gel network and as a 
consequence, the rehydrated wafers were expected to show an increased 
expansion. However, in the case of irradiated CHD-impregnated wafers of SA 
and SA-KAG, this phenomenon is not evident as the CHD incorporated within 
the irradiated matrix further restricted the matrix’s ability to expand. The 
ability of impregnated CHD to confine the expansion of wafers was also noted 
for non-irradiated CHD wafers, previously mentioned in Chapter 3 (Figure 
3.5). Although irradiated CHD wafers did not demonstrate an increase in 
expansion ratio, there was evidence that the restricted expansion was 
associated with increased inhibition ratios. Linear regression analysis 
presented in Figure 5.16 (c) and (d) demonstrated that there was an inversely 
proportional correlation between ER and IR for CHD impregnated wafers of SA 
and SA-KAG. 
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Dissolution profiles of irradiated CHD-loaded SA wafers demonstrated 
that there was a faster release of CHD from the irradiated SA matrices, where 
the accumulation of CHD at 24 hours almost doubled for the irradiated wafers 
compared to non-irradiated SA wafers (Figure 5.17, Table 5.9). In addition, 
increased doses of irradiation (40 kGy) slightly decreased the ability to absorb 
and retain water (Figure 5.18) while increasing the release of CHD from the 
irradiated matrix. The results are in agreement with the previous work of 
Maggi et al. (2004) and Desai and Park (2006), indicating that irradiated 
polymers, in which gamma-rays cause degradation and chain scission, 
generally lose their ability to control water uptake, while they demonstrate a 
faster release of the impregnated therapeutic compound. However, in the case 
of polymers where the impregnated drug interacts with the polymeric carrier, 
the situation is more complex.  
Linear regression of CHD released from SA irradiated wafers, analysed 
with the Korsmeyer-Peppas model (Figure 5.19, Table 5.9) demonstrated that 
this model represents an appropriate model for release kinetics, from the 
irradiated polymeric matrices under sink conditions, as correlation coefficients 
were approximately 0.97. Although, there was almost a 2-fold increase in the 
accumulation of CHD from the irradiated SA matrices, the calculated release 
exponent indicated that diffusion of CHD follows Fickian behaviour. These 
results suggest that the interaction occurring between the impregnated drug 
(CHD) and the polymer play an important role in the general behaviour of the 
antimicrobial polymeric matrix, in terms of exhibited flow behaviour 
(rheological properties), ability to absorb and retain fluids and release of the 
impregnated antimicrobial compound. The efficacy of antimicrobial polymeric 
systems depends on the interactions developed within the polymeric matrix 
between the drug and the polymeric chains. A sound understanding of such 
interactions is critical to the development, performance and activity of 
antimicrobial gel formulations intended for the control of infection and 
management in chronic wounds. An attempt to elucidate and interpret drug 
polymer interactions between biopolymers and selected broad spectrum 
antimicrobials is summarised in the next Chapter (6). 
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Chapter 6 
In silico, molecular modelling studies on the 
components of karaya (KAG) antimicrobial 
wafers 
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6.1 Aim 
Attempt to interpret drug-polymer interactions affecting the rheological 
behaviour of KAG-antimicrobial complexes by using molecular modelling 
studies.  
 
6.2 Introduction 
Recently, there has been an increasing interest in the investigation and 
use of natural polymers as drug delivery carriers. Biopolymers such as guar 
gum, chitosan and karaya gum have been investigated as potential, non-toxic, 
biocompatible and biodegradable vehicles for therapeutic compounds. 
However, the design of novel delivery systems such as biopolymeric-drug 
conjugates appears to be not an easy task, especially when the properties of 
either biopolymers or their combination with ionised drugs are unknown.  
Different types of intermolecular forces may develop between 
incorporated drugs in polymeric carriers. Some of them include electrostatic 
interaction, hydrogen bonding, hydrophobic interaction and Van der Waals 
forces. Electrostatic forces may occur between charged or partly charged ions 
of molecules and can be either repulsive or attractive, where the degree of 
ionisation influences the intensity of such interactions. They can be short-
ranged (weak) or long-ranged (strong). Hydrophobic interactions are entropic, 
moderately strong attractive interactions occurring between non-polar groups 
separated by water. Hydrogen bonding and Van der Waals are generally 
considered weak attractive interactions which decrease with increasing 
temperature (Dickinson 1998). 
Previous studies have shown that chitosan, a polyionic natural polymer, 
develops electrostatic interactions when it is used as a carrier of antimicrobials 
such as with amoxicillin trihydrate and/or amoxicillin sodium (Torre et al. 
2003). Bani-Jaber et al. (2009) recently reported drug- polymer interactions 
occurring between chitosan and diclofenac. Heun et al. (1998) have 
investigated drug-polymer interactions occurring between Eudragit RL/RS 
resin and four model drugs. The latter authors demonstrated excellent 
correlation between in silico data and data obtained from in vitro experiments. 
Generally, molecular modelling studies have proven to be a useful tool in 
 170 
 
increasing understanding of the interactions between drugs and their 
polymeric carriers. In addition there are a plethora of studies reporting a good 
correlation between experimental data obtained in vitro and in silico 
(Subashini et al. 2011; Cairns et al. 2002), indicating that molecular modelling 
studies provide a reliable method for the investigation and profound 
understanding of drug-polymer interactions.  
However, understanding the relationship between molecular structure 
and physicochemical properties of polymers is a challenging task, which gets 
even more complex when the ionised or partly ionised polymer serves as a 
carrier of an ionised drug. Although there are many reported investigations of 
the type of interactions occurring between a polymeric carrier and an ionised 
drug, there is limited information about how the entrapped interactive drug 
may influence the rheological behaviour of the biopolymer, adhesion 
properties, water uptake ability and diffusivity of the compound from the ionic 
polymeric network.  
In the current project, selected biopolymers such as sodium alginate, 
xanthan gum, guar gum and karaya gum have been used as carriers of 
antimicrobial compounds. These were intended for the formulation of 
lyophilised antimicrobial wafers that demonstrated initially altered rheological 
properties when mixed with broad spectrum antimicrobial compounds. The 
influence of the incorporated drugs was generally reflected on the performance 
of antimicrobial wafers. For instance, the significant effect of the incorporated 
drugs on the adhesion properties of the KAG-antimicrobial wafers. In addition, 
expansion ratios of CHD wafers appeared to be different to those of 
antimicrobial-free wafers. Moreover, diffusivity of solute CHD was considerably 
affected by the CHD-polymer interactions occurring within the swollen 
biohydrogel network. Drug-polymer interactions developed between the 
entrapped drugs and the polymer network may also be an important factor on 
the effect of gamma-rays upon the physicochemical properties and 
performance of the antimicrobial matrix. 
Therefore, a brief investigation was undertaken in order to better 
understand and attempt to interpret the drug polymer interaction developed 
between a partly ionic biopolymer and incorporated drugs. Molecular modelling 
studies undertaken focused generally on the molecular behaviour of 
biopolymeric carrier KAG in association with four different antimicrobial 
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compounds. Molecular simulation between constructed compounds was initially 
investigated in vacuo, and provided information about macroscopic 
(thermodynamics and optical properties) and microscopic (molecular motions 
and intermolecular forces) behaviour of molecules and created complexes. 
 
6.3 Materials and methods 
Molecular modelling studies were undertaken to attempt to interpret and 
decipher the drug polymer - interaction occurring between KAG and selected 
antimicrobials, when mixed together. Chemical structures of antimicrobials 
were taken from the supplier (Sigma-Aldricht, UK), and conformation of KAG 
was based on the information given in the Merck Index (12th edition 1997), 
Verbeken et al. (2003) and De Brito et al. (2005). Molecular modelling was 
carried out on a Silicon Graphic Octane II or Hewlett Packard 3000 series 
workstation using the Insight-II 2004 graphics interface and Discover 3.0 
simulation software (Accelrys, UK).  The energy calculations, minimisation and 
dynamic simulation of biopolymer KAG, NS, CHD and pluronic F68 surfactant 
were analysed using the cvff force field, while cff91 was used for PVP-I and 
SS. Models for each antimicrobial and polymer were constructed (Insight-II) 
and partial atomic charges approximated from a single-point PM3 calculation. 
Each antimicrobial was docked manually with the polymer. The optimised 
models were subjected to molecular dynamics simulation (10 ps equilibration 
and 200 ps production, 1-fs timesteps) with initial atomic velocities taken from 
a Maxwell-Boltzmann distribution at 300K and 500K. The time-averaged 
structures from 200 samples taken at 1-ps intervals were minimised. Ligand 
structures were sampled for conformational averaging in vacuo. Atomic 
trajectories saved every 1 ps were used for conformational averaging, and 
these structures were finally minimised to an energy convergence criterion of 
0.1 kcal mol–1 Å–1. Binding enthalpies were obtained by subtraction of the 
potential energy of the antimicrobial and polymer from that of the complex:  
                               Ebind = [Ecomplex] – [Edrug + Epolymer] 
 where, Ebind = calculated binding enthalpy between antimicrobial and 
polymer; Ecomplex = potential energy of complex after final minimisation; Edrug = 
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potential energy of antimicrobial after final minimisation and Epolymer = 
potential energy of polymer after final minimisation. Negative values of Ebind 
indicate favourable interactions between the drug and the polymer matrix, 
while positive values of Ebind indicate unfavourable interactions between the 
polymer and the incorporated drug. 
 
 
Figure 6.1 Summarised work diagram of the molecular modelling stages: 
Build molecules: Construction of molecules based on a specific coordinate 
system (Cartesian x, y, z) and calculation of potential energy surfaces, which 
is considered to be the movement on a multi-dimensional surface (Leach 
1996). 
Minimisation: The minimum energy arrangements of atoms, equivalent to a 
‘plausible’ starting geometry, also known as global energy minimum, which is 
generally considered to be a stable state of the constructed molecular system 
(Leach 1996). Polymers have a more complex energy surface profile, 
compared to small molecules, mainly due to the large number and variety of 
atoms or sub units that they possess (Figure 6.2). 
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Dock: Docking is defined as the affinity of molecules with an optimal 
orientation and energy to form a stable complex (Lengauer and Rarey 1996). 
Merge: Permanent unification of minimised structures of constructed 
molecules (polymer and drugs) in order to form a polymer-drug complex. 
Dynamics: Molecular dynamics (MD) is a virtual simulation of constructed 
minimised molecules and created complexes in order to investigate their 
conformational space as a function of time. Virtual simulation usually involves 
the application of realistic temperatures (300 K = 26.85 0C and 500 K = 
226.85 0C), allowing simulated structures to become more conformationally 
flexible and capable of reaching a global energy minimum. During this process 
mobile molecules generate a trajectory (history of motion) which 
demonstrates the conformational behaviour of the molecules/complexes and 
confirms the accuracy of generated values of enthalpies (Leach 1996). It has 
to be mentioned that the generated values of enthalpies of simulated 
molecules and created complexes depend on the size of molecules/complex 
and provided heat.  
Average structure: This is a final arrangement of structures generated from 
the trajectory of the simulated molecules/complexes. 
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Figure 6.2 A schematic one-dimensional energy surface of small molecules. 
Minimisation moves downwards the nearest minimum. X1, X2 – local minima, Y 
– global energy minimum, which can be only reached following molecular 
modelling simulations (Leach 1996). (—) Folding-energy landscape for a 
biological heterogeneous polymer (protein) (Frauenfelder and Wolynes 1994). 
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Figure 6.3 Schematic folding pathways of polymers, used to reach a global 
minimum energy conformation (Adapted from Judson 1992).  Note that the 
conformational variation ability (flexibility) of a polymeric molecule, which 
can produce different values of minimisation energy (kcal mol-1). 
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6.4 Results 
 
 
 
 
 
 177 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4 Molecular modelling configurations [Corey-Pauling-Koltum (CPK 
rendering)] of minimised structures of KAG polymer and selected 
antimicrobials. Note the interesting three dimensional shape of chlorhexidine 
(CHD) (‘Z’ structure) and silver sulfadiazine (SS) (‘butterfly’ structure). Please, 
note that the structures are not presented at the same magnification.            
A – KAG, B – NS, C – CHD, D – SS and E – PVP-I 
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Figure 6.5 Molecular modelling of minimised (CPK rendering)                    
KAG – antimicrobial complexes: A – KAG-CHD, B –KAG-NS, C –KAG-PVP-I and 
D –KAG-SS (with pluronic F68).  
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Table 6.1 Optimal docking energies of KAG with the incorporated drugs in 
vacuo. Note from the merged complexes above (Figure 6.3) that the most 
favourable residence of the associated drugs is the ‘pocket’ created from the 
structure of KAG. PVP-I and SS-F68 have a higher affinity to KAG compared to 
CHD and NS, as they possess a higher number of atoms (docking energy is 
proportional to the number of atoms in molecule). 
 
Complex Energy of affinity (kcal mol-1) 
 
KAG-CHD 
 
 
106.08 
 
KAG- NS 
 
 
667.70 
 
KAG-PVP-I 
 
                
                 -956666.00 
 
KAG-SS-F68 
 
                
                 -987576.00 
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Table 6.2 Binding enthalpies (Eb) of compounds and complexes (1 : 1 ratio) 
calculated in vacuo at 300 K. Note that calculated Eb values of complexes were 
negative, except of KAG-NS, indicating favourable interactions between karaya 
gum (KAG) and incorporated drugs. 
 
Molecules 
Energy 
of 
molecules 
(kcal mol-1) 
Energy of complex  
KAG/drug 
(kcal mol-1) 
Energy of binding 
Eb = Ec – [Ed + Ep] 
(kcal mol-1) 
KAG 9171.8 
CHD     22.2   9106.0    -88.0 
NS 1412.9 11194.8    610.1 
PVP-I  -639.3   5840.4 -2692.1 
SS 
pluronic F68 
   -69.7 
      2.9 
  6464.9 -2640.1 
 
Table 6.3 Binding enthalpies (Eb) of compounds and complexes (1: 1 ratio) 
calculated in vacuo at 500 K. Note that calculated Eb values of complexes were 
negative indicating favourable interactions between karaya gum (KAG) and all 
incorporated drugs. 
 
Molecules 
Energy 
of 
molecules 
(kcal mol-1) 
Energy of complex  
KAG/drug 
(kcal mol-1) 
Energy of binding 
Eb = Ec – [Ed + Ep] 
(kcal mol-1) 
KAG 9771.3 
CHD   100.9   9823.1   -49.1 
NS 1442.8 10602.3 -611.8 
PVP-I  -720.0   5631.4         -3419.9 
SS 
pluronic F68 
   -36.5 
       108.0 
 6496.5         -3346.3 
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Table 6.4 Sugars present in karaya gum (KAG). 
Sugars 
Formula 
(Molecular weight) 
O
OH
H
H
HO
H
H
OHH
OH
OH
 
β-D GALACTOPYRANOSE 
 
 
 
C6H12O6 
(180.16) 
O
OH
H
H
HO
H
OH
OHH
H
COOH
 
α-D GALACTURONIC ACID 
 
 
 
 
 
C7H12O7 
 
(208.17) 
O
H
HO
H
HO
H
H
OHH
OH
COOH
 
β-D GLUCURONIC ACID 
 
 
 
 
C7H12O7 
 
(208.17) 
 
α-L RHAMNOSE 
 
 
 
 
C6H12O5 
 
(164.16) 
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Figure 6.6 Proposed model for Sterculiaceae gelation; A-ordered ionic 
interaction between galacturonic acid residues and calcium ions (Ca2+) (the 
‘egg-box model’), B - hydrogen bonding between rhamnose segments, C - 
ionic interaction between two or more galacturonic acid residues of the 
backbone and /or  branches of glucuronic acid (Adopted from Silva et al. 
2003).  
 
Figure 6.7 A plausible block configuration of karaya gum (KAG) consisting of 
α-L-rhamnose (Rh) residues linked to 1, 4-α-D-galacturonic acid (GA) 
backbone and branches linked to 1, 2- linked-β-D-galactopyranose (G), 1, 3-
linked-β-D-glucuronic acid (Gu) to the backbone residues. (----) represents 
the entrapped drug (CHD) within the KAG network (C - zone of Figure 6.6), 
where the antimicrobial compound (which displayed a ‘Z’ shape)  is hooked 
between the polymer residues, disrupting the 3-D structure of the polymer 
network, weakening polymer-polymer interactions and resulting in a ‘thin’ gel 
network. 
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6.5 Discussion  
Molecular modelling may be generally defined as the investigation and 
conceptualisation of molecules via physical, mathematical and graphical 
representations.  In other words, molecular modelling is a virtual simulation of 
molecules or of molecular systems in order to understand and/or predict their 
behaviour (Schlecht 1998). Although MD is found to be a powerful tool to 
further understand and also predict the properties of molecules, including 
polymers, complex biopolymers represent a major challenge when trying to 
mimic their properties in silico. Cross-linking between different chains 
increases the variations in the constitution and structures of a polymer, which 
sometimes can have a dramatic affect upon the overall properties of the 
molecule (Leach 1996). 
Karaya gum (KAG) is a complex, partly acetylated branched polymer, 
which originates from the dry grounded exudate of Sterculia urens tree. 
Analysis of the structure of KAG demonstrated that this biopolymer consists of 
a backbone of α-D galacturonic acid and α-L rhamnose residues. Branches are 
linked by 1, 2-linkage of β-D-galactose and/or by 1, 3-linkage of β-D-
glucuronic acid (Verbeken et al. 2003). Although the chemical composition of 
the biopolymer differs with the place of origin and harvested period, it has 
been reported that generally KAG contains 60 % acetyl free, neutral sugars 
(galactose and rhamnose) and 40 % acidic residues (glucuronic and 
galacturonic acids) (De Brito et al. 2005). In addition, it has been reported 
that KAG contains traces of proteins (approximately 1 %); however protein 
content was found lower than in other biopolymers of natural gum extracts 
(Verbeken et al. 2003). There is, therefore, an extensive degree of chemical 
variation in samples of KAG. 
De Brito et al. (2005) have investigated the rheological properties of 
KAG aqueous solutions and demonstrated that KAG forms a relatively strong 
gel network at concentrations higher than 2 % (w/v). These results are in 
agreement with the rheological properties of 3 % (w/v) KAG gels investigated 
in the present project, which have been reported previously (Chapter 2). An 
aqueous solution of 3 % (w/v) KAG demonstrated a pseudoplastic flow with no 
yield stress, where the calculated viscosity did not exceeded 13.00 Pa.s. The 
gelling mechanism of branched, partly ionic biopolymers is a complex process. 
A gelation model for Sterculiaceae has been proposed by Silva et al. (2003) as 
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presented in Figure 6.6 and it has been reported that the presence of acetyl 
groups, in particular glucuronic and galacturonic acid residues, are essential in 
the formation of the KAG gel network as they promote the interactions 
between the polysaccharide chains.  In addition, it has been reported that the 
presence of electrolytes, such as sodium and chloride, decrease the gel 
strength of aqueous solution of KAG and lead to a less viscous gel (De Brito et 
al. 2005).  
The incorporation of clinical concentrations of broad spectrum 
antimicrobials in the KAG gel network was associated with a considerable 
decrease in viscosity (Chapter 2, Table 2.3). Rheological analysis showed that 
the incorporation of NS and CHD caused a notable decrease in viscosity of 
KAG, which was approximately 8 times and 3.4 times respectively. The 
incorporation of PVP-I and SS (prepared with pluronic F68) also decreased the 
viscosity of KAG gel approximately 2-times. These results indicate that the 
incorporation of ionic molecules, such as CHD and NS, have a greater affect 
upon the gel network of KAG. However, it is apparent that the incorporation of 
non-ionic compounds of either PVP-I and SS (with pluronic F68) also affected 
the KAG gel network. In the case of PVP-I, the situation appears to be more 
complex, as small quantities of other compounds included in the standardised 
commercial solution of PVP-I, such as glycerol, monoxynol-9, sodium 
phosphate, sodium hydroxide, potassium iodate and citric acid, may also have 
an additional effect on the KAG gel network. 
Molecular modelling studies initiated with the construction of molecules. 
Drug molecules of CHD, NS and SS were created based on their chemical 
conformation and therefore the CPK rendering (Figure 6.4) indicates plausible 
and realistic geometries. PVP-I was constructed as the connection of twelve 
blocks of polyvinylpyrrolidone (PVP), where four large atoms of iodine where 
tethered within the PVP matrix. The structure of karaya gum (KAG) was based 
on a plausible configuration of sugars present in KAG, taken from the existing 
literature. The final structure of KAG consisted of 30 sugar molecules (Table 
6.4) including α-D galactopyranose (20 %), α-L rhamnose (30 %), α-D 
galacturonic acid (30 %) and β-D glucuronic acid (20 %). Although the actual 
length of polymer is variable, the KAG molecule was constructed to mimic 
closely the structure of KAG biopolymer. 
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Complexes of KAG-drug were constructed as presented in Figure 6.5. It 
is apparent that the most optimal residence of the incorporated drugs was 
found to be within the ‘pocket’ created within the minimised structure of KAG. 
This pocket arises due to gross folding of the modelled polymer as a result of 
the minimisation algorithm. According to Mingaleev et al. (2002) 
”conformational flexibility is considered to be a fundamental property of 
polymers which differentiates them from small molecules and promote their 
remarkable properties”. This ability of polymers is generally mediated from the 
complex structures of the constituent’s sub-units. The energy of a polymeric 
molecule is a function of a topological arrangement of the sugars. Generally, 
the energy of polymers is described as a hypersurface, with many energy 
valleys (or craters) and hills (Figure 6.2), where each of the valleys is 
indicative of a particular conformational state of the polymer (Frauenfelder 
and Wolynes 1994). Figure 6.3 presents a schematic folding pathway, which 
can lead to different conformations and different energy values that a 
polymeric molecule can possess. In addition, it is apparent from the 
schematic, one-dimensional energy surface (Figure 6.2) that there is a notable 
difference between the surface energy profiles of small and polymeric 
molecules. Therefore, the KAG polymer is expected to display a linear 
geometry and a high degree of flexibility, dissimilar to the incorporated small 
drug molecules, which may play a critical role on the calculated binding energy 
behaviours of the drug-polymer complexes. 
The absolute energy of affinity of drugs with the KAG structure ranged 
from 106.08 – (-987576.00) kcal mol-1 (Table 6.1), but these values are 
calculated from the number of atoms present. Large molecules consisting of 
numerous atoms will display an increased energy value. The incorporation of 
PVP-I and SS-F68 demonstrated the highest energy of affinity. On the other 
hand, CHD and NS showed positive values of proximity with KAG indicating an 
unfavourable interaction of KAG to either CHD or NS. However NS 
demonstrated the highest repulsive behaviour to KAG. 
Data obtained from the in vacuo simulation at 300 K (Table 6.2) 
indicated that all incorporated drugs showed a favourable interaction (-ve 
binding enthalpy) with the KAG, except for NS. The most favourable 
interaction was displayed from PVP-I and SS (with pluronic F68). Although it 
was expected that CHD would have shown the most favourable interaction 
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with KAG, as the cationic structure of CHD would be attracted to the partly 
anionic KAG residues, calculated enthalpies at 300 K did not represent such a 
trend. In the case of NS, the incorporated drug demonstrated a positive value 
of binding energy, indicating unfavourable interaction with the KAG network. 
The most favourable interactions were obtained with PVP-I and SS-F68. These 
components are not cationic and are therefore not expected to bind strongly to 
a partly anionic polymer. The high interaction energy obtained from the 
molecular modelling suggests that the size of the antimicrobial is important 
and that hydrophobic effects (interactions which occur between non-polar 
molecules) are more influential in this type of ‘polymer-polymer’ interaction.  
Molecular dynamics of generated molecules and complexes were also 
performed at 500 K in order to further simulate the motility of structures 
(Table 6.3). Generally, the energy of molecules was slightly increased 
compared to those values obtained at 300 K. Only PVP-I displayed a slightly 
decreased energy when simulated at 500 K. Interestingly, CHD and F68 
increased their energy by 4.5 and 37 times respectively, however, the energy 
values of complexes remained generally similar. The calculated binding 
enthalpies for each complex simulated at 500 K, demonstrated that all drugs 
showed a favourable interaction (-ve binding enthalpy) to the KAG matrix. 
These results are similar to the calculated binding enthalpies obtained at 300 
K, except for NS. 
Rheological analysis of KAG antimicrobial gels demonstrated that the 
viscosity coefficient of gels showed a decreasing trend compared to control 
(antimicrobial-free gel), where KAG > SS-F68 > PVP-I > CHD > NS. These 
results suggest that the presence of the antimicrobial compound disrupts the 
three-dimensional polymer network, weakening polymer-polymer interactions 
and ‘thinning’ the gel (Figure 6.7). The calculated binding enthalpies 
determined at either 300 K and 500 K supported this hypothesis i.e. all the 
complexes displayed negative binding enthalpies, where generally PVP-I > SS-
F68 > NS > CHD, indicating a favourable interaction with the polymer. The 
rank order of effect was however different, with the compounds displaying the 
greatest binding energy demonstrating only a modest drop in viscosity. 
However, the viscosity lowering appears to be possibly the result of a bulk 
physical presence of the drug disrupting the close three-dimensional lattice of 
the polymer.  
 187 
 
The differences in rank order may be due to a number of effects and these are 
listed below: 
 Molecular modelling counts best where there are simple molecular 
interactions occurring between drug and polymer. It may be that 
‘bulk’ effects are not captured well by a technique which relies upon 
specific atom-atom interactions. 
 
 Some of the structures modelled in this study are large and are very 
conformationally flexible. It is possible that 100,000 fs of molecular 
dynamics (MD) was insufficient to captures all available trajectories 
and that the study could be repeated allowing for a greater 
production phase of MD (e.g.  MD occurring at 600 K for 200,000 fs). 
 
 Similarly, the temperature of the molecular modelling may be 
insufficient to completely relax the high molecular weight structures 
found in these polymers. It is reported that the relaxation process in 
complex biomolecules can be reached under extensive simulation at 
increased temperatures (Frauenfelder and Wolynes 1994).  
 
 Modelling was carried out ‘in vacuo’. It may be that a better 
correlation would be obtained if an explicit solvent was employed. 
There are pitfalls, however, with the use of explicit solvent in that 
the type of modelling undertaken must be strictly controlled to 
ensure that sufficient production time is allowed to capture all 
possible trajectories. 
 
In silico interpretation of interactions taking place within miscible 
complexes of drugs with polymers is not an easy task. Biopolymers are 
generally heterogeneous molecules, which are difficult to mimic precisely in 
silico. They possess remarkable properties as thickeners, stabilisers and drug 
delivery vehicles, mainly due to their ability to from a complex 3-D network in 
aqueous solution. The chemical variation of biopolymers, however, can lead to 
unexpected rheological behaviours when used as carriers of charged or non-
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charged molecules. Such variations in consistency were noticed in KAG-drug 
blends. Attempts to decipher and understand the behaviour of KAG-drug 
conjugates were undertaken using molecular modelling simulation. In silico 
simulations proved to be very useful in conceptualisation and visualisation of 
the geometries of small drug molecules and in vitro, the incorporation of ionic 
drug molecules had a profound effect on the 3-D gel network of KAG, in silico 
simulations were unable to capture all atom-atom interactions occurring 
between oppositely charged groups. However, this effect was mainly due to 
conformational flexibility of the polymeric carrier (KAG) and large drug 
molecules such as PVP-I and or SS-F68 complexes.  
Additional modelling studies are required in order to shed light on the 
interactive behaviour of biopolymer-drug complexes. These include the 
investigation of the effects of a longer production phase for the dynamics 
simulations and the effects of increased temperature during simulations in 
solvents upon polymer relaxation. Secondly, investigation of polymers under 
conditions of restraints of mobility and reduced flexibility. Thirdly, 
investigation of drug-polymer interaction, performed with different docking 
orientations, with regards to drug’s residence (i.e. putting the drug in ‘upside 
down’ or outside the polymeric ‘pocket’) and fourthly, the formation of drug-
polymer complexes based on an automatic docking logarithm. 
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General discussion  
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7.1 General discussion and future work 
The complex nature of non healing wounds and a poor understanding of 
the aetiologies that govern impaired healing, represents a challenge for 
physicians and scientists alike. Chronic wounds are a major cause of disability, 
social isolation and even mortality for affected individuals. In addition, 
treatment involves a high economic cost and the risk of spreading hospital and 
community acquired antimicrobial resistant bacterial strains. Therefore, 
treatment of chronic, non healing infected wounds represents a great 
challenge for both patients and healthcare workers in terms of application of a 
suitably effective therapy. 
Chronic wounds result from the inability of the broken skin to follow a 
well-coordinated and complex physiological healing process, which relies on 
the overlapping stages of coagulation, inflammation, proliferation and 
remodelling. In other words, impaired healing results from an imbalance of 
promoters and inhibitors and disrupted interaction between biochemical 
mediators with the extracellular matrix (ECM).  Instead, the skin restoration 
process is trapped in an uncontrolled and self-sustained phase of inflammation 
(Schreml et al. 2010).  There are several aetiologies that can delay and/or 
stop the healing process. They include wound type and pathophysiology, the 
patient’s immune system, age and bacterial infection. Currently, it is not yet 
well defined which of all the above factors play a primary role in impaired 
healing as they all interplay, however, infection and bacterial colonisation is 
considered a common cause of chronic inflammation. 
Chronic inflammation is usually caused by persistent bacterial 
colonisation and infection, as an open ulcer provides a favourable habitat for a 
variety of bacterial species. The mixed microbiological flora of wounds, in 
terms of density, diversity and biofilm formation, has been shown to be a 
common cause of impaired wound healing. Common pathogens of non healing 
wounds, such as S. epidermidis, S. aureus, Porphyromonas spp, 
Peptostreptococcus spp, Enterococcus spp, E. coli, P. aeruginosa, Clostridium 
spp, which arrive from both external and internal environments, adhere to the 
injured skin tissue (Parker 2000). The protein content of wound exudate 
provides a nutritional substrate for bacteria to survive and proliferate in an 
unprotected ulcer (Landis 2008). As a consequence, control of exudate and 
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inhibition of bacterial infection can provide an effective therapy to control 
bacterial bioburden and eventually improve wound healing. 
Topical treatment of non-healing, infected wounds can provide many 
advantages with regards to control of wound exudate, optimal moisture of 
wound bed and local delivery of antimicrobials. In particular, application of 
self-adhesive, occlusive and gel transforming formulations have proven to be 
more efficacious than gauzes and/or cotton wool dressings (Jurczak et al. 
2007). Hydrophilic, non-toxic, porous lyophilised wafers, prepared from 
biopolymers, can provide an innovative approach to the management of a 
wide variety of suppurating wounds (Matthews et al. 2005). In addition, the 
incorporation of broad spectrum, widely used antimicrobial compounds within 
the lyophilised matrices can provide a controlled, continuous and targeted 
delivery of the drug at the site of infection. 
In vitro investigation of the properties and antimicrobial efficacy of 
novel formulations, intended for application in a variety of suppurating 
wounds, represent a great challenge. Despite the plethora of traditional, 
modern, advanced and medicated dressings, there is not an established 
universal in vitro wound model. The latter factor is challenged by the fact that 
non-healing, infected wounds beds display a high variability in terms of tissue 
pathophysiology, surface abnormalities and polymicrobial contamination 
(Bowler et al. 2010). In addition, there is restricted information with regards 
to the amount and the consistency of wound exudate produced from non 
healing wounds, as exudation varies with wound type, depth, aetiology and 
healing stage.  
The general aim of this project was to formulate and evaluate 
biopolymeric antimicrobial wafers as a novel technology for infection control in 
chronic wounds. The work undertaken focused on the antimicrobial efficacy 
and quantification of the antimicrobial compounds released from the 
lyophilized matrices of wafers under simulated conditions of exuding wounds. 
Suitable in vitro wound models, existing and original, such as modified disc 
diffusion, the free stranding dissolution raft (FSDR) and antimicrobial diffusion 
cell (ADC) were used to assess the efficacy of antimicrobial wafers. Particular 
emphasis was given to mimicking in vitro, conditions of abnormal and 
contaminated wound exudate and to investigate the activity of antimicrobial 
compounds released in a sustained fashion. In addition, the effect of gamma-
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irradiation, as a well-established sterilisation process, upon the activity, 
performance and physicochemical properties of antimicrobial wafers and 
constituent materials was investigated. Moreover, an attempt was made to try 
to elucidate and understand drug-polymer interactions developed between 
embedded antimicrobials and selected biopolymers, which play a key role in 
the general performance of antimicrobial wafers.  As a result, this thesis 
includes novel data conducive with the stated aims as outlined in Chapter 1.   
Cohesive and non-friable antimicrobial wafers were successfully 
formulated using a variety of natural polymers such as xanthan gum (XG), 
guar gum (GG), sodium alginate (SA) and karaya gum (KAG), impregnated 
with clinical concentration of either neomycin sulphate (NS), chlorhexidine 
digluconate (CHD), povidone iodine (PVP-I) or silver sulfadiazine (SS). In 
addition, binary mixtures of natural polymers led to novel synergistic 
interactions of gels as reported in Chapter 2 (Table 2.2). The original 
rheological properties of SA-KAG gel were quantified and the mixture used as 
a dual polymeric carrier of CHD.  
Mixtures of antimicrobial compounds with natural polymers can be 
compatible or non-compatible. Incompatibility was determined as the 
formation of polymeric aggregations and the inability of the polymer to form a 
homogenous gel. For example, XG and SA were found to be incompatible 
carriers for NS. Incompatibility may be the result of strong attractive and/or 
strong repulsive interactions developed between mixed compounds. NS is a 
soluble salt, aqueous solutions of which contain cationic neomycin and anionic 
sulphate. XG is an anionic polymer, the aqueous solutions of which exhibit 
phase separation, in the presence of anionic electrolytes, driven by repulsive 
interactions (Boyd et al. 2009). Similarly, the sodium salt of alginic acid is 
soluble in water. The presence of oppositely charged electrolytes in the mixed 
solutions of SA and NS are likely to lead to long-range attractive and/or 
repulsive interactions that result in aggregation of the polymer. Interestingly, 
compatible combinations of biopolymers with selected drugs altered the flow 
behaviours of the gels. This was associated with a considerable increase or 
decrease in apparent viscosity or yield stress. Rheological measurements 
undertaken provided a reliable and essential method to quantify the flow 
properties of controls and antimicrobial pre-lyophilised gels. 
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The combination of KAG with either NS, CHD, PVP-I or SS led to 
considerably decreased consistency of the KAG gel. The decrease in 
consistency was likely associated with interactions developed between KAG 
and incorporated antimicrobial compounds. Cationic compounds of CHD and 
NS caused a greater decrease in viscosity of KAG compared to SS and PVP-I. 
This phenomenon was associated with the profound effect of ionised molecules 
upon the acetylated residues of complex KAG, which have been reported to 
play a key role in formation of the 3-D gel network of KAG (De Brito et al. 
2005). Previous studies have also reported the ‘thinning’ effect of electrolytes 
upon the flow behaviour of KAG (De Brito et al. 2005). 
Although, reduced consistency of KAG antimicrobial gel was expected to 
be associated with an increased expansion ratio of the wafers, that was not 
apparent in the case of KAG antimicrobial wafers tested in a modified disc 
diffusion assay. The expansion of KAG antimicrobial wafers on a seeded agar 
substrate was mainly governed by equilibrium conditions created in the 
incubated Petri dish. The main factors that influence the expansion of wafers 
include hydrophilicity, rate of hydration, rate of evaporation, polymer chain 
entanglements developed at the interface of wafer and gel substrate and drug-
polymer interactions (n.b. when referring to such interactions, the term ‘drug’ 
may be conveniently substituted for ‘antimicrobial compound’).  
The incorporation of CHD within the biopolymeric matrices of SA, XG 
and SA-KAG generally improved the flow properties of the gels. In particular, 
the combination of CHD with SA or binary combination of SA-KAG led to a 
considerable increase in apparent viscosity and yield stress, respectively. 
Improved flow properties of pre-lyophilised gels of SA, XG and SA-KAG were 
associated with a notable decrease in the expansion ratio of CHD wafers. 
Similar behaviour for SA and XG lyophilised formulations, rheological 
properties of which were improved with additions of methylcellulose (MC), was 
observed by Matthews et al. (2005). These results suggest that flow behaviour 
of pre-lyophilised gels is directly related to the expansion ratio of the re-
hydrated wafer. In addition, enhanced rheological properties of an 
antimicrobial gel may prove beneficial for the in vivo performance of the 
antimicrobial wafer. It has been reported that enhanced flow behaviour of 
polymeric carriers generally ensures prolonged retention times at the site of 
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application, and accurately delivered doses of therapeutic agents, hence 
improved efficacy (Andrews and Jones 2006). 
Analysis of adhesive properties of lyophilised wafers were undertaken 
using a soft, modified agar surface prepared with the same quantities of 
sodium, calcium and chloride electrolytes found in wound exudate. Work of 
adhesion of KAG wafers was similar for all articles and range from 0.27 ± 
0.016 – 0.37 ± 0.022 N.mm, where antimicrobial wafers exhibited slightly 
lower values compared to controls. It was evident that the incorporation of 
antimicrobials caused a drop in viscosity and a significant decrease in tensile 
stress (peak detachment force/cm2) for the medicated wafers, in particular for 
PVP-I, compared to controls, as reported in Chapter 2 (Figure 2.8). These 
results suggest that a smaller force was required to detach antimicrobial 
wafers from the model surface; however, the drop in viscosity of KAG-
antimicrobial gels was not proportional to the reduced tensile strength 
exhibited from the antimicrobial KAG wafers. Other factors such as porosity 
(matrix microstructure) and wettability can also influence adhesion of wafers. 
Although all KAG wafers demonstrated highly porous microstructures, 
visualised using scanning electron microscopy (S.E.M), there was an apparent 
difference between polymeric matrices containing different antimicrobials. The 
matrix of KAG impregnated with 1.0 % PVP-I, in particular, demonstrated 
small and semi-formatted pores. The distinctive morphology of the 
microstructure of PVP-I wafers was likely due to the presence of additives with 
cryoprotective properties such as glycerol. 
Although the incorporation of CHD within the matrix of different 
biopolymers generally improved the rheological properties of the gels, 
adhesive properties (work of adhesion and tensile strength) of CHD wafers 
were slightly decreased compared to CHD-free wafers. These results suggest 
that the embedded CHD had a considerable affect on the wettability of the 
biopolymers. Analysis of the water uptake capacity undertaken with the FSDR, 
as reported in Chapter 4 (Figure 4.5), demonstrated that CHD-loaded wafers 
had a decreased ability to retain water compared to CHD-free matrices. 
Visualisation of the geometry of CHD, using molecular modelling studies, 
indicated a symmetrical ‘Z’ shape compound, which could be easily hooked 
between flexible and interactive branches of biopolymers (Figure 7.1). This 
plausible ability of CHD may have a profound affect on the 3-D gel network, by 
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minimising the volumetric capacity of compartments formed by the cross-
linking and therefore the ability of the polymer matrix to retain water.  
 
 
 
Figure 7.1 A plausible block configuration of sodium alginate consisting of     
1,4-linked-β-D mannuronic acid residues (Mu-a), also known as 
polymannuronate, linearly linked. (----) represent the interlinked CHD 
between linear chains of SA. This ability of CHD is likely mediated from the ‘Z’ 
shape geometry of the cationic drug which can be electrostatically attracted to 
the negatively charged residues of mannuronic acid.  The interlinking of the SA 
network by CHD induced approximately a 2-fold increase in the consistency of 
SA gel. 
 
CHD interlinked between the polymeric chains of the carrier probably 
has a profound affect on the mobility of these chains. In addition, CHD 
impregnated wafers demonstrated smaller expansion ratios than controls. This 
phenomenon was more apparent for gamma-irradiated CHD wafers. Even 
though gamma-irradiation totally degraded KAG polymer, the expansion ratio 
of CHD wafers was generally smaller compared to irradiated controls, reported 
in Chapter 5 (Figure 5.9). It was evident from the rheological analysis of 
consistency, plotted as ‘ln of shear rate vs. ln of shear stress’ reported in 
Chapter 5 (Figure 5.7-8), that the drop in consistency for post-lyophilised 
irradiated CHD gels was smaller than the CHD-free, post-lyophilised, irradiated 
gels. These results indicate that CHD can generally withstand irradiation and 
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both the geometry and cationic nature of the incorporated drug play key roles 
in the performance of the polymeric carrier. 
Analysis of the release profiles of CHD wafers and gels demonstrated 
that neither gels nor wafers released 100 % of the incorporated drug. 
Although this release behaviour was partly due to the equilibrium conditions 
(e.g. humidity, water uptake and evaporation) created in the FSDR, drug- 
polymer interaction played a key role in the amounts of CHD released. It was 
expected that gels would demonstrate a faster release of CHD than wafers, 
but that was not apparent except in the case of GG gel. Rheological analysis of 
pre-lyophilised gels of GG demonstrated that the incorporation of CHD had a 
minor effect on the flow behaviour of the gum. This may indicate that the non-
ionic polymer of GG offers a weaker interaction with CHD. The burst release of 
CHD from the strong gel network of GG (viscosity = 65.49 Pa.s, yield stress = 
93.63 Pa) indicates that drug polymer interactions play an important role in 
the amounts of antimicrobial released and therefore in the activity the 
antimicrobial matrix.  
Analysis of release profiles of SA wafers and gels loaded with CHD 
demonstrated the restricted ability of SA-matrix to release the incorporated 
drug. The total amount of CHD accumulated within 24 hours did not exceed 
10.7 ± 2.07 % and 3.5 ± 0.04 % for SA-CHD gel and wafer, respectively. The 
bulk of CHD remained entrapped in the SA polymeric matrix. Inhibition ratios 
of CHD-loaded wafers further support this scenario, where the CHD 
impregnated matrices of SA and SA-KAG demonstrated significantly decreased 
antimicrobial activities, compared with GG, XG and KAG. However, the 
decrease in inhibition ratios of SA and SA-KAG wafers was affected to some 
extent by the small expansion that the latter wafers exhibited on the seeded 
agar surface. The significant, yet moderate correlation (R2 = 0.5882) between 
expansion and inhibition ratios of CHD wafers indicates that the zone of 
inhibition created from the diffusion of the drug is proportional to the ability of 
the polymeric carrier to expand. Therefore, drug-polymer interactions 
developed within the matrices of antimicrobial wafers play a primary role in 
both performance and activity of the specimens. 
The efficacy of lyophilised wafers is of prime importance, as 
antimicrobial wafers aim to control and inhibit microbial bioburden in 
suppurating wounds. The modified disc diffusion assay is a reliable, yet semi-
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quantitative method for the initial investigation of the flow and antimicrobial 
activity of antimicrobial wafers. All wafers demonstrated antimicrobial activity 
against common wound pathogens, however, the efficacy of antimicrobial 
varies with the potency of compounds and the intrinsic sensitivity of different 
microbial species. Interestingly, SS and PVP-I, two potent and rapid 
bactericidal compounds, exhibited a moderate antimicrobial activity in vitro 
compared to CHD and NS. These results suggest that in vitro, other 
parameters such as the solubility of the compound and the presence of organic 
nutritional supplements play a detrimental role in the activity of the 
antimicrobial compounds tested. For instance, the antimicrobial activity of 
PVP-I was minor against Gram negative species of E. coli and P. aeruginosa 
and recent studies have reported that some iodine dressings such as 
Iodozyme were not effective in vitro, when tested against either E. coli, S. 
aureus or P. aeruginosa in a disc diffusion method (Bradshaw 2011). Other 
authors have also reported the quenching activity of organic matter upon PVP-
I (Messager et al. 2001). On the other hand, in vivo, iodophores and/or iodine 
dressings are generally reported as very effective antimicrobial treatments in 
wound management. For example, Fumal et al. (2002) reported that the 
application of hydrocolloid dressings impregnated with broad spectrum 
antimicrobial compounds such as silver sulfadiazine (SS), chlorhexidine 
digluconate (CHD) and povidone iodine (PVP-I), demonstrated similar 
antimicrobial activity when reducing the bacterial load in chronic leg ulcers. 
These topical antimicrobials showed different levels of toxicity upon a variety 
of dermal cells, however, PVP-I was the most effective compound with regards 
to overall clinical effect (Fumal et al. 2002).  
The antimicrobial diffusion cell was designed in order to elucidate and 
understand the activity of the slowly released broad spectrum antimicrobials 
such as NS, PVP-I, CHD and SS against a common and dangerous pathogen 
such as MRSA. The activity of antimicrobials was assessed in the presence of a 
pseudo-exudate containing similar quantities of electrolytes and protein as 
found in wound exudate.  Data obtained, as reported in Chapter 3 (Figure 
3.10), showed that the activity of antimicrobials is altered in the presence of 
these additives. CHD and PVP-I showed an impaired antimicrobial activity in 
the presence of protein. In contrast SS and NS enhanced their activity in the 
pseudo-exudate. The antimicrobial potency of PVP-I was totally lost. These 
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results are in agreement with previous authors such as Messager et al. (2001) 
and Pitten et al. (2003) who reported the inhibition effect of organic matter on 
the antimicrobial activity of some antimicrobial compounds including PVP-I and 
CHD. In addition, these results explained the tolerant nature of P. aeruginosa 
against PVP-I. This opportunistic Gram-negative bacterium possesses the 
ability to produce a protein layer (Hardegger et al. 1994) which makes it able 
to withstand the lethal effect of PVP-I, as the latter antimicrobial is neutralised 
in the presence of proteins. However, these results lead to the question as to 
what makes iodophoric dressings an effective therapy for chronic, non-healing 
wounds? Recently, Eming et al. (2006) have reported the novel role of PVP-I 
in inhibiting the excessive protease levels in wound fluids obtained from 
venous ulcers. The latter authors demonstrated that the affinity of PVP-I to 
proteins leads to inhibition of plasmin and elastase activity, re-establishing the 
balance between promoters and inhibitors in chronic wound beds. These 
results suggest that the assessment of protein levels and identification of 
microbial species in open non-healing ulcers, prior to application of 
antimicrobial regimes, are important factors for effective treatments. 
Despite its poor solubility, silver sulfadiazine (SS) wafers produced a 
considerable decrease of MRSA populations (approximately 99 %) at 24 hours, 
when tested with antimicrobial diffusion cell (ADC) assay. It was apparent 
from the results presented in Chapter 3 (Figure 3.8, 10) that the abundance of 
chloride ions and protein enhance the solubility of SS, releasing sulphonamide. 
These results were in agreement with Tsipouras et al. (1995) and Fox and 
Modak (1974) who have reported that disassociation of SS is improved in the 
presence of human serums that contain both chloride ions and proteins. In 
addition, these data clearly explain the effect of SS impregnated dressings in 
burns. The activity of SS dressings in burns is associated with large volumes of 
wound fluid containing high concentrations of proteins. It has been reported 
that the albumin fraction in wound fluids exuding from burns range from 69 – 
86 % within 32 hours post injury (Lehnhardt et al. 2005). The abundance of 
wound exudate rich in proteins absorbed by SS impregnated dressings, 
enhance the disassociation of SS and therefore increases the antimicrobial 
activity of the dressings.   
The volume of exudate produced by chronic wounds, protein content 
and type of microbial species are some of the most important parameters that 
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should be known prior to the application of any suitable topical antimicrobial 
therapy. These factors play an important role in the quantities and activity of 
antimicrobials released from the polymeric dressings. In addition, the use of 
known quantities of broad spectrum topical antimicrobial compounds is 
essential in order to inhibit a polymicrobial flora usually present in the majority 
of chronic wounds. Although the release profiles of CHD from biopolymeric 
wafers was minimal and ranged from 3.5 ± 0.001 – 17.4 ± 0.39 %, the 
accumulated concentration exceeded the MIC/MBC values of CHD against the 
majority of tested strains. Even though most of the antimicrobial remained 
within the swollen wafer matrix, that in itself did not undermine the use of 
antimicrobial wafers as effective and contemporary potential dressings, 
especially when the self-adhesive properties of such formulations are 
appreciated. In addition, release of small, yet effective quantities of broad 
spectrum antimicrobials may prove beneficial for dermal tissue, as precise and 
reduced amounts can minimise the adverse cytotoxic effect of such 
compounds. 
The restoration of broken and infected skin is not an easy task as many 
factors (internal and external) interplay. Although the majority of modern 
dressings, including antimicrobial lyophilised wafers, can provide many 
advantages of the ideal dressing, treatment of chronic wounds will continue to 
remain a challenge for physicians, formulation scientists and microbiologists. 
Multidisciplinary approaches to wound management may provide novel 
combination treatments of therapeutic compound and /or new materials with 
poly-therapeutic properties (e.g. both pharmacological and antimicrobial). A 
profound understanding of the healing process and molecular and 
physiological mechanisms that govern it; the role of microorganisms in the 
wound bed, in association with available, effective therapeutic agents and 
unquestionable evidence of their activity in chronic wound therapy; will ensure 
the success of research in this challenging and interesting area. 
 
 
 
 
 200 
 
7.2 Conclusions and future work 
7.2.1 Conclusions   
Cohesive, non-friable lyophilised antimicrobial wafers were successfully 
formulated using a variety of biopolymers miscible with known broad spectrum 
antimicrobial compounds. The efficacy of antimicrobial wafers was 
demonstrated in vitro, under simulated conditions of suppurating wounds, 
using modified disc diffusion and an original antimicrobial diffusion cell (ADC). 
The ADC was shown to be a superior method to disc diffusion for assessing the 
efficacy of slowly released antimicrobials. It was clear that the activity of 
antimicrobial compounds changed in the presence of pseudo-exudate. The 
presence of protein and electrolytes inhibited the antimicrobial activity of PVP-
I and CHD, while enhancing the activity of SS and NS against MRSA. The 
performance of antimicrobial wafers in terms of expansion and release of 
impregnated drug depended on drug-polymer interactions developed within 
the gel structures. Gamma-irradiation affected considerably the 
physicochemical properties of the majority of polymers, except XG, but did not 
generally affect the antimicrobial properties of lyophilised wafers. However, 
degraded polymer matrices considerably influenced the general performance 
of antimicrobial wafers in terms of expansion and faster release of the 
impregnated drug. Although a variety of methods and disciplines were utilised 
in the investigation and evaluation of novel antimicrobial wafers, additional 
research is required to elucidate issues with regards the sequestration and 
bactericidal activity within the swollen wafer matrix. Finally, additional 
investigations are required to elucidate the synergistic interactions between 
natural polymers and antimicrobial compounds (‘drug-polymer interactions’). 
The physical stability of lyophilised wafers is also of great interest. 
 
7.2.2 Future work 
(a)  To quantify the amount of bacteria absorbed by lyophilised matrices. 
Bowler et al. (1999) has used an in vitro wound model to quantify the 
bacterial sequestering capacity of absorbent dressings. 
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(b)   To examine bacterial immobilisation within the swollen matrix of 
biopolymeric formulations, medicated and/or non medicated. Walker et al. 
(2003) have visualised encapsulated bacterial populations within 
carboxymethylated cellulose (AQUACEL®) and alginate dressings using 
scanning electron microscopy (S.E.M). It is necessary, to visualise entrapped 
populations of common wound pathogens and to assess the bactericidal 
activity of biopolymeric dressings (with or without containment of 
antimicrobial) upon immobilised microorganisms. Newman et al. (2006) 
investigated the efficacy of Hydrofiber® wound dressings, which had absorbed 
different concentrations of S. aureus and P. aeruginosa, using rapid confocal 
laser scanning microscopy (RCLSM) and BacLightTM fluorescent dyes. 
 
(c)  Analysis of the conformability and occlusiveness of biopolymeric 
lyophilised wafers using an in vitro shallow microbial wound model (Bowler et 
al. 2010).  
 
(d) Analysis of the elasticity of wafers prepared with different biopolymers 
and the effect of impregnated antimicrobials on the elasticity and 
conformability of lyophilised wafers. 
 
(e)  Physicochemical characterisation of polymer-polymer and polymer-drug 
interactions using Fourier transform infrared spectroscopy (FTIR) and Fourier 
transform Raman spectroscopy (FTRS). Sarisuta et al. (1999) and 
Puttipipatkhachorn et al. (2001) have used FTIR to investigate interactions 
developed between impregnated drugs and polymeric vehicles. 
 
(f)   To investigate the physical stability of lyophilised formulations at 
different temperatures and humidities. Physical stability of lyophilised 
formulations can be assessed in environmental simulation chambers or by 
dynamic vapour sorption (DVS) methods (Airaksinen et al. 2005). The 
equilibrium moisture levels at which lyophilised wafers collapse may have 
implications for stability on storage. 
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